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Summary
Tuberous sclerosis complex (TSC) is characterised by the development of benign 
growths across the body and is caused by mutations in TSC1 or TSC2. The TSC 
gene products have an established role in the regulation of mammalian target of 
Rapamycin (mTOR) signalling. Clinical trials are underway for the treatment of TSC- 
associated tumours using mTOR inhibitors. Here, we show that many of the earliest 
renal lesions from Tsc1+I~ and Tsc2+/' mice (cysts) do not exhibit mTOR activation, 
suggesting alternative pathways should be targeted to prevent tumour formation. 
Patients with TSC often develop renal cysts (derived from dilated tubules) and those 
with inherited co-deletions of the autosomal dominant polycystic kidney disease 
(ADPKD) gene 1 (PKD1) develop severe, early onset polycystic kidneys. Using 
mouse models, we have shown that the Tsc and Pkd1 gene products are required 
for correct cell polarisation during renal tubule and bile duct elongation. When 
polarity is disrupted in Tsc1+I' t Tsc2+I' and Pkd1+,~ mice, we found significant 
alterations in the length of primary cilia projecting from pre-cystic tubule and duct 
cells (consistent with the highly polar nature of this organelle). The primary cilium is 
proposed to facilitate many signalling events and provides a mechanosensory input 
into renal tubule cells. Despite widespread defects in cell polarity and primary cilia in 
the developing kidney of a Tsc1+ I Tsc2+I' or Pkd1+I' mouse, we found no evidence of 
tubule dilation, occlusion or cyst formation until around 3-6 months of age. On the 
basis of this delay period, combined with our data showing significantly higher levels 
of cleaved caspase-3 in pre-cystic renal tubules from these mice, we suggest that 
apoptosis destroys these misaligned cells to protect against cyst formation. We 
found that almost all cysts without mTOR-activation failed to stain for cleaved 
caspase-3, and therefore sought activation of a pro-survival pathway. There was 
strong upregulation of Bcl2 in mTOR inactive cysts that were not undergoing 
apoptosis, suggesting this was the mediator of survival in our cysts. In cysts without 
activation of mTOR or apoptosis, we found significant activation of Jak2 and its 
downstream target Stat3. We finally sought gain-of-function mutations in this 
pathway, and found several somatic Jak2 mutations with likely oncogenic potential in 
Tsc-associated cysts. These data suggest that defective cell polarity in the context of 
abnormal Jak2 signalling can drive Tsc-associated cystogenesis in the absence of 
mTOR dysregulation and targeting of this pathway may be of key therapeutic benefit.
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CHAPTER ONE
General Introduction 
1.1 Tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised 
by multiple hamartomatous growths across many organs.
1.1.1 History of the disease
The earliest reported case of TSC was in a neonate with cardiac rhabdomyomata 
(von Recklinghausen 1862), but it was not until 1879 that D6sir6-Magloire 
Bourneville clearly documented what we now know of as the disease in a 3 year old 
girl with seizures, facial angiofibroma and mental handicap with the term ‘sclerose 
tub6reuse des circonvolutions c6r6brales’ (Bourneville 1880). By 1905, Gaetano 
Perusini began to associate the cerebral, renal, cardiac and skin lesions found in 
TSC sufferers and in 1908 Heinrich Vogt proposed the notion of a clinical triad (Vogt 
1908) of seizures, mental retardation and adenoma sebaceum (facial angiofibroma). 
However, only ~29% of individuals will present with the full triad (Gomez 1988), 
which led to an underestimate of TSC prevalence at 1:100,000 (Nevin et al. 1968). 
Technological advances such as computer tomography (CT) (1974), renal 
ultrasound and echocardiography (1982) and magnetic resonance imaging (MRI) 
(1984) provided non-invasive ways to diagnose TSC in patients not presenting with 
the classical triad or mental retardation (Lagos et al. 1967). It was a combination of 
these new diagnostic tools and work done by Gomez (1988) to establish a major and 
minor clinical feature list that helped increase the accuracy of population studies into 
TSC and raise the number of cases significantly. TSC is now thought to affect 
between one in 6,000 and one in 10,000 individuals (Sampson et al. 1989, Osborne 
1991). The genes responsible, TSC1 and TSC2 (encoding hamartin and tuberin 
respectively) have been characterised and their roles in the repression of mTOR 
signalling has led to trials of Rapamycin (an mTOR inhibitor) as a TSC treatment. A 
timeline of key events in the history of TSC is included in Table 1.1.
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Table 1.1 Timeline of tuberous sclerosis complex, adapted from Gomez e t  al. 1999.
Date Name Contribution
1835 Pierre Frangois Publishes atlas of skin disorders including a diagram highly likely to be a 
Rayer facial angiofibroma.
1862 Friedrich von Documents the disease in a neonate with classic TSC cardiac
Recklinghausen rhabdomyomatas and cortical tubers.
1879 D6sir6-Magloire Gives first detailed description of TSC, and names it tuberous sclerosis of
Bourneville the cerebral convolutions.
1881 Hartdegen Post-mortem study of TSC brain pathology.
1885 Balzer, M6n6trier & Recognises and names “adenoma sebaceum”, notes the link with this
Pringle and mental handicap and seizures.
1901 Pellizzi Noted the dysplastic nature of TSC cerebral lesions.
1905 Perusini Associated skin, renal, cardiac and cerebral lesions.
1908 Heinrich Vogt Proposed the clinical triad in diagnosis of TSC.
1910 Kirpicznik & Berg Both reported on the hereditary nature of TSC.
1914 Schuster Discovered TSC patient with incomplete Vogt’s triad.
1918 Lutenbacher Proposed the involvement of the lung in TSC.
1920 Van der Hoeve Similarity of TSC, neurofibromatosis and von Hippel-Lindau disease, also 
studied TSC retinal phakomas.
1924 Marcus Radiographic findings to aid in diagnosis.
1932 Critchley & Earl Noted diagnostic value of hypomelanotic skin macules in TSC; detailed 
review of the disease.
1942 Moolten Coins the term “Tuberous Sclerosis Complex”.
1967 Lagos & Gomez 38% of TSC group studied had normal intelligence.
1974 Invention of computed tomography for the head.
1979 Gomez New diagnostic criteria, decline of Vogt’s triad.
1982 Renal ultrasound and echocardiography introduced.
1984 Magnetic resonance imaging-refinement of non-invasive TSC diagnosis.
1987 Fryer et al. First mutated TSC gene ( TSC1) linked to 9q34.3.
1992 Kandt et al. Second TSC gene ( TSC2) linked to 16p13.3.
1993 The European TSC2 cloned and its product, tuberin, is identified; tuberin is found to
Chromosome 16 
TSC Consortium
have a region of homology to the GTPase-activating protein, GAP3.
1994 Green et al. & Loss of heterozygosity shown in renal and cardiac TSC hamartomas; also
Carbonara et al in TSC cerebral lesions.
1997 Van Slegtenhorst et TSC1 is cloned and its 130 kDa protein product, hamartin, is identified. 
al.
1998 Plank et al. Strong binding interaction between tuberin and hamartin demonstrated in 
vivo (1:1 stoichiometry).
2002 Tee et al. Observed that tuberin and hamartin functionally interact to inhibit the 
mammalian target of rapamycin (mTOR) signalling pathway.
2005 Inoki et al. Calls for rapamycin clinical trials on TSC lesions.
2005 Kenerson et al. Size reduction in renal tumours from Eker rats (TSC model) treated with 
rapamycin.
2008 Davies et al. & Two year trial of rapamycin in human TSC patients reveals a size
Bissler et al. reduction in astrocytomas and renal angiomyolipomas.
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1.1.2 Clinical manifestations of TSC
TSC primarily manifests as benign hamartomatous growths across many organs, 
including the brain, skin, kidneys and heart. TSC hamartomas consist of a group of 
dysplastic, disorganised cells that possess at least some ability for growth 
(Kwiatkowski 2003). Hamartomas are defined as a subtype of benign tumour, where 
cells will retain normal differentiation but display disorganised tissue architecture 
(Inoki et al. 2005). Table 1.2 outlines the various dermatological, neurological, renal, 
hepatic, pulmonary and cardiac manifestations of the disease.
After skin lesions, which are found in nearly all TSC patients, cerebral pathology is 
the second most common finding (-90%). It is tumours of the central nervous system 
(CNS) that cause the majority of morbidity and mortality in TSC (Hockenberry 2003). 
However, significant contributions to TSC pathology are made from renal 
involvement (Rosser et al. 2006). Liver manifestations of TSC are limited to hepatic 
angiomyolipomas (AMLs), which are often asymptomatic and non-progressive 
(Carmody et al. 1994). TSC-associated pulmonary defects occur exclusively in post- 
pubescent females, at a low incidence of 1% to 6% (Uzzo et al. 1994; Kwiatkowski et 
al. 1994) but can be devastating enough to require lung transplantation.
Other manifestations associated with TSC include retinal tumours (Robertson 1991), 
which are seen in -50% of TSC patients (Robertson 1988). These have strong 
diagnostic value (Casteels 2010) but rarely affect vision (Kwiatkowski et al. 2010). 
Pathological hormone changes can be induced by AML growth on the adrenal 
glands (llgren et al. 1984). TSC adenomas can grow on the pancreas (Kim et al. 
1995) or thyroid (Adhvaryu et al. 2004) to further subvert the endocrine system. 
Digestive tract involvement is divided between the mouth (nodular tumours and 
papillomas), and the rectum (hamartomatous colorectal polyps) (Gould 1991). These 
colorectal polyps have minimal malignant potential. Bender et al. (1981) have 
commented on splenic involvement, characterised as nodules of large abnormal 
cells throughout the parenchyma. Skeletal lesions in TSC occur as asymptomatic 
foci of sclerotic growth (Umeoka et al. 2008).
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Table 1.2 The pathological findings of tuberous sclerosis complex
System Symptom Manifestation
Facial Angiofibroma Adenoma sebaceum present across the cheek bones and bridge 
of the nose, seen in 75% of TSC patients (Weiner et al. 1998). 
Lesion composed of abnormal vasculature and fibrous tissue.
Skin
Hypomelanotic
Macules
White patches are visible on most sufferers (Alper et al. 1983), 
although these pigmentation defects can also be present in the 
general population with no pathological significance.
Ungual Fibromas, 
Shagreen Patches
Nail bed tumours and connective tissue hamartomas commonly 
appear around puberty and are relatively frequent in TSC.
Cortical Tubers
Hypomyelinated hamartomas arising from the cerebral cortex and 
surround white matter. Detectable as early as 20 weeks gestation 
(Park et al. 1997) and a characteristic TSC lesion.
Brain
Sub-ependymal 
nodules (SEN)
Develop in the lining of cerebral ventricles and typically calcify 
with time (Gerard et al. 1987). Present in 80% of TSC patients.
Sub-ependymal giant 
cell astrocytomas 
(SEGA)
May grow large enough to block CNS fluid flow, believed to 
develop from SENs and frequently calcify (Kwiatkowski 2010). 
Histologically, SENs and SEGAs are identical, but the two are 
distinguished on their ability to grow (Fujiwara et al. 1989).
Angiomyolipoma (AML)
A common TSC finding (-7 0% ) (Bernstein et al. 1991), but 
asymptomatic in many cases (O ’Callaghan et al. 2004). AMLs are 
age-dependent (Gomez 1988) benign tumours formed from 
smooth-muscle cells, mature adipose tissue and abnormal blood 
vessels (Stillwell et al. 1987).
Kidney Cysts
In -3 5 %  of TSC patients (Cook et al. 1996), commonly multiple 
and bilateral, arise from all portions of the nephron (Gomez 
1988), lined with hyperplastic epithelial cells derived from tubule 
cells. Severe renal cystic disease occurs in -2 %  of patients with a 
contiguous deletion of both TSC2 and the adjacent PKD1 gene.
Renal Cell Carcinoma 
(RCC)
Suggested to occur earlier (Lendvay et al. 2002) and more 
frequently in TSC patients than the general population 
(O ’Callaghan et al. 2 004, Kwiatkowski 2010, Washecka et al. 
1991). Lesions most likely derive from the lining of cysts, not 
AMLs (Robertson et al. 1996). The prevalent type of RCC in TSC  
is clear cell carcinoma (Bjornsson et al. 1996).
Liver Angiomyolipoma (AML) Hepatic AMLs occur at a significantly lower incidence to renal 
manifestations (Galant et al. 1995). Fricke et al. (2003) found 
AMLs in 13% of TSC patients.
Lungs Lymphangioleiomyo- 
matosis (LAM)
Exclusively in post-pubescent females, at an incidence of 1% to 
6% (Uzzo et al. 1994, Kwiatkowski et al. 1994). Characterised by 
hyperproliferation of smooth muscle cells throughout the lung and 
results in destruction of functional pulmonary tissue with multiple 
thin-walled cysts (Kwiatkowski et al. 2010).
Heart Cardiac
rhabdomyomas
Heart lesions occur in half of infant TSC sufferers (Bass et al. 
1985; Smith et al. 1989), with rhabdomyomas derived from 
cardiac muscle cells being the only cardiac lesion directly 
associated with the disease (Nir et al. 1995). Lesions are small 
and commonly regress with time (Kwiatkowski et al. 1994).
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1.1.3 Diagnosis of TSC
TSC has highly variable penetrance, causing a plethora of abnormalities in a variety 
of organs. This presents medical professionals with a diagnostic challenge that 
requires careful clinical evaluation (Osborne 1988). Many cases of TSC will first 
come to the attention of a clinician through parental concern over small raised facial 
tumours or spasms in early childhood. Some children may remain undiagnosed until 
adolescence if symptoms are phenotypically mild. Typically, minor dermatological 
features will lead to eventual suspicion of TSC in these cases. A new diagnosis of 
TSC will include a detailed family history, physical examination (skin lesions), cranial 
imaging (cortical tubers and SENs), renal ultrasonography (renal AMLs and cysts) 
and echocardiography (cardiac rhabdomyoma).
Vogt’s triad of seizures, mental retardation and facial angiofibroma was the principle 
guide in diagnosing TSC for many years. Upon the discovery by Manuel Gomez that 
patients may not exhibit some or all of these clinical cornerstones (Gomez 1988), a 
definite need for updated and more inclusive diagnostic criteria arose. A new 
criterion was produced to include many more of the previously sidelined aspects of 
TSC (Gomez 1979) and this was later revised by a panel of experts at the Tuberous 
Sclerosis Complex Consensus Conference in Annapolis, Maryland (Roach et al.
1998). A more recent version has been released with minor changes in 2004 (Roach 
and Sparagana 2004). This revised consensus diagnostic criteria for TSC reflects an 
increased understanding of the disease and how it manifests, and is included in full 
in Table 1.3.
Clinical features of TSC are classified into major and minor categories, the presence 
of which will allow a diagnostician to give definite, probable or possible confirmation 
of TSC. Diagnosis can alternatively be carried out or backed up by genetic testing of 
the TSC1 and TSC2 genes. This will involve sequence analysis of the two genes 
followed by deletion testing if no initial mutation is detected. There are patients with a 
spectrum of TSC-associated manifestations in whom no mutation in TSC1 or TSC2 
can be found (no mutation identified, or NMI), but it does not mean those individuals 
do not have TSC. NMI may be accounted for by mutation detection failure, a 
pathogenic mutation in a non-coding region, a third undiscovered TSC locus or 
mosaicism. These issues are discussed in more detail later on.
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Table 1.3 Diagnostic criteria for tuberous sclerosis complex.
Major Features
Location
Head
Brain
Eyes
Skin
Fingers / Toes 
Heart 
Lungs 
Kidneys
Feature
Facial angiofibroma or forehead plaque. 
Cortical tuber §
Subependymal nodule 
Subependymal giant cell astrocytoma 
Multiple retinal nodular hamartomas 
Hypomelanotic macules (>3 lesions) 
Shagreen patch (connective tissue nevus) 
Non-traumatic ungual fibromas 
Cardiac rhabdomyoma (single or multiple) 
Lymphangiomyomatosis ¥
Renal angiomyolipoma ¥
Minor Features
Location
Teeth
Rectum
Bones
Brain
Gums
Liver / Spleen 
Eyes 
Skin 
Kidneys
Feature
Multiple randomly distributed pits in dental enamel 
Hamartomatous rectal polyps (histologically confirmed) 
Bone cysts (radiographically confirmed)
Cerebral white matter radial migration lines §
Gingival fibromas
Non-renal hamartoma (histologically confirmed)
Retinal achromic patch 
"Confetti" skin lesions
Multiple renal cysts (histologically confirmed)
Definite - Either two major features or one major feature with two minor features. 
Probable - One major and one minor feature.
Suspect - Either one major feature or two or more minor features.
§ Cerebral cortical dysplasia and cerebral white matter migration tracts occurring 
together are counted as one rather than two features of TSC.
¥ When both lymphangiomyomatosis and renal angiomyolipomas are present, other 
features of TSC must be present in order for definite diagnosis.
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1.1.4 Identification of the TSC genes
The genetic aspect of TSC was fully appreciated by Kirpicznik and Pringle at the turn 
of the 19th century (Kirpicznik 1910, Pringle 1890). Subsequent work by Berg (1913) 
and Gunther et al. (1935) revealed a dominant inheritance pattern. In the following 
years, several researchers documented TSC-affected families (Dickerson 1951, 
Lagos et al. 1967), but it was not until the 1980s when progress was made in 
uncovering the genes responsible for TSC.
1.1.4.1 TSC1
Fryer et al. (1987) conducted a linkage study in 19 multigenerational families with 
TSC, and found linkage between a TSC-causing gene and the ABO blood group 
gene on chromosome 9q34. Following this breakthrough, the locus was named 
TSC1 (tuberous sclerosis complex type 1). The lack of linkage in other families lead 
to suggestions of another TSC locus (Sampson et al. 1989, Haines et al. 1991, 
Northrup et al. 1992). Using polymorphic DNA markers, the TSC1 candidate region 
was tracked to a 1.4Mb gene-rich (30-45 genes) region (Kwiatkowski et al. 1996). 
Several of these genes were good candidates based on predicted roles in signalling 
pathways, but no mutations were found in these genes in DNA from TSC patients 
(van Slegtenhorst et al. 1997). To find the TSC gene, predicted and confirmed exons 
from this region were screened for mutations using heteroduplex analysis. This was 
done on a set of 60 DNA samples from 20 unrelated TSC families that linked to 9q34 
and 40 sporadic TSC cases. The 62nd exon screened showed shifts that indicated 
mutations in 10 of the 60 patient samples (Gomez et al. 1999). Sequencing of patient 
DNA from TSC1 linked families confirmed truncating mutations in this exon, showing 
that it was likely to be part of the TSC1 gene (van Slegtenhorst et al. 1997).
A final comparison between the genomic and cDNA clone sequences revealed the 
TSC1 gene consisted of 23 exons, the last 21 of which are translated into a 130 kDa 
protein product, hamartin (van Slegtenhorst et al. 1997). TSC1 has a 4.5kb 3’ 
untranslated region (3’UTR), a 221 bp 5’ untranslated region (5’UTR) (exons 1-3) and 
3492bp coding region (exons 3 through 23) (Gomez et al. 1999).
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1.1.4.2 TSC2
A genome-wide search revealed a TSC gene linking to a polymorphic marker near 
the autosomal dominant polycystic kidney disease type 1 (ADPKD1) locus on 
chromosome 16p13 (Kandt et al. 1992). At around the same time, a family with both 
TSC and autosomal dominant polycystic kidney disease (ADPKD) was found to 
segregate a translocation between chromosomes 16p and 22q. While the mother 
and daughter had a balanced translocation involving 16p13.3 and signs of PKD, the 
son inherited an unbalanced karyotype and displayed many of the skin and CNS 
symptoms of TSC in addition to renal cysts (European Chromosome 16 Tuberous 
Sclerosis Consortium 1994).
Identification of the TSC2 locus was quick due to advanced mapping of 16p13.3. The 
distal short arm of chromosome 16 had already been of much interest due to the 
nearby a-globin gene (Deisseroth et al. 1977; Simmers et al. 1987; Buckle et al. 
1988) and the PKD1 gene (Reeders et al. 1985). A cosmid contig of the 300kb 
candidate region was constructed and used to generate probes. These probes, 
along with pulse field gel electrophoresis (PFGE) and southern blotting were used to 
screen a cohort of 255 unrelated TSC patients. Deletions ranging from 30kb-100kb 
were observed in 5 of these patients and all mapped to the same 120kb segment, 
containing 4 genes (only one was disrupted in all 5 deletions). This candidate gene 
had 4 smaller intragenic deletions revealed under further analysis, confirming the 
discovery of the TSC2 gene (European Chromosome 16 Tuberous Sclerosis 
Consortium 1993).
TSC2 spans ~43kb of genomic DNA, with 41 exons and an 1807 amino acid 
transcript (Gomez et al. 1999). This is translated into a 198kDa protein product, 
named tuberin (European Chromosome 16 Tuberous Sclerosis Consortium 1993). 
Northern blotting has shown this 5.5kb transcript to be widely expressed. The gene 
lies proximal to the aforementioned PKD1 gene. These are orientated 3’ to 3’ and the 
pair has polyadenylation signals separated by a mere 60bp.
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1.1.5 Mutation analysis
Around two thirds of TSC cases are de novo (i.e. sporadic) (Sampson et al. 1989a). 
TSC1 mutations are found in 10-15% of sporadic TSC cases, while TSC2 mutations 
account for about 70% (Kwiatkowska et al. 1998, Jones et al. 1999, Niida et al.
1999), an outcome which is perhaps a result of the larger size of the TSC2 gene (it is
1.5 times longer than TSC1) and the more complex genomic structure (it has twice 
the number of splice sites, affording an increased opportunity for various types of 
small mutations). However, a 4:1 ratio is higher than would be predicted from their 
relative genome extents and coding regions (Cheadle et al. 2000).
Around 700 disease causing mutations have so far been discovered in TSC1 or 
TSC2 (Au et al. 2007). TSC1 mutations are mainly small deletions and insertions. 
The distribution of mutations in TSC2 is quite different -  many large deletions and 
rearrangements are detected, and missense mutations (a single base substitution 
leading to a single amino acid change) are far more common (Gomez et al. 1999) 
(Figure 1.1). While no ‘hotspots’ are apparent, 70% of TSC1 mutations are found 
within exons 8, 9, 10, 15, 17 and 18. TSC2 has a somewhat wider distribution, 
perhaps reflecting the larger number of exons (Au et al. 2007).
Six percent of TSC2 mutations are missense and found within the GAP-domain- 
encoding exons 36-40 (Au et al. 2007). This would fit with the role of the GAP 
domain in regulating cellular growth through promoting the inactive GDP bound state 
of Rheb. A further 6% of TSC2 mutations are contained within exon 16 on codon 
R611. This particular codon is known to play an important role in regulating mTOR 
function and a change here has been shown to lead to major conformational 
changes in tuberin (Nellist et al. 2005).
1.1.6 Genotype -  phenotype correlations
1.1.6.1 A contiguous deletion syndrome involving TSC2 and PKD1 
Due to the large amount of phenotypic variability in TSC, researchers have tried to 
establish a link between phenotype and genotype. The most successful correlation 
established so far is in the event of a contiguous deletion affecting TSC2 and the 
nearby PKD1 gene, which results in a severe renal cystic phenotype (Sampson et al.
1997). From a cohort of 27 patients with TSC and renal cystic disease, 17 were
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found to have a contiguous deletion syndrome with non-mosaic deletions of the 
coding regions of TSC2 and PKD1 and shared similar renal symptoms (Sampson et 
al. 1997). All TSC2/PKD1 co-deletion patients had enlarged kidneys in childhood and 
radiographic features resembling advanced stage ADPKD.
1.1.6.2 Is a TSC2 disease more severe than a TSC1 disease?
There is a clear over-representation of TSC2 mutations in sporadic cases of TSC (a 
ratio of around 4:1 (Au et al. 2007)) when compared to familial cases (a ratio of 
around 1:1) (Au et al. 2007). This would imply that patients with sporadic TSC1 
mutations have a better chance of founding a family and are therefore less severely 
affected by TSC-associated symptoms than those with a TSC2 mutation (Cheadle et 
al. 2000). In order to back such a hypothesis, large scale clinical evaluations of TSC 
patients are needed, and many studies have attempted to address this issue (Jones 
et al. 1999, Dabora et al. 2001, Sancak et al. 2005, Au et al. 2007). Sancak et al. 
(2005) noted a higher frequency of clinical features in males than females matched 
for age. Smalley et al. (1992) has also found males with TSC to be of increased risk 
of learning difficulties and autism compared to females. Dabora et al. (2001) studied 
224 TSC sufferers of all ages, and showed sporadic TSC1 mutations to be 
associated with a milder disease than TSC2, after matching for age. Studies by Au et 
al., Dabora et al. and Sancak et al. all suggest patients with TSC2 mutations have 
more severe symptoms than those with TSC1 mutations.
1.1.6.3 Intellectual disability in TSC1 and TSC2
Intellectual disability may be more frequent among sporadic TSC2 cases compared 
to TSC1 (Jones et al. 1999), but others have failed to replicate this finding 
(Kwiatkowska et al. 1998, Young et al. 1998, van Slegtenhorst et al. 1999), and the 
issue remains a contentious one. If a difference does exist, this would go some way 
to explaining the difference between sporadic and familial TSC2 cases, as a 
moderate to severe intellectual handicap would undoubtedly limit reproductive 
potential.
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Figure 1.1 Mutational spectrum of TSC1 and TSC2
Familial Cases
(39.3%)
Sporadic Cases 
(60.7%)
TSC2 (52.8%)
TSC case distribution 
(Sampson etal. 1989)
TSC1 (47.2%)
Familial TSC case distribution 
1:1 ratio (Au etal. 2007)
TSC2 (81.1%) TSC1 (18.9%)
Sporadic TSC case distribution 
4:1 ratio (Au etal. 2007)
TSC1 TSC2
In-Frame (1% )
Splice-site (9%)
cnsense (45% ) Frameshift (45% )
Missense (20% )
Larger 
Rearrangements (7% )
In-Fram e (5% )
Splice-site (15% )
r i
Nonsense (24% ) Frameshift (29% )
Types and frequencies of mutations found at the TSC1 and TSC2 loci (adapted 
from Sancak et al. 2005). Only data from patients with confirmed TSC1 or TSC2 
mutations is included in the case distributions.
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1.1.7 Knudson’s two hit hypothesis
Biallelic inactivation of TSC1 or TSC2 is required for most of the clinical 
manifestations of TSC. This suggests the TSC genes are functioning as tumour 
suppressor genes (TSGs) (Knudson 1971). Knudson’s theory states how an 
individual with a germline TSG mutation is more likely to acquire cancer because a 
single somatic event is needed to completely remove TSG function (Figure 1.2). 
Hence, we see lower numbers of tumours and later development of cancer in 
sporadic cases, as both alleles must be inactivated through independent somatic 
events (Knudson 1971). Loss of heterozygosity (LOH) at TSC1 or TSC2 has been 
found in up to 60% of renal AMLs (Henske et al. 1996). The first hit in these cells is a 
germline mutation which inactivates the wild-type copy of TSC1 or TSC2. The 
second, somatic mutation inactivates the remaining wild type gene and may be 
detected by LOH analysis (Gomez et al. 1999). The complete abolition of TSC 
function removes any restrictive effect on cell proliferation (Tomasoni et al. 2011) 
and tumourigenesis can occur.
1.1.8 Loss of heterozygosity, haploinsufficiency and TSC3
According to Knudson’s two hit hypothesis, TSGs such as TSC1 or TSC2 would 
require second hits before tumour progression (Figure 1.2). Indeed, this has been 
observed in TSC-associated lesions such as SEGAs, AMLs, RCCs and cardiac 
lesions (Green et al. 1994, Carbonara et al. 1994, Parry et al. 2001). However, some 
lesions (brain and early renal cysts) can occur without complete removal of hamartin 
or tuberin. Using Tsc1+I' mice, Wilson et al. (2006) found somatic Tsc1 mutations in 
-80% of renal cystadenomas and RCCs but only 31.6% of renal cysts (P<0.0003), 
raising the possibility that haploinsufficiency for Tsc1 can initiate cystogenesis. 
Furthermore, many cysts showed little or no staining for phosphorylated mTOR 
(53%) or phosphorylated S6 ribosomal protein (37%), while >90% of cystadenomas 
and RCCs displayed strong staining for these markers (P<0.0005). Examples 
outside TSC have been found where haploinsufficiency can lead to tumourigenesis 
(Santarosa et al. 2004). Haploinsufficiency occurs when a single functional allele 
remains after a mutagenic event, but a reduction in gene dosage is sufficient to 
jeopardise the tumour suppressor role played by the protein and creates 
tumourigenic conditions (Santarosa et al. 2004). Various types of TSGs have been 
shown to behave in this manner, such as cell cycle regulators like p27Kip1 and p53;
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signalling molecules like PTEN and LKB1\ and genome stabilisers such as MSH2 
and MAD2. Compound haploinsufficiency may also contribute to tumourigenesis, 
whereby haploinsufficiency in a gene will only manifest itself in a context of other 
genetic changes. Why some lesions in TSC may develop through haploinsufficiency 
while others require second hits is unknown. Tissue specific differences, perhaps 
together with compound haploinsufficiency brought on through differential gene 
expression may explain this.
Some groups have tentatively suggested a third TSC gene (TSC3), with a protein 
product associated with the TSC complex (Jbzwiak et al. 2008). Somatic mutation at 
this additional site may amount to a critical hit to the activity of the TSC complex and 
dysregulate downstream signalling, creating tumourigenic conditions. A TSC3 locus 
would also account for the relatively poor mutation detection rates in TSC 
(Kwiatkowski 2005) although many groups stress the lack of material evidence for 
this additional gene.
Some heterozygous TSC lesions may be developing through a combination of the 
loss of a single TSC allele and alternative pathogenic mechanisms (Henske et al. 
1996, Niida et al. 2001). In TSC brain lesions, the presence of wild-type hamartin 
and tuberin is typical (Jbzwiak et al. 2008). Work on TSC brain lesions by Han et al. 
(2004) identified a mechanism of post-translational inactivation of tuberin to account 
for this discrepancy. Because abnormal activation of Akt and MAPK pathways is 
common in brain tumours, it has been proposed that a functional copy of TSC2 
remains in these cells, but the protein product will be inactivated through 
inappropriate phosphorylation (Han et al. 2004). It has previously been shown that 
Akt can phosphorylate tuberin and inhibit tuberin-hamartin function (Inoki et al.
2002), thereby deregulating mTOR activation without additional somatic mutations at 
the TSC loci. Whether a similar mechanism of TSC 1/2 silencing occurs in other 
heterozygous lesions remains to be seen, but it is unlikely all mechanisms of disease 
progression in TSC can be accounted for by loss of mTOR control.
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Figure 1.2. Loss of tumour suppressor gene function in cancer.
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1.1.9 Mosaicism
Mosaicism occurs when a fraction of the cells making up an organism (rather than 
every cell) contain a particular DNA mutation, for example, when a mutation arises 
during developmental of a fertilised egg (Roberts et al. 2004). In TSC mosaicism, a 
fraction of the patient’s cells contain a TSC1 or TSC2 mutation. Due to the high 
mutation rate in these genes (illustrated by the high levels of de novo mutations) 
TSC mosaicism is relatively likely (Gomez et al. 1999). The extent to which the 
mutation is present in cells of the patient will modify the clinical features of TSC 
(Figure 1.3). This will be a function of when the initial mutation occurred -  if the de 
novo change arose late on in development in a small population of cells there may 
be little clinical manifestation (Gomez et al. 1999). Mild TSC clinical features have 
been seen in cases of 13% and 15% mosaicism (Jones et al. 2001). Both somatic 
and germline mosaicism for pathological mutations in TSC1 and TSC2 have been 
described in numerous patients (Cheadle etal. 2000).
Low level mosaicism may explain the poor detection rate of TSC1 or TSC2 
mutations in patients with a clear diagnosis of TSC (around 85% in studies by 
Sancak et al. 2005, Jones et al. 1999, Dabora et al. 2001). Studies have shown 
some TSC mutations to be missed by direct sequence analysis of PCR products 
(Jones et al. 2001). Alternatively, the presence of a third TSC gene may account for 
this persistent subgroup of around 15% of TSC patients across several studies that 
do not have detectable mutations (Kwiatkowski 2005). This small subset invariably 
has milder symptoms than those with identified mutations (Dabora et al. 2001, 
Sancak et al. 2005). Qin et al. have recently used an ultradeep sequencing 
technique to screen a cohort of TSC patients without a confirmed mutation. They 
found 2/33 (6%) had TSC2 mosaicism , and a further 5 had non-mosaic TSC2 
mutations missed the first time. The study concluded that mosaicism may not 
account for the majority of unidentifiable TSC mutations (Qin et al. 2010). However, 
evidence is stacked in favour of TSC1/2 being the sole genes responsible for TSC 
(Kwiatkowski 2005) and it may be a failure to detect mosaicism at levels <2% in 
patients, or simply missing intronic mutations with splicing importance, that accounts 
for the majority of these unidentifiable mutations (Qin etal. 2010).
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Figure 1.3 Mosaicism in TSC
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A sporadic mutation occurring in the TSC1 or TSC2 genes during the early stages of 
embryogenesis will result in an individual with both normal and altered cells. The distribution 
of these altered cells around the embryo will dictate which organs are formed from mutant 
and normal cell populations. The TSC-status of cell populations that comprise a mosaic 
individual’s organs will decide the clinical manifestations of TSC. LOH is commonly seen in 
advanced TS C  lesions, implying a classic Knudson 2-hit model of tumourigenesis, with cells 
derived from a mutant precursor more likely to acquire a second hit and hence form lesions. 
However, TSC-associated lesions in the brain, heart and early cysts in the kidneys often do 
not show LOH or loss of the remaining functional TSC gene (Wilson et al. 2006), implying 
tuberin or hamartin haploinsufficiency is sufficient for TSC  manifestation. In either case, a 
somatic mutation during early embryogenesis will lead to more compromised cells than a late 
event, with an increased risk of lesion formation and a wider range of organs affected.
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1.1.10 Biochemistry of the TSC proteins
Hamartin and tuberin are evolutionarily conserved proteins that share little homology 
to one another or to other proteins (Huang et al. 2008). Much research has been 
conducted on the various domains of these proteins, with the rap1 GTPase- 
activating protein domain of TSC2 being the best characterised to date. Early work 
has shown the two proteins to form a functional complex (van Slegtenhorst et al.
1998) of around 450kDa which is predominantly cytosolic (Nellist et al. 1999).
1.1.10.1 Hamartin
Northern blot analysis of TSC1 gene expression has shown the transcript to be 
widely expressed, particularly in skeletal muscle (van Slegtenhorst et al. 1997). 
Hamartin is a generally hydrophilic 1164 residue (130kDa) protein, with targets for 
several kinases and phosphatases. It has been localised to cytoplasmic vesicles and 
also the centrosome (Plank et al. 1998, Astrinidis et al. 2006).
Compared to tuberin, very little is known about the function of hamartin, but the fact 
that patients with TSC1 and TSC2 mutations have such similar symptoms would 
imply hamartin is essential to the function of tuberin (Astrinidis et al. 2005). A C- 
terminal binding domain allows hamartin to form heterodimers with tuberin and this 
interaction could direct subcellular localisation of tuberin, or it may have a more 
direct role, such as activating tuberin’s functional domain (Astrinidis et al. 2005). 
Through the ezrin-radixin-moezin (ERM) family interacting domain, it is able to 
physically link with several actin-binding proteins, and a loss of hamartin can result in 
defects in cell-matrix adhesion (Lamb et al. 2000). Hamartin can form homodimers 
(Nellist et al. 1999) through a coiled-coil domain. This self-aggregation is inhibited 
through tuberin binding and may be an important level of control in mammalian 
target of Rapamycin (mTOR) signalling. A portion of the protein is able to interact 
with neurofilament-L (NF-L) (Haddad et al. 2002) which, along with the ERM-family 
interacting domain, may imply a role as a scaffolding protein in the localisation of 
tuberin (Astrinidis et al. 2005). Additional domains and functions are listed in Figure
1.4 and Table 1.4.
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Figure 1.4. Hamartin, the TSC1 protein product
Tuberin binding 
domain (302-430)
T_
ERM  interaction 
domain (881-1084)
Transm em branal 
domain (127-144)
I
S 487 >K
Rho-G TPase  
activating domain 
(145-510)
S511 >k
Coiled-coil domain 
(730-996) NF-L
interaction
domain
(674-1164)
T1047T417
1164
Hamartin is an 1164 amino acid protein with a molecular mass of 130kDa. It has a number 
of phosphorylation sites to regulate activity -  red lines indicate inhibitory phosphorylation 
sites, green lines show activating phosphorylation sites. A  range of kinases act on 
hamartin and carry out these phosphorylation events: * GSK3p, ¥  CDK1, >k IKKp.
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1.1.10.2 Tuberin
Tuberin is an 1807 residue (198kDa) protein. Northern blot data indicates expression 
in a wide variety of human and rodent tissues, especially the brain, heart, kidney, 
cerebellum and developing spinal cord (European Chromosome 16 Tuberous 
Sclerosis Consortium 1993, Geist et al. 1995). This expression pattern overlaps with 
hamartin (i.e. the brain, heart, lungs, liver, adrenal gland, gut, pancreas and prostate 
(Johnson et al. 2001)) but is not identical (Fukuda et al. 2000). Subcellular tuberin is 
present throughout the cytoplasm, but also localised to the Golgi apparatus 
(Wienecke et al. 1996). A subset of tuberin is nuclear (Lou et al. 2001).
1.1.10.2.1 Tuberin functions as a GTPase activating protein 
A C-terminal region of tuberin shares significant homology with the rap1 GTPase- 
activating protein (GAP). This homology covers around 160 amino acid residues 
(Maheshwar et al. 1997) encoded by exons 36-40 (Au et al. 2007). In general, GAP 
domains function to inhibit the signalling of Ras-related family of small G-proteins, 
which includes Rap1, Rab5 and Rheb (Ras homolog enriched in brain) (Inoki et al.
2003). This family of proteins can bind GDP (guanosine 5’-diphosphate) and GTP 
(guanosine 5’-triphosphate), and act as molecular switches, with the GTP-bound 
form being able to transduce signals. It was initially thought tuberin functioned as a 
GAP for rapl, but this was subsequently shown to not be the case (European 
Chromosome 16 Tuberous Sclerosis Consortium 1993). It is now known that 
tuberin’s GAP domain (active only when in a heterodimer with hamartin (Rosner et 
al. 2008)) has a strong affinity for Rheb, a potent regulator of mTOR signalling (Tee 
et al. 2003). Rheb has an intrinsic GTPase domain that slowly converts GTP to GDP, 
but upon interaction with the tuberin/hamartin GAP domain, this process is rapidly 
increased, effectively switching off mTOR signalling by preventing Rheb-GTP 
induced formation of TORCTs active conformation (Tee et al. 2003, Avruch et al.
2006). Additional information on domains and functions are listed in Figure 1.5 and 
Table 1.4.
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Figure 1.5 Tuberin, the TSC2 gene product
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Tuberin is an 1807 amino acid protein with a molecular mass of 198kDa. It has a number 
of phosphorylation sites to regulate activity -  red lines indicate inhibitory phosphorylation 
sites, green lines show activating phosphorylation sites. A range of kinases act on tuberin 
and carry out these phosphorylation events: X  ERK2, €  AKT, f  MK2, ± AMPK, t t  RSK1 
(Rosner et al. 2008).
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Table 1.4 The domains of hamartin and tuberin
Hamartin
Protein Domain Function
Transmembrane
(127-144)
Shown to localise hamartin to the membrane of cytoplasmic vesicles 
(Plank et ai. 1998); points to a role in vesicular trafficking.
Rho GTPase 
activating domain 
(145-510)
Activates the small GTP-binding protein Rho (Lamb et ai. 2000), 
thereby regulating cytokine-induced reorganisation of the actin 
cytoskeleton (Astrinidis et ai. 2002)
Tuberin binding 
(302-430)
Heterodimerisation with hamartin to form a functional complex 
capable of repressing mTOR signalling (Hodges et al. 2001).
NF-L interaction 
domain (674-1164)
Capable of binding neurofilament-L and anchors neuronal 
intermediate filaments to the actin cytoskeleton (Haddad et al. 2002).
Coiled coil 
(730-996)
Allows homodimerisation and self aggregation with other hamartin 
molecules. Disrupted by tuberin interaction (Nellist et al. 1999).
ERM interaction 
domain (881-1084)
Region interacts with ERM proteins, a group of cytoskeletal anchors. 
Hamartin is required for cell-matrix adhesion (Lamb et al. 2000).
Tuberin
Protein Domain Function
Hamartin binding 
(1-418)
High affinity binding with hamartin, specifically with the tuberin 
binding domain at residues 302-430 (Hodges et al. 2001).
Leucine zipper 
(81-98)
Motif known to be involved in protein-protein interactions (European 
Chromosome 16 Tuberous Sclerosis Consortium 1993).
Coiled coil (346- 
371; 1008-1021)
Motifs outside the hamartin binding domain required for hamartin 
interaction (van Slegtenhorst et al. 1998; Hodges et al. 2001).
Transcriptional 
activation domains 
(1163-1259; 1690- 
1743)
The presence of two transcriptional activation domains, along with 
cellular localisation data, suggests a direct role for tuberin as a 
transcriptional regulator (Tsuchiya et al. 1996). The first domain 
(1163-1259) is the more potent of the two.
GTPase activating 
protein (15IT- 
1674)
A key domain in the repression of mTOR signalling -  able to activate 
the intrinsic GTPase properties of Rheb (European Chromosome 16 
Tuberous Sclerosis Consortium 1993).
Calmodulin binding 
(1740-1755)
Interaction with the calcium-binding protein, calmodulin. A key 
regulator of cell signalling (Noonan et al. 2002).
PATJ interaction 
domain 
(1538-1758)
Creates a direct link between tuberin and the Crumbs (CRB) 
complex, and allows PATJ, a key polarity protein, to exert control 
over the mTOR signalling pathway (Massey-Harroche et al. 2007).
21
1.1.10.3 The tuberin-hamartin complex
Hamartin and tuberin physically interact to form a heterodimeric cytosolic complex 
(Nellist et al. 1999) that functions in a common signalling pathway as a key repressor 
of the mTOR complex (Orlova et al. 2010). This dimerisation is mediated through N- 
terminal specific binding motifs (Hodges et al. 2001). The interaction with tuberin has 
been previously shown to be important for the stability of hamartin and prevents self- 
oligomerisation (Nellist et al. 1999). In return, hamartin is able to prevent 
ubiquination and subsequent degradation of tuberin (Benvenuto et al. 2000). Tuberin 
and hamartin also contain multiple phosphorylation sites for a range of kinases, the 
action of which has been shown to regulate the formation of the complex (Astrinidis 
et al. 2005). Through integration of these signals, and by funnelling them through a 
dichotomous event (activation or repression of Rheb and therefore mTOR), the 
TSC1-TSC2 complex acts as a molecular switchboard (Figure 1.6). It controls a 
bottleneck in the mTOR signalling pathway, where many signals converge, before 
the numerous targets of active mTOR lead to signal divergence and widespread 
downstream effects (Huang et al. 2008). The tuberin-hamartin complex functionality 
may reside within tuberin’s GAP domain, but clearly the interaction with hamartin is 
well regulated and required for optimal function. The GAP activity of tuberin is 
boosted dramatically when in a complex with hamartin (Tee et al. 2003). 
Phosphorylation of hamartin by cyclin-dependent kinase-1 (CDK1) disrupts this 
interaction and markedly reduces tuberin GAP activity during the G2/M phase of the 
cell cycle (Astrinidis et al. 2003).
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Figure 1.6 The role of the hamartin / tuberin complex in mTOR regulation
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1.1.10.4 The mTOR pathway
The Tor (target of Rapamycin) genes were originally described in yeast as a set of 
proteins that were responsive to the immunosuppressive drug Rapamycin (Heitman 
et al. 1991). The TOR proteins are serine/threonine kinases of the phosphoinositide 
3-kinase-related kinase family, with orthologues present in all eukaryotes (Huang et 
al. 2008) including mammals (mTOR) (Inoki et al. 2005). TOR has a conserved role 
in control of cell growth, proliferation, survival and metabolism in response to nutrient 
and growth signals (Tee et al. 2005). This is carried out through regulation of 
translation, transcription, mRNA and protein stability, actin cytoskeleton organisation 
and autophagy (Inoki et al. 2005). mTOR functions in two separate complexes on 
two pathways -  mTOR complex 1 (mTORCI) and mTOR complex 2 (mTORC2). 
mTORCI is well characterised and consists of mTOR, regulatory associated protein 
of mTOR (Raptor) and LST8 (lethal with SEC13 protein 8). Rapamycin acts on this 
with high specificity. The Rapamycin-insensitive form, mTORC2, is composed of 
mTOR, Rapamycin-insensitive companion of mTOR (Rictor), SIN1 (stress activated 
protein kinase interacting protein 1) and LST8. Little is known about mTORC2, other 
than that it can regulate aspects of the actin cytoskeleton by acting upstream of Rho 
GTPases (Jacinto et al. 2004) and has Akt as a direct target (Sarbassov et al. 2004). 
mTORCI has two classes of downstream targets- the ribosomal S6 kinases, S6K1 
and S6K2, and eukaryotic initiation factor 4E (elF4E)-binding protein (4e-BP1) 
(Huang et al. 2008). Activated S6K will phosphorylate a range of targets to promote 
mRNA translation and increased ribosome biogenesis (Astrinidis et al. 2005). Upon 
phosphorylation of 4e-BP1 by mTORCI, its release is triggered from elF4E at the 
methyl-GTP cap of mRNAs, leading to cap-dependent translation (Gingras et al.
2001).
1.1.10.5 mTOR syndromes
Mutation in the TSC proteins leads to mTOR dysregulation and widespread benign 
tumour growth. This is largely down to mTOR’s central role in regulation of cell 
growth (Inoki et al. 2005). However, mutations in other genes have been linked to 
the mTOR pathway and Table 1.5 lists examples from the literature and Figure 1.7 
llustrates the signalling networks involved.
24
Figure 1.7 Hamartoma disease genes in mTOR signalling
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The m TOR pathway has a central role in regulating cell growth and proliferation. Dysregulated 
m TOR activity is associated with several hamartoma syndromes. The TSC  proteins are key 
regulators of m TO R through control of Rheb-GTP levels, and these are mutated in TSC. The 
NF1 gene product is a G TPase activating protein for the Ras G protein (an activator of the 
m TOR pathway) and is mutated in Neurofibromatosis. PTEN, mutated in Cowden’s Disease, 
Bannayan-Riley-Ruvalcaba Syndrome and Proteus Syndrome encodes a negative regulator of 
PI3K. PTEN deficiency leads to increased levels of activated Akt, an important regulator of 
TSC2. Familial Adenomatous Polyposis is caused by mutations in APC, a negative regulator of 
Wnt-p-catenin signalling. Loss of APC results in hyperactive p-catenin and upregulation of 
proto-oncogenes such as c-myc and cyclin D. m TOR has been shown to upregulate translation 
of these genes and TSC  1/2 may interact with components of the APC complex. Juvenile 
Polyposis syndrome is caused by mutations in BM PR1A or SMAD4. The ligand for BMPR1 
(BM P4) activates STAT3 in an m TOR-dependent manner. SMAD 3, a binding partner of SMAD  
4, is able to physically interact with TSC 2 and Akt (not shown on diagram). Birt-Hogg-Dube 
syndrome is caused by mutations in FLCN, and has similar clinical features to TSC, but has a 
higher risk of malignancy. Hartman et al. (2009) have suggested FLCN may regulate m TOR  
signalling. Von Hippel-Lindau syndrome is caused by mutations in VHL, which encodes a 
component of the E3 ubiquitin complex, involved in the degradation of HIF (a stimulator of 
angiogenesis) under normoxic levels of oxygen. FLCN -  folliculin, HIF -  hypoxia inducible 
factor, PTEN -  phosphatase and tensin homologue, LKB1 -  liver kinase B1. Diagram  
constructed from Inoki et al. 2005, Han et al. 2009, Linehan et al. 2010, Hartman et al. 2009, 
Mak et al. 2003.
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1.1.11 Treatments
Loss of TSC1 or TSC2 leads to dysregulated mTOR signalling, and so TSC 
treatment has primarily focused on Rapamycin (also called Sirolimus), a natural 
inhibitor of mTOR (Tee et al. 2003). It has antibiotic properties and anti-fungal, 
potent growth-inhibitory, anti-inflammatory and immunosuppressive functions. It was 
first used for this latter property following organ transplants. It is an analogue of the 
macrolide antibiotic FK506 (Abraham et al. 1996) and by binding to the receptor 
protein FKBP12, and subsequently mTOR, it is able to specifically inhibit TOR 
function (Inoki et al. 2005). Farnesyltransferase inhibitors and angiogenesis inhibitors 
are also under active consideration for TSC treatment (Kwiatkowski 2003). 
Angiogenesis inhibitors may be of clinical value as many of the TSC-associated 
lesions are characterised by aberrant vascular channels, likely to arise through the 
expression of VEGF by Tsc1 or Tsc2 null cells (Kwiatkowski 2003).
Rapamycin use in an Eker rat model of TSC demonstrated reductions of ribosomal 
S6 kinase activity, smaller cell sizes, induction of apoptosis and a promising 
decrease in renal tumour size (Kenerson et al. 2005). Although a clear effect is 
observed on the progression of these TSC lesions, little or no reduction was found in 
the number of microscopic precursor lesions. This suggests that mTOR activation 
may be necessary for lesion progression but other pathways drive tumourigenesis 
(Kenerson et al. 2005). A reduction in subcutaneous tumours was observed by 
Rauktys et al. (2008) in a nude TSC mouse model following topical application of 
Rapamycin. This gives hope for the treatment of disfiguring skin lesions in TSC 
patients.
Human trials with Rapamycin have started to generate results. A small scale MRI 
study involving 5 patients that looked at the effects of Rapamycin on SEGAs found 
regression in all lesions (Franz et al. 2006). A larger study was conducted over 2 
years by Bissler et al. (2008) with 12 months on and 12 months off Sirolimus. The 
study focused on AMLs from TSC patients and sporadic LAM cases, using MRI and 
CT scans to measure changes in tumour volumes, and pulmonary function tests to 
compliment the LAM findings. AMLs were found to regress under the 12 months of 
drug administration, but enlarged once treatment was stopped. Some of the LAM 
patients showed improved lung function after treatment (Bissler et al. 2008). Another
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2 year trial by Davies et al. (2008) demonstrated reduction of AML volume in TSC 
patients treated with Sirolimus. On the basis of these promising results, randomised 
control trials have been initiated to test Rapamycin in a range of TSC or LAM-related 
clinical problems (Davies etal. 2010).
Several concerns have been raised with Rapamycin treatment in TSC. Long term 
use is undesirable because of the immunosuppressive nature of Rapamycin (Franz 
et al. 2006). Unfortunately, TSC is a long term condition, and a short Rapamycin 
course may not be clinically effective, with several studies showing tumour regrowth 
once treatment is stopped (Bissler et al. 2008, Franz et al. 2006). Side effects also 
include a dose dependant reduction in blood platelet count (Murgia et al. 1996), 
ulcers, diarrhoea and upper respiratory tract infections (Bissler et al. 2008). The 
discovery of the Akt feedback loop (Manning 2004) has raised further questions over 
the safety of Rapamycin treatment. Rapamycin-mediated mTOR inhibition induces 
negative feedback activation of Akt (Wan et al. 2007). Since Akt is one of the most 
frequently hyperactivated protein kinases in human cancer and associated with 
resistance to apoptosis and increased cell proliferation (Wan et al. 2007), doubts 
remain as to whether this is something desirable to stimulate in patients. However, 
clear advantages may remain from Rapamycin treatment, as it would also shut down 
aberrant activation of elF4E and cap-dependant translation. Several studies have 
shown elF4E to be a potent oncogene (Mamane et al. 2004), and possibly at the 
heart of tumourigenesis in mTOR overexpression syndromes (Manning 2004). In this 
case, Rapamycin would block the primary cellular process that drives tumour growth.
1.1.12 TSC models
The multi-systemic phenotype associated with TSC is a testament to the widespread 
importance of the TSC genes, and the high variability seen in the clinical 
manifestations demonstrate the intricate nature of signalling that surrounds the 
proteins. Rodent models have proved invaluable in studying human genetic disease 
for many reasons. They can provide an insight into mechanisms of disease, and 
allow the development of therapeutic targets which can be translated into human 
patients. Additional advantages include the ability to inbreed strains, the ease of 
handling and husbandry.
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1.1.12.1 Ekerrat
The first genetic model of TSC was described in the 1950s (Eker 1954, Eker et al. 
1961) and arose spontaneously through germline inactivation of a TSC2 allele. It 
served as a model of RCC (Pan et al. 2004, Kobayashi et al. 1997) before 
sophisticated methods existed to recapitulate carcinogenic phenotypes with precise 
gene targeting. A homozygous Eker mutation is embryonically lethal at E10-12 days, 
indicating the importance of TSC2 in development (Everitt et al. 1995). Heterozygous 
rats are born healthy but go on to develop kidney lesions such as cysts, branching 
cysts and cyst adenomas within 12 months (Eker et al. 1981). These lesions develop 
from altered renal tubules, which start to appear after around 2 months (Hino et al.
2002). The RCCs seen are part of a wider cancer syndrome consisting of 
haemangiomas of the spleen, reproductive tract leiomyomata and vascular 
neoplasms (Everitt et al. 1992). The mutation has been mapped to 10q12, and 
consists of a 6.3kb retrotransposon insertion into an intronic sequence of Tsc2 (Hino 
et al. 2002) which leads to aberrant RNA expression from this gene and no stable 
tuberin being produced from the mutant allele (Kobayashi et al. 1995). The nearby 
Pkd1 gene, located in a tail-to-tail orientation as in humans, is unaffected in this 
model (Hino et al. 2002).
The stages of renal carcinogenesis can be observed in the Eker rat. Initially, 
abnormal renal tubules will appear after 2 months and are characterised by partial 
replacement of the tubular epithelium with cells that are enlarged and have abnormal 
nuclei. These tubules develop into foci of overproliferative cells, then onto adenomas 
(Hino et al. 2002). With time, these lesions may progress to carcinomas, with a small 
minority becoming malignant and metastasize to the lungs, pancreas and liver (Eker 
etal. 1981).
Kobayashi et al. (1997) detected LOH in many neoplastic lesions from the rat model, 
including very early and preneoplastic renal tubules. This led them to suggest that a 
somatic mutation in the wild-type allele of Tsc2 was a rate-limiting step for renal 
carcinogenesis in the Eker rat. In spontaneous renal carcinomas from the Eker rat, 
around 60% show LOH (Kubo etal. 1994), demonstrating consistent loss of the wild- 
type Tsc2 allele.
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1.1.12.2 Tsc1 knockout mouse
Several different knockout alleles in Tsc1 have been developed, with the most recent 
model (Wilson et al. 2005) exhibiting a more severe phenotype than the two existing 
mouse lines (Kobayashi etal. 2001; Kwiatkowski etal. 2002).
Wilson et al. (2005) engineered a functionless allele of Tsc1 by replacing part of 
exon 6 and all of exons 7 and 8 with a (3-Galactosidase reporter/neomycin selection 
cassette. TscV1' mice from this strain were found to be unviable past E13, as was the 
case with the other Tsc1 mouse models (Kobayashi et al. 2001, Kwiatkowski et al.
2002). Examination of TscV1' embryos revealed them to be developmental^ retarded 
and prone to neural tube closure defects.
Strain background may have profound effects on the number and severity of renal 
lesions in Tsc1+/' mice (Wilson et al. 2005). When matching for age at 3-6 months, it 
was found that significantly more Tsc1+/' mice on a C3H background experienced 
some form of renal lesion (44%) compared to those from Balb/c (13%) or C57BL/6 
(8%) strains. Interestingly, a high incidence of renal cell carcinoma (80%) in Tsc1+I' 
Balb/c mice was detected at 15-18 months, far higher than the other backgrounds. 
However, regardless of background, all Tsc1+I' mice were found to have microscopic 
renal lesions by 15-18 months (Wilson et al. 2005). Lesions found at this age range 
included cysts, cysts with papillae projections, branching cysts with branching 
papillae projections and solid carcinomas. These were noted to undergo a clear 
progression from small cysts to renal cell carcinomas. LOH at the wild-type Tsc1 
locus was found in 5 of 12 renal lesions (Wilson et al. 2005), while Kobayashi et al. 
(2001) reported LOH in 2 of 6 lesions, implying a second hit in Tsc1 may lead to 
renal tumour initiation / progression.
1.1.12.3 Tsc2 knockout mouse
In 1999, two separate Tsc2+/ mouse lines were reported and found to display 
identical phenotypes (Onda et al. 19 99, Kobayashi et al. 1999). Both removed 
germline Tsc2 function through targeting exon 2. A third null Tsc2 allele has since 
been developed through deletion of exons 2-4, and phenotypically, the resultant 
mice appear to be similar (Hernandez et al. 2007).
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As in TscT1' mice, 7sc2v' mutant embryos die in utero between E9.5 and E12.5. 
Many demonstrate open neural tubes and are significantly less developed than 
Tsc2+I' littermates (Onda et al. 1999, Kobayashi et al. 1999). The primary cause of 
foetal death appeared to be liver hypoplasia, although cardiac hypertrophy was also 
seen.
Renal lesions in Tsc2+I' mice develop by 6-12 months (100% penetrance by 15 
months) and progress as the mouse ages (Onda et al. 1999, Kobayashi et al. 1999). 
As in Tsc1+/' kidneys, examination of these lesions revealed a mix of pure cysts, 
cysts with papillae projections and solid adenomas. These cysts arise from the 
cortical region of the kidney and have similar expression profiles to collecting duct 
interstitial cells (Onda et al. 1999). Liver haemangiomas were noted in 50% of Tsc2+I' 
mice at 18 months, characterised by smooth muscle cell proliferation and large 
vascular spaces (Kwiatkowski et al. 2010). This liver phenotype appears to be strain 
specific, with the incidence much higher in Tsc2+I' 129 / SvJae mice (Kwiatkowski et 
al. 2010). LOH of Tsc2 was noted in 9 of 37 renal cystadenomas and carcinomas, 
and 7 out of 14 liver haemangiomas (Onda et al. 1999). As with Tsc1, these results 
imply loss of remaining wild-type Tsc2 can lead to tumour development in several 
organs.
1.2 Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) (MIM 173900) is the 
commonest form of inherited renal cystic disease (Torres et al. 2007). It is estimated 
to occur in around 1 in 1000 live births (Dalgaard et al. 1957). Primarily, it is a 
disease of the kidneys, but extra-renal manifestations include cysts in other organs 
such as the liver, seminal vesicles and pancreas.
1.2.1 History and epidemiology of ADPKD
Prior to a study by Dalgaard confirming the autosomal dominant nature of 
inheritance (1957), ADPKD was known as adult polycystic kidney disease. Drawing 
from a Danish population, the incidence of ADPKD was placed by Dalgaard at 1 in 
1000. A more recent study in Olmsted County, MN, USA confirmed this level of 
incidence (Iglesias et al. 1983). Thousands of people every year succumb to end 
stage renal disease (ESRD) as a result of ADPKD (Torres etal. 2007).
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1.2.2 Clinical manifestations of ADPKD
It is possible to subdivide ADPKD into two types, depending on the mutated gene 
(PKD1 or PKD2). In ADPKD type 1 (PKD1) disease progression may be more rapid 
but in most other ways, ADPKD type 1 and 2 share identical features (Sutters et al.
2003).
1.2.2.1. Renal manifestations
The development and enlargement of renal cysts eventually gives rise to many of the 
morbidities of ADPKD (Torres et al. 2007). Main complications include renal failure, 
back pain, cyst haemorrhage and infection (Zhou et al. 2008). The occurrence of 
these cysts is age dependent and occurs in all ADPKD patients. Renal function 
deteriorates as cysts compress and destroy normal renal parenchyma (Sutters et al.
2003). Sex is known to play a role in disease progression, as men have higher rates 
of cystic expansion than women (Harris et al. 2006). Interestingly, an MRI study by 
Grantham et al. (2006) found that while PKD1 kidneys had more cysts and were 
larger than those in PKD2, there was no difference in the rates of cystic growth over 
time. This suggests the disease gene may modulate cyst initiation but not 
progression.
Renal cyst numbers do not tend to exceed one or two in people under the age of 30, 
but by the age of 50, these same patients may have a cystic load of hundreds. As a 
result, ADPKD kidneys can reach 40cm in length (compared to 10-12cm in 
unaffected individuals) and be around 10 times heavier (8kg compared to 500g in 
unaffected individuals) (Gabow et al. 1993). Kidney cysts are derived from the 
epithelial cells lining renal tubules, and can develop in all areas of the nephron and 
collecting ducts (Torres et al. 2006). 80% of 70 year old patients with ADPKD will 
develop ESRD (compared to under 5% in sufferers under 40 years old) (Zhou et al. 
2008).
1.2.2.2. Hepatic manifestations
Aside from renal manifestations, ADPKD only ranks behind haemochromatosis in 
terms of inherited disorders involving the liver (D’Agata et al. 1994). As in the kidney, 
the number and prevalence of hepatic cysts will increase with time, and by the age of 
60, 80% of ADPKD sufferers will have hepatic cysts (Gabow et al. 1990). Men and
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women with ADPKD have similar chances of developing hepatic cysts, but women 
can expect greater numbers of lesions and larger sizes (Gabow et al. 1990, Everson 
et al. 1993, Everson et al. 1990). Consistent with this hormonal component, severe 
hepatic disease correlates both with puberty (Gabow et al. 1990), pregnancy and 
use of female steroid hormones (Qian etal. 2003).
Patients that develop small hepatic cysts (<2cm) will tend to remain asymptomatic, 
while larger cysts will commonly present with abdominal pain, early postprandial 
fullness or shortness of breath. Cysts have a risk of haemorrhage, infection or post- 
traumatic rupture (Telenti et al. 1990). Large scale cystic expansion can also lead to 
symptoms consistent with advanced liver disease, such as portal hypertension and 
variceal haemorrhage (Everson et al. 2004).
The hepatic cysts in ADPKD arise from intrahepatic cholangiocytes derived from bile 
ducts that have become dilated (Masyuk et al. 2006). Hepatic cyst epithelium is 
known to retain a biliary phenotype, and remains able to secrete fluid into a 
developing cyst lumen (Masyuk et al. 2006). Oestrogen receptors are also present in 
the epithelium lining (Alvaro et al. 2006), rendering the cysts sensitive to oestrogen- 
mediated cell proliferation.
1.2.2.3. Other manifestations
The main pathology in ADPKD of progressive bilateral renal cystogenesis leads to 
several other morbidities. Hypertension (blood pressure over 140/90 mm Hg) is a 
concern in ADPKD, and is present in 50% of patients aged 20-34 years. As these 
patients age and develop ESRD, hypertension incidence rises to almost 100% 
(Kelleher et al. 2004). Stretching and compression of vasculature due to cyst 
expansion is thought to cause ischemia and lead to subsequent activation of the 
renin-angiotensin system, raising blood pressure (Gabow et al. 1990).
Pain is common in adults with ADPKD (60%) (Bajwa et al. 2004). Events such as 
cyst haemorrhage and infection are known sources of pain in ADPKD (Torres et al.
2007). Kidney stones occur at an increased frequency (around 20%) and these are 
very painful to excrete (Torres et al. 1993).
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1.2.3 Diagnosis of ADPKD
With a positive family history for ADPKD, diagnosis will be based around imaging 
testing (Torres et al. 2007). Due to low cost and high safety (compared to MRI or 
CT), renal ultrasonography is commonly used for detecting ADPKD (Pei et al. 2010). 
An age graded ultrasound criteria for ADPKD has been established (Ravine et al. 
1994), but in younger patients, small cysts may escape sonographic detection 
(especially for patients with milder PKD2).
Where imaging results are contentious, genetic testing (linkage analysis or direct 
mutation screening) for ADPKD can be used (Pei et al. 2010). However, the large 
size and complexity of PKD1 makes molecular testing by direct DNA analysis a 
challenge (Torres et al. 2007). Linkage analysis is an option in less than 50% of 
cases, because it requires the consent of a reasonably sized family. Furthermore, 
family participants must all have a definite clinical diagnosis. It also cannot be used if 
the proband has a de novo mutation (Pei et al. 2010). In contrast, direct mutation 
analysis involves sequencing the entire coding regions of both PKD1 and PKD2. 
While more expensive, this method does have the advantage of only requiring one 
blood sample. Definite disease causing mutations are only found in 40-60% of 
cases, with likely disease causing mutations making an additional 26-37% (Rossetti 
et al. 2007, Garcia-Gonzalez et al. 2007).
1.2.4. Treatment options for ADPKD
Treatment of ADPKD centres on reducing morbidity and mortality due to 
complications of the disease (Torres et al. 2007). Hypertension is treated with ACE 
inhibitors or angiotensin receptor blockers. These have a low side-effect profile, 
reduce blood pressure and have been shown to increase renal blood flow (Chapman 
etal. 1990, Torres et al. 1991, Watson etal. 1992).
Pain arising due to ADPKD will need further investigation before treatment, as a 
number of non-ADPKD related causes could be responsible (infections, tumours and 
stones) (Torres et al. 2007). Acute episodes of pain can be dealt with by narcotic 
analgesics, but these are not recommended for long term use. Lifestyle modification 
to avoid unnecessary strain may help too. If pain management fails, cyst surgery is 
an option (Torres etal. 2007, Elzinga etal. 1992).
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Cyst haemorrhages can often be managed by bed rest, analgesics and hydration 
(Torres et al. 2007). Occasionally the resulting drop in haematocrit following rupture 
will require hospitalisation, transfusion and arterial embolisation. Cysts that become 
infected are hard to treat (Elzinga et al. 1996) because of poor antibiotic penetration 
to the lesion, but lipophilic agents can help.
ADPKD patients on dialysis for ESRD often do well due to relatively high 
concentrations of erythropoietin and haemoglobin (Abbott et al. 2002). However, 
transplantation is the treatment of choice for ESRD in ADPKD. This can be limited to 
the kidneys, or in tandem with a new liver.
No curative or preventative therapy exists for the polycystic liver disease 
experienced by ADPKD patients (Masyuk et al. 2006). Symptomatic relief is limited 
to surgical intervention, and includes aspiration of cyst fluid, cyst fenestration, liver 
resection and organ transplant (Everson et al. 2004, Shneider et al. 2005).
1.2.4.1. Rapamycin in ADPKD treatment
The mTOR pathway is regulated by polycystin-1 (Shillingford et al. 2006) and mTOR 
has been shown to be aberrantly activated in ADPKD (Shillingford et al. 2010). 
Studies using mTOR inhibitors in animal models of PKD have shown promising 
results, with inhibition of renal cyst growth, regression of kidney size and 
preservation of renal function (Shillingford et al. 2006, Tao et al. 2005, Wahl et al. 
2006). Clinical trials are underway to test the response of ADPKD-associated cysts 
to mTOR inhibitors in humans (Walz et al. 2006, Serra et al. 2007). Data from a 
clinical trial of Sirolimus has been shown to reduce polycystic liver volume in ADPKD 
patients (Qian et al. 2008), implying that mTOR inhibition may hold therapeutic 
options in the future.
1.2.5 Identification of the ADPKD genes
ADPKD is caused by mutations in at least two genes: PKD1 and PKD2. The first 
locus to be localised (Reeders et al. 1985) was PKD1 to the short arm of 
chromosome 16, but families soon emerged that had no linkage to markers on 
chromosome 16p (Kimberling et al. 1988, Romeo et al. 1988). A second ADPKD
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locus (PKD2) was subsequently found on chromosome 4q13-q23 (Peters et al. 1993, 
Kimberling etal. 1993).
1.2.5.1 The PKD1 gene
PKD1 (chromosomal region 16p13.3) is roughly 53kb in length and split into 46 
exons. Exon 15 is the largest of these and exons 1 and 2 are separated by a large 
intron of 15kb. The mRNA transcript is 14.5kb (The International Polycystic Kidney 
Disease Consortium 1995). The translational product of PKD1 is polycystin-1 (PC1).
1.2.5.2 The PKD2 gene
PKD2 (chromosomal region 4q13-q23) is considerable smaller than PKD1, being 
approximately 68kb in length and split into 15 exons. The mRNA transcript is 5.4kb 
long, which encodes a 968 amino acid product, polycystin-2 (PC2) (Mochizuki et al.
1996).
1.2.5.3 A third PKD locus?
Several families with a clinical diagnosis of ADPKD have been discovered with no 
linkage to PKD1 or PKD2 (Daoust et al. 1995, de Almeida et al. 1995, Turco et al. 
1996, Ariza et al. 1997). Although tempting to attribute such a finding to a third, 
unidentified ADPKD locus, other factors may explain the lack of linkage. Human 
error is possible -  genotyping errors, sample mix ups and misdiagnosis 
(phenocopies and non-penetrance) (Paterson etal. 1998, Paterson etal. 1999).
1.2.6 Mutation analysis of ADPKD
ADPKD is genetically heterogeneous, with mutations in PKD1 and PKD2 making up 
~85% and -15% respectively of the pedigrees identified (European Polycystic 
Kidney Disease Consortium 1994, Mochizuki et al. 1996). A handful of rare, unlinked 
families have been discussed previously. The de novo mutation rate for PKD1 has 
been estimated at 1.8 x 10'5 per generation (Rossetti et al. 2001), although other 
studies have placed it as high as 6.9 x 10'5 (Dobin et al. 1993). Rossetti et al. (2001) 
found no mutation hotspots, with variants spread throughout exons 1 to 46. Most of 
the changes were protein truncations through nonsense mutations (32%), insertions 
or deletions (29.6%) or splicing changes (6.2%). Large deletions are rare but result 
in deletion of the adjacent TSC2 gene and severe infantile cystic kidney disease
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(Brook-Carter et al. 1994, Laas et al. 2004). PKD2 has a similar heterogeneity in 
mutation clusters (Rossetti et al. 2007), but a lower mutation rate (Rossetti et al. 
2001). This may be because a large number of different mutation seem able to 
cause PKD1, and PKD1 itself is a large mutational target (12,906bp coding region). 
Also, PKD1 is unusually CpG rich, meaning it contains more highly mutable 
sequences (Rossetti et al. 2001). Clinical bias may exist, as PKD1 disease is more 
severe than PKD2, it is more likely to come to clinical attention. PKD2 is often 
subjected to truncating mutations (as in PKD1), with up to 91.5% of mutations 
causing a truncated protein product (Rossetti etal. 2007) (Figure 1.8).
1.2.7 Genotype I phenotype correlations
The phenotypes arising from ADPKD are highly variable in penetrance, both in terms 
of the severity of renal disease and the characteristics of any associated extra-renal 
lesions (Rossetti et al. 2007). However, PKD1 mutations will generally result in a 
more severe disease than PKD2. This includes a younger age of clinical 
presentation and accelerated kidney failure, with ESRD occurring around 20 years 
earlier (54.3 years versus 74 years) (Hateboer et al. 1999, Torra et al. 1996).
Clinical variability, the lack of mutation hotspots and a wide range of mutations have 
made specific genotype / phenotype correlations hard to make in ADPKD (Gallagher 
et al. 2011). However, it appears mutations in the 5’ region of PKD1 (0-7812bp) lead 
to more severe disease (earlier onset of ESRD) compared to patients with 3’ 
mutations (7812bp and on) (Qian et al. 2002, Rossetti et al. 2002, Watnick et al.
1999). It also appears that splice site mutations tend to result in a milder renal 
phenotype than other mutation types (Magistroni et al. 2003).
Sex also plays a significant role in ADPKD progression. Male gender has been 
associated with a poorer outcome in PKDf-linked families (Gabow et al. 1992). 
Similarly, female ADPKD2 sufferers had a later average age of ESRD compared to 
males (76.0 years versus 68.1 years) (Rossetti et al. 2007). This perhaps correlates 
with the data obtained from MRI studies of kidney volume and cyst size that show 
the rate of cystic expansion to be higher in men than women (Harris et al. 2006).
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Figure 1.8 Mutational analysis of PKD1 and PKD2
PKD1 
-85% of ADPKD cases
Missense 
(19%)
licing defects 
(14%)
deletions (6%)
Nonsense (33%)
Frameshift (28%)
PKD2 
■15% of ADPKD cases
Other (1%)Missense (6%)
Splicing defects 
(17%) - -
Nonsense (37%)
Frameshift (39%)
es and frequencies of mutations found at the ADPKD loci (Rossetti et al. 2001, 
setti et al. 2007, Magistroni et al. 2003). Large deletions of PKD1 (and contiguous 
Jtion of TSC2) are not included in the data, although this is thought to be a very rare 
jrrence. Neither PKD1 nor PKD2 have mutation hotspots.
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1.2.8 Loss of heterozygosity and haploinsufficiency in ADPKD
The renal cysts associated with ADPKD are focal and sporadic (Pei et al. 2001). 
These lesions also form in an age-dependent manner (Gabow et al. 1991), 
consistent with a ‘two-hit’ process (analogous to Knudson’s classic model for 
carcinogenesis) (Reeders 1992). Independent studies have reported ADPKD cysts 
are monoclonal, with LOH found in 17-24% of those sampled (Qian et al. 1996, 
Brasier et al. 1997). Up to 30% of the hepatic cysts seen in ADPKD (PKD1) also 
have second hits (Watnick et al. 1998). Liver cysts from ADPKD patients with a 
PKD2 mutation show a similar frequency of second hits (Pei et a i 1999, Torra et al. 
1999, Koptides et al. 1999). Interestingly, groups have noted PKD1 inactivating 
mutations in cysts from patients with a PKD2 mutation, and the converse, PKD2 
somatic mutations in cysts from patients with PKD1 mutations. This implies a trans- 
heterozygote two-hit model of cystogenesis could operate with the polycystin 
proteins (Watnick et al. 2000, Koptides et al. 2000). Under these circumstances, a 
cyst from a PKD1 patient with apparently functional polycystin-1 may have suffered a 
separate mutation in PKD2, changing what may be termed haploinsufficient 
cystogenesis to a trans-heterozygote two-hit model of progression.
However, a two-hit model of cystogenesis does have some inconsistencies with 
reported data. If second hits are indeed required for cystogenesis in ADPKD, a 
higher rate of somatic mutations would be expected in the cysts (Jiang et al. 2006). 
Using a highly sensitive screening method, all 15 exons and splice junctions in the 
PKD2 gene were analysed and somatic hits were detected in 71% of cysts from 
ADPKD patients with a PKD2 mutation (Watnick et al. 2000). A large proportion of 
cysts appear show no second hit. Another concern is the strong immunoreactivity for 
polycystin-1 and polycystin-2 seen in the majority of cyst epithelia (Ong et al. 1999a, 
Ong et al. 1999b). Mutations leading to IHC-detectable but non-functional protein 
may account for this discrepancy, but the vast majority of PKD mutations identified to 
date are stop or frame-shifting changes (Figure 1.8). While trans-heterozygosity may 
be put forward to explain both these phenomena, it is only seen in approximately 
10% of ADPKD cysts and cannot account for all the instances of single-hit and/or 
polycystin expressing cysts (Pei 2001, Lantinga-van Leeuwen etal. 2004).
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What may explain the failings of a two-hit model in a proportion of ADPKD cysts is 
haploinsufficiency, or gene dosage. Alterations in polycystin levels outside of a 
normal physiological range have been shown to cause renal cysts in ADPKD animal 
models. A reduced dosage (but not complete loss) of wild type Pkd1 was sufficient 
for cystogenesis in a mouse line with a hypomorphic Pkd1 allele (with only 15-20% 
normally spliced polycystin-1) (Lantinga-van Leeuwen et al. 2004). Jiang et al. 
(2006) found similar results in a conditional Pkd1 knockout mouse model. The 
haploinsufficiency effect has also been demonstrated in Pkd2 mice. Chang et al. 
(2006) found a highly elevated proliferative index in non-cystic tubules of Pkd2 
heterozygote mice, 5-10 times that of wild-type controls.
Taken together, these data suggest complete loss of polycystin-1 or polycystin-2 may 
not be strictly required for development of ADPKD (Jiang et al. 2006). The primary, 
germline mutation can, in a low but significant number of cases, lead to spontaneous 
cystogenesis. The focal and age-dependent nature of ADPKD cyst formation implies 
second hits are occurring and driving cyst formation in many lesions, but the two-hit 
model cannot account for all the cystogenesis seen. A reduction in gene dosage may 
well need additional factors, such chemical or physical renal injury and hits outside 
or in the polycystin-1/2 pathway to induce cystogenesis. It is important to note there 
may bias when screening for second hits, which would mask haploinsufficient cyst 
formation. Later lesions may acquire further mutations to both the PKD1 and PKD2 
loci as the cyst progresses. What was an initial driver mutation (and absolutely 
required for cystogenesis) and what was acquired as the cyst progressed (as a result 
of increased cell proliferation, poor cell cycle control and genetic instability) may 
become poorly defined.
1.2.9 Biochemistry of the ADPKD proteins
Polycystin-1 (Figure 1.9) is 4302 amino acids in length, of which, 3074 residues 
constitute a large extracellular domain. It has a total of 11 transmembrane spanning 
segments and a short, highly charged cytoplasmic tail (197 residues) (Hughes et al. 
1995, Nims et al. 2003, Weston et al. 2003). The extracellular domain contains 
several motifs for protein-protein and protein-carbohydrate interactions (Hughes et 
al. 1995, Sandford et al. 1997), a receptor egg jelly (REJ) domain (Moy et al. 1996), 
and a G protein coupled receptor proteolytic site (GPS) (Ponting et al. 1999).
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Following autoproteolytic cleavage at the GPS site, an extracellular NH2-terminal 
fragment is released. This cleavage appears to be essential for normal function 
(Qian et al. 2002). The remaining COOH-terminal fragment stays tethered to the cell 
membrane (Qian et al. 2002). Several groups have suggested that the cytoplasmic 
tail of polycystin-1 also undergoes cleavage. Chauvet et al. (2004) found the C- 
terminal tail to translocate to the nucleus following cleavage, where it modulates 
gene transcription. Low et al. (2006) report that a different fragment can be produced 
from the C-terminus that is able to interact with STAT6 and p100 to stimulate 
transcription. The protein is likely to play a role as a receptor for an unknown ligand 
(Torres et al. 2007), and is able to form a functional complex with polycystin-2 (Qian 
et al. 1997) through C-terminal tail interactions. Table 1.6 lists these domains and 
their functions in full.
The C-terminal tail of polycystin-1 can also be phosphorylated at several sites. Cyclic 
adenosine monophosphate (cAMP) - dependent kinase A phosphorylates polycystin- 
1 at S4159 and S4252, while T4237 may be phosphorylated by c-src (Parnell et al. 
1999, Li etal. 1999).
Polycystin-2 (Figure 1.9) is a non-selective cation channel with a high permeability to 
calcium ions (Ca2+). It is a 968 amino acid protein with 6 transmembrane domains, 
with both C and N termini extending into the cytoplasm (Koulen et al. 2002). It has 
been localised to both the plasma membrane and the endoplasmic reticulum 
(Witzgall 2005), and it appears shuttling proteins such as PIGEA-14 (polycystin-2 
interactor, Golgi and endoplasmic reticulum associated protein with a molecular 
weight of 14 kDa) may determine its final location. Polycystin-1 has also been shown 
to localise polycystin-2 to the plasma membrane (Hanaoka et al. 2000), and 
together, the polycystin-1- polycystin-2 complex is thought to function as a receptor- 
ion channel complex, in which polycystin-1 regulates the activity of polycystin-2 
(Delmas et al. 2002, Delmas et al. 2004). An EF-hand domain (EF stands for the E 
and F helices of parvalbumin) is present on the C-terminus of polycystin-2 and is 
able to co-ordinate Ca2+ ions. This is thought to induce conformational changes in 
the whole protein and may modulate polycystin-2 channel functions (Cai et al. 1999). 
Table 1.6 lists these domains and their functions in full.
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Polycystin-1
Extracellu lar
Intracellu lar
Cell wall integrity and stress response component
PKD domain
C-lectin domain
Low density lipoprotein A
REJ module
GPS domain
Polycystin-2
Transmembrane region
Lipoxygenase homology 
Cysteine-rich region
Leucine-rich region
G-protein activation sequence
EF hand, calcium binding domain
Endoplasmic reticulum retention signal
COOHCOOH
PC1 and PC2 interact via their C-terminal tails. Details of domains and regions of homology are contained in the key. Domain 
functions are listed in table 1.5. Arrow heads indicate potential cleavage sites required for normal function. Adapted from Torres 
et al. 2007. Domains not drawn to scale
Table 1.6 Domains and functions of polycystin-1 and polycystin-2
Polycystin-1
Protein domain Function
Cell wall integrity and stress 
response com ponent (W S C )
Carbohydrate-binding domain, may be acting as a regulator of stress 
response pathways (Weston et al. 2003).
Extracellular PK D  dom ains Immunoglobulin-like repeats, involved in cell-cell adhesion in a 
calcium-independent manner (Ibraghimov-Beskrovnaya et al. 2000).
C-Lectin dom ain Ca2+-enhanced cell adhesion through binding carbohydrate matrices 
and collagen I, II and IV in vitro (Weston et al. 2001).
Low density lipoprotein A  
(LD L-A)
Hydrophobic nature implies a ligand binding site. Studies unable to 
confirm its predicted presence in PC1 (Weston etal. 2003).
Receptor for egg jelly (R EJ) 
domain
Module is a known regulator of ion transport, likely to support Ca2+ 
influx (Weston et al. 2003, Ikeda et al. 2002).
G-protein coupled receptor 
proteolytic site (G P S )
Endogenous cleavage site, lysis is dependent on the presence of the 
adjacent REJ module (Ponting et al. 1999, Qian et al. 2002).
Lipoxygenase homology 
(LH 2)
Mediates interactions with other membrane proteins and appears 
crucial for normal PC1 function (Bateman et al. 1999).
Cysteine-rich regions (C R R ) Usually flank LRRs and aid in their adhesive properties (Kobe et al. 
1994).
Leucine-rich repeats (LR R ) Provides structural framework for the formation of protein-protein 
interactions, also involved in cellular adhesion (Kobe et al. 2001).
G-protein activation  
sequence
Intracellular domain that binds and activates G-proteins in a process 
physically regulated by PC2 (Parnell et al. 1998, Delmas et al. 2002).
Polycystin-2
Protein domain Function
EF-hand, calcium binding 
dom ain
A Ca2+ binding motif, undergoes Ca2+-dependent conformational 
changes and regulates ion channel function (Petri et al. 2010).
Endoplasm ic reticulum  
retention signal
Anchors PC2 at the endoplasmic reticulum, trafficking proteins such 
as PIGEA-14 deliver PC2 to plasma membrane (Witzgall 2005).
Polycystin-1 and Polycystin-2
Protein domain Function
Coiled-coil domain Protein-protein interaction domain that binds the C-terminal tails of 
PC1 and PC2 (Foggensteiner etal. 2000, Qian etal. 1997).
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1.2.9.1 Polycystin-1 and polycystin-2 associate in vivo
Mutations in PKD1 or PKD2 disrupt the same pathway and give rise to identical 
symptoms, suggesting a co-dependency and implying physical interaction is required 
for function. Polycystin-1 and polycystin-2 have been proved to associate in vivo and 
modulate their cellular location. A C-terminal endoplasmic reticulum retention signal 
on polycystin-2 leads to its accumulation in the ER membrane when polycystin-1 is 
absent (Hanaoka et al. 2000). Polycystin-1 expression allows polycystin-2 to localise 
to the plasma membrane, although polycystin-2 may have important roles to play as 
a Ca2+ channel in both these subcellular regions. Through a coiled-coil domain on 
their C-termini, polycystin-1 and polycystin-2 have been shown to interact and form a 
receptor-channel mechanosensory complex at the cell membrane (Nauli et al. 2003). 
The extent of polycystin-1 or polycystin-2 functionality outside of this complex is 
currently unknown. For example, polycystin-1 can be cleaved in several places and 
fulfil a signalling role which may be polycystin-2 -independent, but instead restricted 
by subcellular localisation. Polycystin-2 has been shown to localise to the cell 
membrane in polycystin-1 knockout mice, suggesting membrane-targeting can be 
polycystin-1-independent (Geng et al. 2006). Figure 1.9 shows polycystin-1 and 
polycystin-2 interacting at the cell surface membrane.
1.2.9.2 Tissue expression patterns of the ADPKD proteins
The ADPKD proteins have a wide expression pattern slightly at odds with their 
specific pathology of renal and hepatic tissue in disease. Both are expressed in the 
kidney, liver, brain, pancreas and vasculature (Wilson 2001). Expression of 
polycystin-1 is developmentally-linked, and the high levels seen during tissue 
development tail off to a low level in adult life (Geng et al. 1997, Van Adelsberg et al.
1997). Renal levels of polycystin-1 peak at E15 in mice and fall to a low level by two 
weeks post-birth (Geng et al. 1997). This is around the time mice with a homozygous 
mutation in Pkd1 will die, suggesting a crucial role for polycystin-1 in embryogenesis 
at this stage. Renal polycystin-1 expression is predominantly in the collecting duct 
and distal convoluted tubules (Braun 2009), although Foggensteiner et al. (2000) 
found lower expression in most areas of the nephron.
Despite many theories of co-dependence, polycystin-2 has a different renal 
expression pattern to polycystin-1 and is present at higher levels in tubule cells
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throughout adult life, especially the thick ascending Loop of Henle and the distal 
convoluted tubule (DCT) (Foggensteiner et al. 2000). This seems slightly at odds 
with the view that polycystin-1 and polycystin-2 function solely as a receptor-channel 
complex and adds weight to the idea that polycystin-2 at least, may have roles 
outside the polycystin complex.
Polycystin-1 and polycystin-2 have recently been linked to the primary cilium of renal 
tubules in vivo and in cell culture, placing the mechanosensory complex at the 
luminal surface of collecting ducts in the kidney (Nauli et al. 2003, Yoder et al. 2002, 
Luo et al. 2003). Figure 1.10 outlines the renal and subcellular locations of 
polycystin-1 and polycystin-2.
1.2.9.3 Polycystin-1 and polycystin-2 signalling pathways
The polycystin-1 / polycystin-2 receptor-channel complex has been localised to both 
the ER membrane and the outer plasma membrane, at organelles called primary 
cilia. The most well characterised functions of the polycystin-1 / polycystin-2 complex 
are its roles in mechanosensatisation and cellular Ca2+ modulation, but the 
polycystins also have links to other significant processes, such as the mTOR and 
Wnt pathways.
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Figure 1.10 Renal distribution of polycystin-1 and polycystin-2
PC1 and PC2 are expressed throughout the body, in the brain, vasculature, liver 
and pancreas. Both are expressed in renal tissue, especially during 
development. PC1 is expressed predominantly in the distal convoluted tubule 
and collecting ducts, while PC2 is expressed mainly in the distal convoluted 
tubule and Loop of Henle. Both transmembrane proteins are known to localise to 
the primary cilium, present on almost all renal tubule cells. PC1 and PC2 also co- 
localise to the ER membrane.
Legend
Polycystin-1
Polycystin-2 
Polycystin-1 and 2
1.2.9.3.1 Primary cilia and calcium signalling
Primary cilia (Figure 1.11) are single, hair-like structures that protrude from the apical 
surface of most eukaryotic cells, including renal tubule cells and hepatic bile duct 
cells (cholangiocytes). Primary cilia consist of 9 microtubule (MT) doublets (9+0 
arrangement) while motile cilia generally have an extra central doublet (9+2 
arrangement) (Hildebrandt et al. 2005). Dynein arms linking MTs are present only on 
motile cilia, allowing ATP-dependent conformational changes in MT structure to 
result in cilia movement (Fliegauf etal. 2007).
Primary cilia are sensory organelles that are highly conserved throughout evolution. 
Although it appears they can detect a wide variety of chemical and physical stimuli, 
the specific function they carry out depends on the cell type (Hildebrandt et al. 2005). 
Renal primary cilia extend into the tubule lumen and sense fluid flow (urine) through 
the nephron. Fluid flow results in cilium deflection and this is immediately followed by 
an influx of extracellular Ca2+ mediated by the polycystin proteins (Praetorius et al. 
2001, Praetorius et al. 2003, Nauli et al. 2003). The large extracellular region of 
polycystin-1 may be able to sense fluid sheer stress as the cilia bends and transmit 
this mechanical information to associated polycystin-2. The Ca2+ channel properties 
of polycystin-2 would then be modulated to trigger an influx of Ca2+ across the cilium 
membrane. High levels of cellular Ca2+, in response to adequate polycystin-1 
stimulation, are proposed to trigger Ca2+-induced Ca2+-release. The heightened 
levels of intracellular Ca2+ can then produce downstream effects such as growth, 
differentiation, alter gene expression and polarity (Nauli et al. 2003). Cells isolated 
from mice lacking functional polycystin-1 showed abnormal Ca2+influx in response to 
physiological fluid flow (Nauli et al. 2003).
Interestingly, lowering the levels of Ca2+ in wild-type renal epithelial cells reproduces 
the altered proliferative response of cyst-derived cells, while restoring Ca2+ to cyst- 
derived cells can dampen their responses to mitogenic stimuli (Yamaguchi et al. 
2004, Yamaguchi et al. 2006). This suggests disruption of the primary cilium, or the 
amount of polycystin-1 12 present in the primary cilium could disrupt Ca2+ 
homeostasis and dysregulate processes involved in cystogenesis such as 
proliferation.
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Figure 1.11 Primary cilia, polycystins and calcium signalling
Ca2+induced
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Main: Primary cilia consist of 9 microtubule doublets that project from 9 triplet 
microtubules of the basal body complex. Motile cilia have a similar structure but an 
additional central couplet of microtubules. Additional dynein arms present only on motile 
cilia have an A TPase activity and allow movement with energy usage. Cilia are 
assembled through intraflagellar transport (IFT), which involves anterograde and 
retrograde trafficking of ciliary proteins. Although the cilia membrane may appear an 
extension of the cell plasma membrane, it is structurally and functionally distinct, filtered 
by a ‘transition zone’. The distal tips of cilia are bound to microtubule capping structures 
(the tip complex) and this links the microtubule doublets and the ciliary m embrane via 
structural filaments. Information from Eley et al. 2005. Both PC1 and PC2 have been 
localised to the ciliary membrane, where they are thought to function as a sensory 
complex and render the cell responsive to its external environment. Inset: In the kidney, 
renal tubule cell primary cilia project into the lumen, and the PC 1/PC 2 mechanosensory 
complex is able to act as an antenna, sensing fluid movement past the cell. Ciliary 
movement is transduced through PC1 to the Ca channel, PC2. The resulting activation 
renders the mem brane permeable to extracellular C a2+ and sufficient stimulation will 
result in C a2+ induced C a2+ release from cellular stores. High levels of cellular C a2+ are 
thought to control many processes, primarily maintaining an epithelial phenotype (Deane  
et al. 2007). An absence of fluid flow, or a loss of PC1 or PC2, leads to reduced C a2+ 
influx. Information from Nauli etal. 2003.
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1.2.9.3.2 JAK-STAT pathway
The STAT (signal transducer and activator of transcription) proteins are phospho- 
tyrosine activated transcription factors latent in the cytoplasm (Calo et al. 2003). 
Activation is normally transient, tightly regulated and achieved though stimulated 
members of the Janus Kinase (JAK) family, tyrosine kinase growth factor receptors, 
non-receptor tyrosine kinases and seven transmembrane pass receptors. STATs 
participate in normal cellular processes such as differentiation, proliferation, cell 
survival/apoptosis and angiogenesis (Horvath 2000).
The JAK-STAT signalling pathway has been suggested to mediate polycystin 
signalling (Bhunia et al. 2002, Low et al. 2006) and at least two STATs are involved 
-  STAT6 and STAT1. Polycystin-1 is able to bind and activate JAK2 but not JAK1 
(Low et al. 2006), providing a direct link to activation of the pathway.
Under fluid flow stress, polycystin-1 localised to renal tubule cell primary cilia is 
subject to C-terminal cleavage (Chauvet et al. 2004, Low et al. 2006). The resulting 
intracellular fragment has been shown to fulfil a signalling role by translocating to the 
cell nucleus and binding DNA through association with STAT6 and P100 (Low etal. 
2006). Cells lining ADPKD cysts have elevated nuclear STAT6, P100 and C-terminal 
polycystin-1 fragments (Low et al. 2006). The researchers propose that polycystin-1 
is acting as a regulator of STAT6 signalling through spatial control. Under normal 
conditions, STAT6 is sequestered to the cell membrane via polycystin-1, but in the 
absence of fluid flow (renal injury) or if reduced levels of polycystin-1 are present, 
STAT6 is able to constitutively initiate STAT6-dependent transcription.
Bhunia et al. (2002) have shown polycystin-1 to directly activate JAK-STAT 
signalling though physical interaction with JAK2, but not JAK1 or Tyk2. The 
activation of JAK2 was found to be dependent on polycystin-2, and resulted in the 
activation of STAT1 and STAT3. Talbot et al. (2011) have recently reported similar 
activation of STAT3 via polycystin-1 in manner dependent on the C-terminal 
cytoplasmic tail. Furthermore, Stat3 was found to be activated in the cysts of an 
ADPKD mouse model. Data now suggests polycystin-1 can differentially regulate 
STAT1, 3 and 6 signalling, depending on factors such as apical fluid flow, polycystin-
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1 cleavage and cytokine/growth factor signalling environment of the cell (Talbot et al. 
2011 ).
1.2.9.3.3 Cell cycle control
The cysts seen in ADPKD are typically lined with a single layer of hyperproliferative 
epithelium (Nadasdy et al. 1995). Links between the polycystin proteins and cell 
cycle control have emerged recently (Figure 1.12). Li et al. (2005) have shown 
polycystin-2 can regulate the cell cycle through direct interaction with Id2, a member 
of the helix-loop-helix (HLH) protein family. Id2 is a transcription factor that promotes 
cellular growth and therefore requires nuclear localisation to function (Pagliuca et al.
2000). The PKD2 gene transcribes a repressor of this activity, as polycystin-2 / Id2 
complexes are excluded from the nucleus. While Id2 has a low level of expression in 
normal kidneys, in renal cysts from ADPKD patients, levels of Id2 are raised, with 
increased amounts of nuclear localisation (Li et al. 2005). The same paper showed 
polycystin-2 / Id2 interactions require polycystin-1-dependent Serine phosphorylation 
of polycystin-2, explaining why raised nuclear Id2 is found in both ADPKD 1 and 
ADPKD2.
The CDK inhibitor, p21 is induced by polycystin-1 overexpression and is 
downregulated in cystic kidneys from ADPKD patients (Bhunia et al. 2002). 
Polycystin-1 is thought to control expression of p21 though the JAK-STAT signalling 
pathway in polycystin-2-dependent manner (discussed in 1.2.9.3.2). Interestingly, 
nuclear Id2 can repress transcription of p21 and promote cell cycle progression in 
kidney cells (Li et al. 2005). The full extent of polycystin control over cell cycle 
progression is not yet known, but clearly proliferation is perturbed in ADPKD 
cystogenesis.
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Figure 1.12 The polycystins and cell cycle control
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PC1 and PC2 have direct links to cell cycle control through the transcription factors 
STAT1 and Id2. The transm em brane PC1 is able to directly interact with JAK2 (Bhunia et 
al. 2002) and activate the kinase to phosphorylate free cytosolic STAT1. The activation of 
JAK2 is dependent on both PC1 and PC2. Phospho-STAT dimerises in the cytosol and 
translocates to the nucleus, where it binds specific response elements. One target of 
activated STAT1 is the p21 gene, W A F-1. p21 is a cyclin dependent kinase inhibitor, and 
therefore a repressor of cell cycle progression. Under normal conditions, the Id2 
transcription factor is bound to PC1-dependent phosphorylated PC2 and sequestered  
from the nucleus. Under pathologic conditions, with a mutation in PC1 or PC2, Id2 is free  
to  translocate to the nucleus, where it can promote cell proliferation through modulation of 
several genes. This includes repression of the p21 CDK inhibitor. Information from 
Bhunia etal. 2002, Li et al. 2005.
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1.2.9.3.4 Canonical Wnt signalling
Canonical Wnt signalling (Figure 1.13) functions through altering levels of active and 
nuclear-localised p-catenin. In doing so, it controls cell proliferation and 
differentiation during development (Moon et al. 2005). The first clues that PKD and 
canonical Wnt signalling may have a link came through phenocopy mouse models. 
Transgenic expression of constitutively active p-catenin or kidney-specific 
inactivation of APC (a crucial component of the pathway) leads to a renal cystic 
phenotype (Karner et al. 2009, Qian et al. 2005, Saadi-Kheddouci et al. 2001). A 
direct connection between polycystin-1, polycystin-2 and Wnt signalling remains 
contentious. The C-terminus of polycystin-1 may activate p-catenin transcription in 
human embryonic kidney cells (Kim et al. 1999), but other more recent studies have 
suggested polycystin-1 has no such role (Le et al. 2004, Low et al. 2006) or is doing 
the opposite, in acting as an inhibitor of p-catenin-mediated transcription (Lai et al.
2008).
1.2.9.3.5 mTOR signalling
Activation of mTOR results in increased protein translation and cell growth 
(Gallagher et al. 2011). While the pathway is known to be stimulated by a variety of 
inputs, feeding through the TSC proteins, several links have emerged between 
polycystin-1, polycystin-2 and mTOR. Studies have demonstrated that downstream 
targets of the mTOR pathway are inappropriately activated in ADPKD cysts 
(Shillingford et al. 2006). Additionally, repression of the mTOR pathway through 
Rapamycin treatment reduces cystogenesis in rodent models of PKD (Shillingford et 
al. 2006, Wahl et al. 2006, Tao et al. 2005). A trial by Qian et al. (2008) also 
highlighted a use for Rapamycin in reducing polycystic liver volume in ADPKD 
patients. Distefano et al. (2009) have since suggested polycystin-1 inhibits the 
mTOR pathway in a TSC2 dependant manner, while Shillingford et al. (2006) have 
previously shown the C-terminal cytoplasmic tail of polycystin-1 to interact with 
tuberin. It has been suggested that a function of the polycystin-1 tail may be to 
assemble a repressive complex with tuberin and mTOR. In a disease state where 
PKD1 is mutated, the tuberin-mTOR complex cannot form correctly, leading to 
aberrant mTOR activation (Shillingford etal. 2006, Mostov et al. 2006).
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Figure 1.13 The canonical Wnt signalling pathway
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Left panel: W hen the W nt receptor complex is not bound to a W nt ligand, the intracellular 
p-catenin turnover complex (consisting of APC, axin and GSK3P) sequesters available p- 
catenin. Following CK-1 phosphorylation of P-catenin on Ser 45, GSK3p further 
phosphorylates p-catenin at specific residues Thr 41, Ser 37 and Ser 33. This 
hyperphosphorylated form of p-catenin is recognised by a ubiquitin ligase and removed 
for ubiquitination and degradation. Through this continual turnover, levels of P-catenin are 
kept low in the absence of a W nt signal. In the nucleus, under low levels of p-catenin, 
Groucho binds TC F  (T-cell factor) elements and inhibits transcription of W nt target genes. 
Dkk is able to further inhibit W nt signalling through binding the LRP portion of the co- 
receptor complex.
Right panel: Following the binding of a W nt ligand to the Fz/LRP co-receptor complex, 
Dkk is displaced and the canonical W nt signalling pathway is activated. Binding of ligand 
to receptor induces a conformational change in the cytosolic region of Fz, allowing Dsh to 
be recruited to the m em brane and phosphorylated. Activated Dsh can in turn recruit Axin 
to the cell surface m em brane and this leads to the dissociation of the p-catenin turnover 
complex. With no turnover complex to target P-catenin for degradation, levels of this 
protein accumulate and translocate to the nucleus. Groucho is displaced by p-catenin  
from T C F  regions and transcription of W nt target genes is initiated. Information from  
Eisenmann 2005.
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1.2.10 Mouse models of PKD
Mouse models have been generated from spontaneous mutations, random 
mutagenesis and targeted transgenic approaches. Several models (cpk, bpk, orpk, 
pcy, and Pkd2WS25/') have been used to test potential therapies (Torres et al. 2007). 
The ideal mouse model will carry a mutation in an orthologous gene to the human 
disease gene and reproduce the phenotypic effects faithfully (Torres et al. 2007). 
Few, if any, of the PKD mice meet this specification. An animal may capture the 
renal phenotype nicely (the cpk line for example (Preminger et al. 1982)) but the 
disease-causing gene (Cys1, in this case) is not associated with renal pathology in 
humans.
Pkd1 and Pkd2 mutant mice have been generated, but the renal phenotype in 
heterozygous animals is often normal or mild, with late onset cystogenesis (Torres et 
al. 2007, Guay-Woodford 2003). Homozygous mutations are embryonically lethal. 
There are exceptions to the mild cystogenesis {Pkd1nl and Pkd2WS251') but phenotypic 
variability is a problem in these animals (Torres et al. 2007). While mice with mild 
phenotypes may not be useful for therapeutic testing, they can capture the 
processes behind a cyst forming. Boulter et al. (2001) have produced a Pkd1del17' 
21(5960 mouse with a truncating mutation in the Pkd1 gene, replacing exons 17-21 with 
a lacZ-neomycin fusion gene (Pgeo) downstream of a splice acceptor site and an 
internal ribosome entry site. The mutant Pkd1 transcript encodes a truncated form of 
polycystin-1 that only includes the extracellular domains of the protein. Homozygous 
Pkdtdel17-21^ eo mice die in utero at E13.5-E14.5 due to severe developmental defects 
involving the heart and skeletal tissue (Boulter et al. 2001).
By 9 months, approximately 50% of p ^ 66117'21^ 0 mjce wj|| have developed renal 
cysts, with some forming as early as 3 months. These are similar to human ADPKD 
lesions (cysts lined with hyperplastic or apoptotic cells), and arose throughout the 
nephron. Liver cysts are occasionally found in heterozygous pkcndel17-21P9eo mjce 
later in life (Boulter et al. 2001).
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1.3 Theories of cystogenesis in TSC and ADPKD
It is unclear why renal tubules and hepatic bile ducts form cysts in TSC and ADPKD. 
Many theories exist, with plenty of scope for cross-talk between them. Interestingly, 
Torres et al. (1999) have suggested multiple causes can all lead to a remarkably 
similar cystic phenotype.
1.3.1 The nature of cysts in TSC and ADPKD
TSC renal cysts can be unilateral or bilateral, diffuse or localised. They are found in 
the cortical region of the kidney, often in the most superficial areas and then later 
extend into the medulla. Large cuboidal cells resembling the tubule epithelium line 
these cysts, often in a monolayer, with an eosinophilic cytoplasm and 
hyperchromatic nucleus. Cells may pile up and protrude into the centre of the cysts, 
forming a multicellular projection and eventually, a branch. This ‘piling-up’ 
distinguishes a TSC cyst from an ADPKD cyst (Cook et al. 1996). Lesions arise 
through clonal expansion of a single cell (Kwiatkowski et al. 2002). Some lesions in 
TSC are thought to be hormone driven (such LAM) but renal cysts do not appear to 
be influenced in this manner (Cook et al. 1996). Whether cyst incidence increases 
with age is a contentious issue - conflicting studies have found both positive (cohort 
of 167, Rakowski et al. 2006) and no association (cohort of 139, Cook et al. 1996).
ADPKD renal cysts have a similar medulla-cortical distribution as TSC cysts and are 
lined by a proliferating layer of epithelial cells. They show characteristic 
mislocalisation of proteins such as Na+K+-ATPase (sodium pump) (Wilson et al. 
1991). Cysts develop after gradual tubule dilation (commonly the proximal and distal 
tubules) following abnormal periods of proliferation, apoptosis and fluid 
accumulation. ADPKD cysts that started as a tubule diverticulum will eventually 
separate from parent tubules and become sac-like structures reaching up to 10cm 
(Boletta et al. 2003). Most ADPKD cysts develop from clonal expansion of single 
cells (Qian et al. 1996), and are able to secrete a rich cocktail of cytokines and 
growth factors. These can act in a paracrine, endocrine or autocrine fashion to 
promote, cell proliferation, vasculistion or matrix remodelling (Ye et al. 1992, 
Munemura et al. 1994). Figure 1.14 illustrates the similarities between cysts in TSC 
and ADPKD.
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ADPKD hepatic cysts arise from dilation of biliary microhamartomas, which in turn 
result from an overgrowth of the biliary epithelium of the intralobular ductules (Qian 
et al. 2003). The liver cyst epithelium retains characteristics of the biliary epithelium 
and is able to secrete fluid in response to secretin stimulation (Everson et al. 1990). 
As in the ADPKD kidney, hepatic cyst development is clonal (Nichols et al. 2004) 
and may be hormonally augmented, with lesions rarely observed before puberty 
(Everson et al. 2004) and enlarged livers reported in women with ADPKD 
undergoing oestrogen therapy (Sherstha et al. 1997). However, cyst initiation may 
not be hormone dependent, as men and women share an equal lifetime risk of 
ADPKD hepatic cysts (Everson et al. 1993). Liver cyst epithelium shares the ability of 
renal cysts to secrete a rich but distinct profile of cytokines and growth factors 
(Nichols et al. 2004). As in the kidney, hepatic cyst incidence increases with age 
(Masyuk et al. 2006). As in TSC and ADPKD renal lesions, hepatic cysts 
demonstrate dysregulated mTOR and are Rapamycin sensitive (Spirli et al. 2010).
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Figure 1.14 Cystogenesis in TSC and ADPKD
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1.3.2 Primary cilia theory of cystogenesis
Defects in primary cilia have been implicated in many forms of cystic disease and 
can have profound consequences for cellular homeostasis (Boletta et al. 2 003, 
Hildebrandt et al. 2005). Table 1.7 lists some of the major cystic kidney diseases and 
their associated genes. Evidence for a link between dysfunctional primary cilia and 
renal cystogenesis is provided by the fact that nearly all genes mutated in cystic 
kidney disease are expressed in the primary cilia, basal body or centrosome 
proximal to the primary cilium (Watnick et al. 2003). Both the TSC (Hartman et al.
2009) and ADPKD (Yoder et al. 2002) proteins have been localised to the primary 
cilia. The cilium is a focal point for many signalling pathways, and as such, a ciliary 
theory of cystogenesis is a collection of hypotheses.
As previously discussed, primary cilia are able to bend under fluid flow in renal 
tubules to trigger a rise in intracellular Ca2+. This is suggested to help maintain an 
epithelial phenotype and suppress growth (Boletta et al. 2003). In the absence of this 
signalling input, epithelial cells dedifferentiate and undergo changes that promote the 
formation and enlargement of cysts, including an elevated level of cAMP (discussed 
in section1.3.6) (Deane etal. 2007).
Aside from modulation of cellular Ca2+ and cAMP levels, cilia have been implicated in 
other flow-sensitive signalling pathways (Deane et al. 2007). The C-terminal domain 
of polycystin-1 is subject to cleavage in a flow dependent manner. The resulting 
polycystin-1 fragment can translocate to the nucleus in a complex with STAT6 and 
P100 and activate the AP-1 pathway (Chauvet et al. 2004). Loss of control over this 
particular aspect of cell signalling, through renal injury or a lack of functional ciliary 
localised polycystin-1, may give rise to cystic changes.
Furthermore, under fluid flow primary cilia are able to act as a switch between 
canonical and non-canonical Wnt signalling by increasing levels of the cilium- 
localised protein Inversin (Simons et al. 2005). During early embryonic development, 
canonical Wnt signalling is important for metanephric mesenchyme induction and 
cell proliferation during branching morphogenesis (Perantoni 2003). Later in 
development, signalling switches to non-canonical Wnt, or planar cell polarity (PCP) 
pathway (Park et al. 2005, Veeman et al. 2003, Wallingford et al. 2005), which is
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required to align mitotic orientations occurring within renal tubules. In this manner, 
tubules can lengthen without increasing their diameter (Fischer et al. 2006). 
Defective switching between canonical and non-canonical Wnt signalling may have 
pathogenic effects in renal tubules. Cyst formation is associated with increased 
numbers of cells in the tubule circumference (Bisgrove et al. 2006), and this may well 
be a result of aberrant polarity signalling and increased cell proliferation.
The cilium itself may also have direct role in cell cycle regulation (Pan et al. 2007). 
During GO phase, the cilium is assembled and projects from the basal body. Before a 
cell can re-enter the cell cycle, the primary cilium must first be disassembled and 
reabsorbed. At this point, the basal body converts back to a centriole and duplicates 
to form two centrosomes that will eventually form the poles of the mitotic spindle 
apparatus. Upon completion of mitosis, the centriole returns to a basal body complex 
and cilia assembly is resumed. Because the primary cilia and cell cycle are so 
closely linked, researchers have suggested a regulatory role for the cilium itself in 
this process. The presence of a primary cilium (regardless of the numerous other 
signalling roles it may be fulfilling) could be enough to block cell cycle progression. 
Therefore, defects in cilium structure may reduce the control of the primary cilium 
over this cycle and lead to aberrant proliferation and misaligned centrioles.
Despite the large body of evidence accumulating in favour of a ciliary hypothesis, it is 
important to note the distinction between passenger and driver causes of 
cystogenesis. Due to the highly polar nature of the primary cilium, it may be 
disrupted as a consequence of other, more fundamental changes in cell physiology 
caused by reduced levels of the TSC or ADPKD proteins. There is no doubt that 
once perturbed, the cilium can disrupt cell homeostasis and bring about a cystic 
phenotype, but it remains to be proved that a ciliary defect is the very first event in 
cystogenesis.
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Table 1.7 Cystic kidney disease proteins located to the primary cilium
Cystic Kidney Disease Gene Protein Subcellular location
T S C
TSC1 Ham artin Basal body, cytosol
TSC2 Tuberin Cilia, cytosol
A D P K D
PKD1 Polycystin-1 Cilia, cell m em brane, ER
PKD2 Polycystin-2 Cilia, cell m em brane, ER
A R P K D PKHD1 Fibrocystin Cilia, basal body
NPHP1 (juvenile) NPHP1 Nephrocystin 1 Cilia, basal body, centrosome
N P H P 2 (infantile) INVS Inversin Cilia, basal body, centrosome
N P H P 3 (adolescent) NPHP3 Nephrocystin 3 Cilia, retinal connecting cilia
N P H P 4  (juvenile) NPHP4 Nephroretinin Cilia, basal body
Senior-Locken NPHP5 Nephrocystin 5 Cilia, retinal connecting cilia
Oral-facial-digital OFD1 O FD1 Cilia, basal body, centrosome
Bardet-Biedl BBS1-8 B B S1-8 Cilia, basal body
ARPKD -  Autosom al recessive polycystic kidney disease, BBS -  Bardet-Biedl syndrome, 
NPHP -  Nephronophthisis, OFD1 -  Oral-facial-digital syndrome type 1, PKHD1 -  
polycystic kidney and hepatic disease 1. Information for table w as taken from Hildebrandt et 
al. 2005 , Bisgrove et al. 2006 .
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1.3.3 Activation of mTOR
Dysregulation of the mTOR pathway, as indicated by positive staining of phospho- 
S6-kinase and phospho-mTOR, is frequently seen in cysts arising from the kidneys 
of TSC and ADPKD patients (Bissler et al. 2008, Boletta 2009, Shillingford et al. 
2006). Additionally, Rapamycin (a potent inhibitor of the mTOR complex) treatment 
has been shown in a number of cystic mouse models to reduce lesion size 
significantly, and trials in humans with TSC and ADPKD have yielded similar results 
(Bissler et al. 2008, Davies et al. 2008, Qian et al. 2008). Figure 1.15 outlines a 
model for the interaction of mTOR, the TSC proteins and the polycystins. The end 
results of constitutive mTOR stimulation (cell growth, proliferation and de­
differentiation) coincide with many features of a TSC or ADPKD lesion, and can 
clearly be a strong driver in an early cell to divert towards cystogenesis.
Another feature of the model outlined in Figure 1.15 is that polycystin-1 may be able 
to sequester tuberin so that it is unavailable as a substrate for inactivating kinases 
such as Akt and RSK1. In ADPKD, defects in this complex formation may expose 
tuberin to GF stimulated kinases, in effect hypersensatising the mutant cell to GF 
signalling, inhibiting tuberin through Akt or ERK-RSK1 phosphorylation and leading 
to activation of mTOR. Since many ADPKD and TSC cysts have been shown to 
secrete a cocktail of cytokines and GFs, this may be a significant in cystogenesis 
(Weimbs 2006).
Interestingly, Tsc1+/' mouse data suggests not all early cysts have loss of control 
over the mTOR pathway. However, many of the later lesions do, implying mTOR 
dysregulation certainly has a hand in cyst progression but questioning its absolute 
role in cyst formation (Wilson et al. 2006). A proportion of cysts were found with 
second hits in the Tsc1+I' gene, suggesting a two hit hypothesis can account for 
some of the cystogenesis seen in TSC, with the subsequent mTOR dependent 
proliferation leading to renal tubule dilation and cystic changes (Wilson et al. 2006). 
Similarly, mTOR upregulation is not observed in all ADPKD-associated cysts either, 
but rather in a subset of the cystic epithelia (Hartman et al. 2009).
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Figure 1.15 mTOR dysregulation in cystogenesis
Normal renal tubule cell Polycystic kidney cell
PC1
Tuberin DR/ TO
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Growth, Proliferation, De-differentiation
PC2
eft panel: Staining data suggests that mTOR is inactive in both normal human and mouse 
jult kidney epithelial cells, indicated by a lack of phospho-mTOR or phospho-S6-kinase 
>6K). Additionally, Rapamycin, an mTOR inhibitor, has no effect in normal kidney. 
Ithough the TSC proteins are the major negative regulators of mTOR, this repression may 
3 mediated by PC1. Interaction data has suggested a function of PC1 cytoplasmic tail may 
3 to assemble tuberin and mTOR into a complex at the cell membrane. Because tuberin- 
ediated mTOR repression is known to occur through its GAP action on Rheb, this is also 
oposed to be a part of this complex. PC1 is facilitating mTOR repression in this model 
rough bringing the various components into close proximity. Right panel: Following 
utation of tuberin, hamartin or the polycystin proteins, the TSC-Rheb-mTOR complex 
)es not form, leading to mTOR activation. Via downstream targets 4E-BP1 and s6K, 
TOR is able to constitutively stimulate cell growth, proliferation and de-differentiation, all 
atures seen in the cysts associated with TSC and ADPKD. Adapted from Mostov 2006.
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1.3.4 Polarity defects in cystogenesis
The non-canonical Wnt (PCP) pathway is well conserved in evolution and examples 
in vertebrates include coordination of inner ear hair cells, organisation of fur growth 
and perhaps most importantly, during development, in convergent extension. It is 
through convergent extension that tissues are lengthened and narrowed during 
development, and it is errors in this process that can to lead to neural tube closure 
defects (Bacallao et al. 2009). PCP is a common feature of many epithelia and is 
perpendicular to the apical/basal (A/B) polarity axis.
One of the first indications of a link between cystic kidney disease and PCP was that 
one of the genes mutated in NPHP, inversin (see Table 1.7), acts as a switch 
between canonical and non-canonical (PCP) Wnt signalling (Simons et al. 2005). 
More recent studies have shown how PCP signalling is required for development of 
normal kidneys and suggest how defective PCP can lead to cystic changes in renal 
tubules (Bacallao et al. 2009). Fischer et al. (2006) used cell lineage tracing and 
precise measurements to show that when epithelial cells in the straight tubular 
segments of the outer medulla divide, 95% of divisions occur with 34° of the axis of 
the tubule. In the emerging model of PCP in kidney tubulogenesis, orientated cell 
division is thought to be essential for producing the precisely structured nephron 
(Figure 1.16). Examination of several cystic kidney mouse models by the authors 
lead to the further discovery that orientated cell division was disrupted in these 
animals, in changes that predate cyst formation.
Links between the ADPKD proteins and PCP have emerged, as Lai et al. (2008) 
have demonstrated that the C-terminal tail of polycystin-1 can associate with p- 
catenin and inhibit canonical Wnt signalling (by inhibiting TCF-dependent gene 
transcription). In this manner, functional polycystin-1 is acting as a switch to ‘turn on’ 
PCP and in human PKD1 cysts, strong evidence suggests canonical signalling 
pathway is aberrantly activated (Lai et al. 2008). While p-catenin association may not 
be directly dependent on the presence of polycystin-2, correct localisation of 
polycystin-1 to the ciliary membrane for cleavage in response to fluid flow is, 
providing a role for both polycystins in this process.
63
Work in the MDCK renal epithelial cell line has shown overexpression of Crumbs3 
(CRB3) (part of a complex that includes Palsl and PATJ) induces A/B polarity 
defects (Roh et al. 2003, Lemmers et al. 2004). PATJ, a key scaffold member of the 
CRB3 complex was able to directly interact with the C-terminus of TSC2 in a two- 
hybrid yeast study, verified through co-localisation and co-immunoprecipitation 
assays (Massey-Harroche et al. 2007). Interestingly, dPatj (the drosophila analogue 
of PATJ) has been shown to bind the cytoplasmic tail of Fz1 (the drosophila 
analogue of Fz) and inhibit its function as a canonical Wnt receptor (Djiane et al.
2005). In this manner, dPatj is acting as a switch between A/B and PCP polarity, with 
tuberin placed at its side. It is therefore possible that animal models and humans 
deficient in hamartin or tuberin may experience defects in polarity.
The ciliary connection to PCP and cystogenesis is a contentious one. The ciliary 
protein Inversin acts as a molecular switch between canonical and PCP signalling by 
targeting dishevelled (Dsh) for destruction (Simons et al. 2005). Additionally, the 
PCP proteins Fat4 and Vangl2 (Saburi et al. 2008, Ross et al. 2005) localise to the 
primary cilium and this has lead to the suggestion that the primary cilium is the 
mediator of PCP in renal tubules and other epithelial cells (Bacallo et al. 2009). 
Defective cilia, therefore, would lead to defective PCP and subsequent cystogenesis. 
However, given the highly polar and apical nature of the primary cilium, it may be 
possible that defects in its length or structure are secondary consequences of 
perturbed polarity. Consistent with this hypothesis, loss of the PCP effector genes 
fuzzy and inturhed, leads to disruption of ciliogenesis (Park et al. 2006).
Regardless of its origins, evidence suggests that defective PCP may not be enough 
to trigger cystogenesis alone. In zebrafish, most of the defects associated with a loss 
of PCP signalling can be ameliorated through blocking cell proliferation (Ciruna et al.
2006). It now appears defective cilia / PCP does not lead to formation of cysts unless 
new proliferation is induced (Bacallao et al. 2009, Patel et al. 2008).
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Figure 1.16 Defective polarity in cystogenesis
Section of renal tubule Orientated cell division Tubule elongation with constant diameter
Misorientated cell division Tubule dilation with enlarged diameter
The lengthening of developing renal tubules is associated with the mitotic orientation of cells along the tubule axis 
and demonstrates intrinsic planar cell polarity. This orientated cell division is thought to ensure a constant tubule 
diameter is maintained during tubular lengthening, thereby preventing cyst formation (Germino 2005).
1.3.5 Ca2+ homeostasis
In normal cells, epidermal growth factor (EGF) is mitogenic but cAMP is not. This is 
because normal Ca2+ influx can inhibit B-raf activation (via PI3K and Akt) (Grantham 
2003). In renal cells with defective primary cilia, there may be an inability to respond 
to flow-induced Ca2+ influx. This lack of Ca2+ entry could change cAMP from an anti- 
mitogenic to a pro-mitogenic compound and the subsequent activation of MEK and 
ERK would lead to strong cell proliferation. cAMP-mediated Raf-1 repression is also 
lost under low cell Ca2+ levels, leading to co-ordinated mitogenic stimulation 
(Grantham 2003). Similar conditions may arise under renal injury, when fluid flow 
across the epithelium is disrupted. Cyst epithelia may contain many times more than 
the normal amount of vasopressin receptors, leading to a rise in the level of cyst cell 
cAMP through inappropriate activation of Adenylate cyclase (Torres et al. 2007). 
Figure 1.17 illustrates the roles of Ca2+ and cAMP in renal cystogenesis.
Through mitogenic stimulation, Ca2+ is an important factor to be considered in 
cystogenesis. It may also have role to play in cyst progression. As a cyst develops 
and occludes tubule fluid flow, mechanical stimulation of polycystin-1/2 may drop 
and promote further cyst expansion. Similarly, cyst formation is often accompanied 
by increased secretion of cytokines and growth factors (Munemura et al. 1994), and 
these may feed back to a growing cyst with defective Ca2+ levels and stimulate 
proliferation via EGFR and Vasopressin receptors.
Further links may exist between cystogenesis and Ca2+ homeostasis. Tuberin 
contains a calmodulin-binding domain (Noonan et al. 2002), rendering the TSC 
complex sensitive to Ca2+ levels. Mutations in this calmodulin-binding region, and a 
subsequent inability to respond to differential Ca2+ levels, have been linked to TSC 
disease pathology (Noonan et al. 2002). Additionally, raised cAMP levels have been 
linked to elevated mTOR signalling, another key feature of cystogenesis 
(Blancquaertetal. 2010).
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Figure 1.17 Calcium and cAMP in cystogenesis
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Left panel: In response to mechanical stimulation, the PC1/PC2 complex mediates 
Ca2+ influx and this inhibits B-raf activation via PI3K and Akt. This in turn, causes 
EGF signalling to be mitogenic and cAMP to be anti-proliferative. A functional TSC 
complex acts further downstream to reduce mTOR activity, providing additional 
breaks on cell proliferation. Right panel: Cells lacking functional polycystins or 
primary cilia do not show the normal Ca2+ influx in response to fluid flow. The result 
is a proliferative response to cAMP (which may be elevated due to increased 
expression of vasopressin receptors on the cell surface). EGFR activation (due to 
cytokine stimulation) is no longer repressed and leads to Ras/ERK signalling 
augmented with B-raf activity. This proliferation stimulation can be reversed with Ca2+ 
ionophores or channel activators. The TSC complex downstream is repressed by 
ERK signalling, leading to mTOR activation and cell proliferation. Faulty TSC genes 
lead to the same result.
EGFR -  Epidermal growth factor receptor, cAMP -  cyclic adenosine 
monophosphate, AC -  Adenylate cyclase, PKA -  activated protein kinase A, PI3K -  
phosphatidyl-inositol 3 kinase. Illustration adapted from Grantham 2003 and Torres et 
al. 2007.
67
1.3.6 Apoptotic defects in cystogenesis
1.3.6.1 Apoptosis overview
Apoptosis (programmed cell death) is vital in normal embryonic development and 
morphogenesis (Woo 1995) but may be perturbed in disease -  either with too much 
(neurodegenerative disorders) or too little (neoplasia) taking place. During the 
process, an apoptotic cell shrinks and becomes denser as its chromatin becomes 
condensed and packed against the nuclear membrane. The whole cell becomes 
rounded and retracts from its surroundings (Majno et al. 1995). In the nucleus DNA 
is fragmented, and a period of membrane blebbing occurs, resulting in the ‘pinching 
off of many of these blebs as small vesicles termed apoptotic bodies (Taylor et al. 
2008). Apoptosis is brought about in a variety of ways, but can be separated into two 
broad pathways -  intrinsic (mitochondrial stimulated) and extrinsic (binding of death 
receptors), which both lead to activation of caspases (Fulda et al. 2006). The intrinsic 
pathway is activated in response to cell stress, such as injury, DNA damage, 
elevated Ca2+ or hypoxia, or when there is a lack of external survival signals 
stimulating the cell. Extrinsic apoptosis is reserved for death receptor signalling in 
response to FasL, TNF or TRAIL stimulation of cell surface receptors. Pro-survival 
signals may also feed into the pathway, in the form of cytokine and GF signalling 
(Figure 1.18). Caspases (Cysteine proteases that cleave aspartic residues) are the 
mediators of controlled cell death, and are typically expressed as latent pro-enzymes 
which are activated in response to pro-apoptotic stimuli (Creagh et al. 2003). The 
enzyme family is divided into two - initiators (caspase-8, -9, -10) and effectors 
(caspase-3, -6, -7). Initiator caspases are often activated through auto-proteolysis 
and will propagate death signals by direct proteolytic activation of downstream 
effector caspases. It is these effectors that will dismantle cellular structures, disrupt 
cell metabolism, inactivate cell death inhibitory proteins and activate additional 
destructive enzymes.
1.3.6.2 Mouse models with aberrant apoptosis display a cystic phenotype 
Evidence for apoptotic defects in cystic disease has come from several sources, 
including phenocopy data. Mice with a knockout of the AP-2f3 gene die after 2 days 
due to polycystic kidney disease. Researchers found down regulation of bcl2 
coordinated with apoptosis in the collecting ducts and distal tubular epithelia. Other 
organs appeared normal but the kidneys were smaller than wild type littermates and
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contained numerous small cysts. Proximal tubuli were unaffected. Cell line work by 
the authors has shown an in vitro ability of AP-2 to suppress c-myc induced 
apoptosis, suggesting AP-2/3 plays a role in renal epithelium cell survival (Moser et 
ai. 1997).
The transcription factor p53 is able to prevent tumourigenesis through its capacity to 
regulate the cell cycle, apoptosis and DNA repair genes (Vousden et al. 2000). By 
binding DNA directly, at specific consensus sequences, p53 can repress 
transcription of proliferative genes (PCNA) and stimulate pro-apoptotic genes (Bax) 
(Saifudeen et al. 2002). Interestingly, a p53'/_ rat model was found to acquire renal 
cysts shortly after birth (5 days old), along with enlarged renal tubules and aberrant 
nephron structure. Cyst epithelia frequently stained positive for PCNA, and the cysts 
themselves appear indistinguishable from those in ADPKD or TSC.
Overexpression of c-myc specifically in renal tissue was found to precipitate a 
polycystic kidney phenotype by Trudel et ai. (1997). C-myc has previously been 
shown to stimulate cell growth and proliferation, while elevated expression is known 
to lead to apoptosis and cell cycle arrest (Schmidt 1999). Mice overexpressing c-myc 
developed cysts at E16.5 and progressed to ESRD by 3-6 months. Cyst number and 
size was found to increase with age, as in ADPKD. Cysts had a proliferation index 
ten times that of non-transgenic controls, while the apoptotic index was ten to one 
hundred times elevated; leading the authors to suggest the cystogenesis seen was a 
result of imbalanced proliferation and apoptosis.
Veis et al. (1993) have reported Bcl2 deficient mice (Bc/2'1') complete embryonic 
development but are growth retarded and have polycystic kidneys. Renal failure in 
these mice was found to result from severe polycystic kidney disease arising from 
dilated distal and proximal tubules. No linear relationship was found between age 
and cyst size, although evidence of lesion progression was seen. Earliest lesions 
appeared around 10 days, with hyperproliferation and ‘piling-up’ around some of the 
cysts, as seen in TSC. An earlier study by Kamada et al. (1995) into Bc/2'1' mice 
found similar results to Veis et al., but also described an additional phenotype of 
poor epithelial cell alignment in the small intestine (a possible polarity defect). The
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authors suggest apoptosis is a crucial part of a developing kidney, and perturbing 
this process (through Bc/2 removal) will lead to a devastating renal phenotype.
1.3.6.3 Apoptosis in ADPKD and TSC
Markers of proliferation and apoptosis share a similar distribution in ADPKD cysts, 
and there appears to be a positive correlation between the degree of proliferation 
and amount of apoptosis (Lanoix et ai. 1996). As highly proliferative cells are known 
to stimulate apoptosis (Vermeulen et al. 2003), this is perhaps not a surprising 
observation. A tilt in this balance can also produce a renal cystic phenotype -  either 
with apoptosis reduced and proliferation proceeding unchecked or with apoptosis 
and proliferation present in excess amounts (see section 1.3.5.2) (Figure 1.19).
A theory as to how too much apoptosis might lead to cystogenesis was put forward 
by Lin et al. (1999). Madin Darby canine kidney (MDCK) cells in a collagen-type 1 
matrix require apoptosis for cyst formation through a process of cavitation. 
Cystogenesis in this system can be blocked by overexpression of Bc/2, a pro­
survival gene. The idea that excess apoptosis may contribute to cystogenesis in TSC 
and ADPKD is borne out by observations of a very low incidence of renal cell 
carcinoma despite high levels of cell proliferation (Torres 1999). However, 
cystogenesis through cavitation is not supported by pathological studies of TSC and 
ADPKD cysts. These are known to form from existing tubules and eventually bud off. 
Cavitation would require a mass of cells undergoing central apoptosis to produce a 
cyst.
Ali et al. (2000) used cpk mice (ADPKD) to confirm high levels of apoptosis in the 
cystic kidneys from these mice. The apoptosis was localised solely to the 
interstitium, with no evidence of cell death in the actual cyst epithelium. This lead the 
authors to suggest accumulation of interstitial mononuclear cells attracted to the 
dying cells, and the resulting induction of interstitial scarring may contribute to cystic 
progression through loss of functional renal mesenchyme. Similarly, Winyard et al. 
(1996) found elevated apoptosis in the interstitium around undilated tubules in 
polycystic kidneys, and suggested that dysregulation of cell survival leads to 
spontaneous involution of renal tubules and contributes to incomplete tissue 
maturation. Nishio et al. (2005) have suggested why apoptosis can promote cyst
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formation. Using a Pkd1 mouse model, early cyst epithelia were found to be 
composed of both PkdV1' and Pkd1+,+ renal tubule cells. With time, the Pkd1~cells 
replaced Pkd1+I+ cyst epithelial cells lost to JNK-mediated apoptosis. Late-stage 
cysts from this model were lined with Pkdl'1' and had downregulated p53. In this 
instance, apoptosis is selectively killing off non-mutant cells and leading to cyst 
progression.
Conversely, increased apoptosis in tubule cells may decrease cyst formation 
(Ostrom et al. 2000). Pax2-deficient mice (with increased apoptosis) were bred onto 
cpk mouse lines (with a renal cystic phenotype). The resultant mice had elevated 
renal apoptosis and less cystic disease than controls. Battini et al. (2006) produced a 
knockdown of polycystin-1 expression in MDCK cells to stop tubulogenesis and 
induce formation of cysts under hepatocyte growth factor stimulation. These 
polycystin-1 deficient cells were significantly less susceptible to anoikis (apoptotic 
cell death through loss of contact with the extracellular matrix). These effects were 
seen under polycystin-1 haploinsufficiency.
Hamartin may have a role in negatively regulating apoptosis. Inoue et al. (2009) 
have found hamartin can be phosphorylated (at T417) and bind to Hsp70 (heat 
shock protein). The hamartin-Hsp70 complex was found to localise to the outer 
membrane of mitochondria, where it was able to inhibit cell death via intrinsic 
apoptosis. This process may be tuberin-independent, as hamartin and Hsp70 
localised in the absence of TSC2.
Shillingford et al. (2006) have treated polycystic mouse models with Rapamycin and 
found startling cyst regression and an overall reduction in kidney size. This result 
was attributed to induction of apoptosis specifically in the cyst lining epithelial cells 
(Shillingford et al. 2006).
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Figure 1.18 Apoptosis overview
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Figure 1.19 Apoptosis in cystogenesis
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Panel A: While apoptosis is a normal part of development, excessive cell death in interstitial 
cells surrounding tubules is a feature of both early and late cystic kidneys. This is suspected 
to contribute to cyst progression by destruction of renal tissue (Winyard et al. 1996). TSC 
and ADPKD cysts are hostile environments that promote cell death through excess 
proliferation, hypoxia and nutrient deprivation. A high turnover of cyst cells under these 
conditions may promote the incomplete tissue maturation seen in cyst epithelial cells.
Panel B: Ali et al. (2000) found a cpk mouse model of ADPKD had high levels of renal 
apoptosis but very little of this was localised to cyst epithelium. The kidney interstitium was 
severely apoptotic in these mice, and accumulation of mononuclear cells (attracted to the 
dying cells) could cause interstitial scarring and contribute to cystic progression.
Panel C: One of the key features of TSC and ADPKD renal cysts is the hyperproliferative 
nature of the cells lining the lesion and the excessive amounts of apoptosis taking place. 
These two processes are thought to be intrinsically linked processes. The ability of cyst cells 
to retain a link between these two processes may explain the low rate of oncogenesis seen 
in TSC and ADPKD and with such a high turnover, the immature phenotype of cystic cells. 
Panel D: Nishi et al. (2005) found a line of chimeric ADPKD mice to have cysts composed of 
both PC1 positive (Pkd1 ) and PC1 negative (Pkd1~'~) renal tubules epithelial cells. Normal 
cells are recruited to the cyst in an effort to maintain tubule diameter. However, as the cysts 
developed from early to late-stage lesions, PkdV1' cells were found to replace Pkd1+,+ cells 
lost by JNK-mediated apoptosis in intermediate stages. Elevated apoptosis in this setting 
would contribute to cyst development and select for abnormal cells.
Panel E: Cavitation is seen in MDCK cells during cystogenesis. Excessive apoptosis leads 
to a central vacuation forming inside a polarised epithelial lining. The process is known to be 
inhibited by Bcl2 but it is unlikely this occurs in TSC or ADPKD kidneys. This is because 
histological evidence has clearly demonstrated cysts form from dilations of renal tubules that 
slowly separate from the parent tubule to become a separate sac-like structure.
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1.4 Aims
The aims of the project were:
-to investigate the renal and hepatic phenotype of Tsc1+'\  Tsc2+I~ and Pkd1+/~ 
mice.
-to examine the structure of primary cilia in pre-cystic renal tubules and 
hepatic bile ducts in Tsc1+I' and Tsc2+I' mice.
-to measure PCP in our Tsc1+/', Tsc2+I~ and Pkd1+/' mouse livers and kidneys 
to assess the role of cell polarity in the pathogenesis of TSC.
-to characterise the role of mTOR activation in early cystogenesis and lesion 
progression in Tsc1+I~ and Tsc2+I' mice.
-to further investigate the possibility of an mTOR-independent route of cyst 
initiation, involving defects in renal tubule apoptosis.
CHAPTER TWO
Materials and methods
2.1 Suppliers
The suppliers of products used in this study are listed below; 
Abeam (Cambridgeshire, UK)
ABGene (Surrey, UK)
Anachem (Bedfordshire, UK)
Applied Biosystems (Cheshire, UK)
Bibby Sterling (Staffordshire, UK)
BioGenex (San Ramen, CA, USA)
Bioquote (Yorkshire, UK)
Bio-Rad Laboratories Ltd (Hertfordshire, UK)
Bright Instrument Co Ltd (Cambridgeshire, UK)
Carl Zeiss Microimaging GmbH (Jena, Germany)
Cell Signalling Technologies (Danvers, MA, USA)
DAKO (Cambridgeshire, UK)
EMScope (Kent, UK)
Eurofins MWG Operon (Ebersberg, Germany)
Eurogentec (Hampshire, UK)
Fresenius Kabi AG (Homburg, Germany)
GE Healthcare (Buckinghamshire, UK)
InterFocus Ltd (Cambridgeshire, UK)
Invitrogen Life Technologies (Paisley, UK)
JEOL (Tokyo, Japan)
Labtech International Ltd (East Sussex, UK)
Leica Microsystems (Heidelburg, Germany)
Millipore (Hertfordshire, UK)
New England Biolabs (Hertfordshire, UK)
Olympus Optical (London, UK)
Qiagen (West Sussex, UK)
Raymond A Lamb (East Sussex, UK)
Roche Diagnostics (West Sussex, UK)
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Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA)
Sigma-Aldrich (Dorset, UK)
Soft Imaging System GmbH (Munster, Germany)
Starlabs (Buckinghamshire, UK)
TAAB Laboratory and Microscopy (Berkshire, UK)
Thermo Fisher Scientific (Surrey, UK)
Vector Laboratories (Peterborough, UK)
VWR International Ltd (Dorset, UK)
2.2 Materials
2.2.1 Chemicals
General chemicals were supplied by Sigma-Aldrich or Thermo Fisher Scientific 
unless stated otherwise.
2.2.2 Histology
Plastic processing cassettes, accu-edge low profile microtome blades, paraffin wax 
and cork discs were all supplied by Raymond A Lamb Ltd. VWR International Ltd 
provided Superfrost slides, 22x50mm cover slips, xylene, optimum cutting 
temperature (OCT) embedding compound, dibutyl phthalate and xylene (DPX) 
mountant, formaldehyde, ethanol, haematoxylin and eosin (H&E) stain, isopentane 
and hydrogen peroxide. Poly-L-lysine and mineral oil were purchased from Sigma- 
Aldrich.
2.2.3 Laser capture microdissection
PALM slides with a 1.0 PEN (polyethylene naphthalate) membrane were supplied by 
Carl Zeiss Microscopy and mounted tissue was stained with toluidine blue dye from 
Sigma-Aldrich.
2.2.4 DNA extraction and purification kits
Proteinase K, QIAamp DNA mini kits and QIAamp DNA microkits were supplied by 
Qiagen. Isopropanol was obtained from VWR International Ltd.
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2.2.5 Oligonucleotide primers and dNTPs
Deoxynucleotidetriphosphates (dATP, dTTP, dCTP and dGTP) were obtained from 
GE Healthcare. High purity salt free oligonucleotide primers were purchased from 
either Eurofins MWG Operon or Eurogentec. Primer stock solutions were made by 
dilution to 100pM in sterile water, produced by Fresenius Kabi AG.
2.2.6 PCR
Applied Biosystems provided AmpliTaq Gold DNA polymerase and 10x PCR buffer.
2.2.7 PCR Purification
New England Biolabs supplied restriction enzyme Exonuclease I and GE Healthcare 
provided the Shrimp Alkaline Phosphatase.
2.2.8 Electrophoresis
Agarose powder was obtained from Roche Biochemicals.
2.2.9 DNA size markers
1Kb DNA ladder was purchased from Invitrogen Life Technologies.
2.2.10 Sequencing and DNA clean up
POP6 polymer, BigDye® Terminator v3.1 and v1.1 Cycle sequencing kits were 
obtained from Applied Biosystems. Montage SEQ96 sequencing reaction clean-up 
kits were purchased from Millipore.
2.2.11 Antibodies
Cell Signalling Technologies supplied the anti-phospho-histone H3 (Ser10) (#9701), 
the anti-phospho-Stat3 (Tyr705) (#9131), the anti-phospho-p65 (Ser276) (#3037), the 
anti-phospho-Akt (Ser473) (#4060) the anti-phospho-Met (Tyr1234/1235) (#3077), the 
anti-cleaved Caspase-3 (Asp175) (#9661) and the anti-phospho-S6 ribosomal protein 
(Ser2407244) (#2211) antibodies. Anti-Cytokeratin 19 (N-13) (sc-33111-R) antibody was 
purchased from Santa Cruz Biotechnology Inc, along with anti-phospho-Jak2 
(Tyr100771008) (sc-16566-R). Anti-Bcl2 antibody (ab7973) was purchased from Abeam. 
BioGenex supplied an anti-p53 antibody. Fluorescein conjugated chicken anti-goat 
IgG and rhodamine conjugated goat anti-rabbit IgG were obtained from Millipore.
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2.2.12 Immunohistochemistry
Vector Laboratories supplied the rabbit Vectastain Elite ABC horseradish peroxidase 
kit and the 3, 3’-diaminobenzidine (DAB) peroxidase substrate kit. Cytomation wax 
pens were supplied by DAKO.
2.2.13 Immunofluorescence
Sigma-Aldrich provided the Triton X-100. Goat serum was purchased from Vector 
Laboratories and Invitrogen Life Technologies supplied the ProLong® Gold anti-fade 
reagent with DAPI.
2.2.14 Scanning electron microscopy
Phosphate buffered saline for use during perfusion fixation was supplied by Sigma- 
Aldrich. Hexamethyldisilazane (HMDS), carbon paint, aluminium stubs, 70% vacuum 
distilled glutaraldehyde and 16% methanol-free formaldehyde were all provided by 
TAAB Laboratory and Microscopy.
2.3 Equipment
2.3.1 Plastics
Sterile pipette tips (all sizes) provided by Starlabs. Plastic eppendorf tubes (0.6ml, 
1.5ml and 2.0ml) purchased from Bioquote. Anachem provided 96-well plastic plates, 
while ABGene produced the adhesive PCR film. Bibby Sterling supplied the sterile 
universal tubes.
2.3.2 Histology
InterFocus Ltd provided tweezers and scissors used in mouse dissection. Fixed 
tissue processing was facilitated by a Thermo Shandon Citadel 2000 tissue 
processor and embedded with a Raymond A Lamb Ltd wax embedder. A Leica 
RM2235 microtome was used to cut paraffin sections and slides were stained with 
H&E on a Thermo Shandon Varistain Gemini machine. Frozen tissue was cut on a 
cryostat, and a sledge microtome with freezing stage (Bright Instrument Co Ltd) was 
used to cut un-embedded fixed tissue. An Olympus BX51 BF light microscope was 
used to analyse H&E and immunohistochemistry samples. Slides for paraffin 
embedded tissue were obtained from Superfrost and for frozen tissue destined for 
laser capture microdissection, special PALM slides with 1.0 PEN membrane were
78
purchased from Carl Zeiss Microimaging GmbH. Both types of slide were pre-treated 
with UV light for 30 minutes and then with Poly-L-Lysine solution for 5 minutes. 
Drying took place overnight in a 40°C oven.
2.3.3 Immunohistochemistry and immunofluorescence
Plastic slide racks and cardboard slide holders were supplied by Raymond A Lamb 
Ltd. An Olympus BX51 BF microscope fitted with a mercury lamp was used to 
analyse the immunofluorescent samples.
2.3.4 DNA quantifications and thermocycling
A NanoDrop 8-Sample Spectrophotometer supplied by Labtech International was 
used to measure DNA concentration. Thermocycling was carried out in a DNA 
thermal cycler 480 from Applied Biosystems. Ninety-six well plates were 
thermocycled on a PTC-225 Peltier thermal cycler from GRI.
2.3.5 Electrophoresis
Invitrogen Life Technologies provided the Horizon 11.14 gel tanks used for agarose 
gel electrophoresis. Power packs were obtained from Bio-Rad Laboratories Ltd.
2.3.6 Scanning electron microscopy
Dehydrated samples mounted on aluminium stubs with carbon paint were sputter 
coated with gold using an EMScope vacuum coater. Samples were then viewed in a 
JEOL 840A scanning electron microscope.
2.3.7 Laser capture microdissection
Samples were viewed and dissected on a PALM Microlaser system and visualised 
using the associated PALM Robo software.
2.3.8 Photography
Agarose gels were photographed using a Gel Doc 2000 ultraviolet Transluminator 
from Bio-Rad Laboratories Ltd and printed via a Mitsubishi P91 video processor 
stocked with high-density thermal paper. A Carl Zeiss Axiocam digital camera was 
used to capture micrographs.
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2.3.9 Software
AxioVision software from Carl Zeiss Vision was used for fluorescent image analysis. 
Soft Imaging System GmbH provided the AnalySIS software used to measure cilia in 
scanning electron micrographs. Minitab 15, SPSS 16 and Microsoft Excel were used 
to facilitate statistical analysis and graph construction. Sequencer 4.6 was used to 
analyse sequencing data.
2.4 Solutions
• 1xTAE (0.4M Tris-acetate, 10mM EDTA, pH 8.0)
• 1xTBS (0.15M NaCI, 0.005M Tris, pH 7.6)
• Tail Buffer (50mM Tris, 100mM EDTA, 100mM NaCI, 1% SDS, pH 8.0)
• 1xTBS/0.3% Triton X-100 (to produce 1 litre solution: 100ml 10xTBS, 900ml 
dH20, 3ml Triton X-100)
• 1xTBS/4% BSA (to produce 50ml solution: 2g BSA in 5ml 10xTBS, 45ml dH20)
• 10mM sodium citrate buffer (to produce 1 litre solution: 2.94g sodium citrate 
trisodium salt dehydrate, 1L dH20, pH 6.0)
• 10% formal saline (to produce 1 litre solution: 100ml 38% w/w formaldehyde, 
900ml dH20, 9g NaCI)
• 0.3% H20 2 solution (for 300ml: 300ml dH20, 3ml 30% w/v H20 2)
• Phosphate buffered 4% formaldehyde/0.2% glutaraldehyde (PBFG)
o Buffer solution of 3.35% sucrose and 0.167M Na2HP04 (pH 7.4). 
o Add 40% formaldehyde (produced from 16% methanol-free formaldehyde 
stock) in a 40:60 ratio with the buffer solution to produce a 4% 
formaldehyde in 100mM buffer + 2% sucrose solution, 
o Filter the cloudy solution through fine filter paper.
o Glutaraldehyde (70% vacuum distilled) is added to 0.2% (2.857ml/L) to 
produce PBFG, which can be transferred into smaller containers and 
stored at -30°C.
2.5 Methods
2.5.1 Animal husbandry
All procedures with animals were carried out in accordance with Home Office 
guidelines. Mice used in this study were kept in filter top cages and supplied with
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filtered food and water. These cages were maintained on a 12 hour light, 12 hour 
dark cycle (7:30 to 19:30 each day) and kept at a constant 22°C temperature. Tsc1+I' 
mice on a Balb/c background (Wilson et al. 2005) were crossed with Tsc2+I' mice on 
a Balb/c background (Onda et al. 1999) and Pkd1+/' mice on a 129/Sv background 
(Boulter et al. 2001) to produce Tsc1+I'' Tsc2+I'' Pkd1H’' Tsc1+/'Pkd1+/' and Tsc2+/' 
Pkd1+I‘ mice, as well as wild-type littermates. Identification of mice was facilitated 
through microchip implantation and tail tip samples were removed for genotyping 
under a local anaesthetic. Mice were killed by cervical dislocation.
2.5.2 Necropsy analysis
Brain, lungs, heart, kidneys, spleen, uterus (in females) and liver underwent 
macroscopic analysis upon dissection. Once removed from the body, organs were 
longitudinally bisected with a scalpel blade, with half fixed and processed to paraffin 
wax for sectioning and the other half being snap frozen. Bisected kidneys and liver 
tissue removed for SEM analysis were fixed overnight in PBFG and transferred to 
1xTBS for longer storage. Large hepatic cysts from 20 month old mice were 
removed, fixed overnight in PBFG and set aside for SEM processing.
2.5.3 Histology
2.5.3.1 Tissue fixation, embedding and sectioning
Formaldehyde based solutions are able to penetrate deep into tissue due to its small 
molecular size. Once immersed, CH2 cross-links form between protein amino groups 
in the tissue, thus preserving tissue morphology and integrity. Formaldehyde is also 
an effective disinfectant, ensuring no fungal or bacterial contamination of the tissue 
at this early stage in processing.
Dissected tissue was transferred to a universal tube containing 10% formal saline 
solution and left on the bench top at room temperature overnight. The sample was 
then drained and moved to a solution of 1xTBS for long term storage of fixed tissue 
at 6°C. Fixed tissue was placed on to the processor in solutions of 70%, 90% and 
100% ethanol for an hour each. This was followed by two sets of 2 hour immersions 
in 100% ethanol solution and 1 hour in xylene. Finally, the tissue was transferred to a 
fresh solution of xylene for 1.5 hours, a step which was repeated, and then moved to
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paraffin wax for 3 hours, twice. During the final embedding stage, tissues were 
placed into paraffin cut side down and at stored at room temperature.
Paraffin embedded livers and kidneys were sectioned at 4pm, placed in a 60°C 
water bath and floated onto poly-L-lysine treated Superfrost slides. Slides were 
moved to a 45°C oven for drying overnight and stored at room temperature the 
following morning.
2.5.3.2 Snap freezing and PALM slide sectioning
Following dissection, tissue was placed cut side down onto cork disks and coated 
with OCT embedding medium. The sample was transferred to a 1-litre glass beaker 
containing liquid nitrogen cooled isopentane and left until the OCT became opaque 
and the tissue was deemed frozen. The frozen tissue was removed using forceps 
and stored in cryotubes at -80°C. A medium was used to snap freeze the samples as 
direct freezing with liquid nitrogen is less efficient in terms of heat transfer and can 
lead to ice crystal formation.
Frozen kidney samples were sectioned at 10pm on a freezing stage cryostat (set to - 
20°C) and transferred onto PALM slides. This thicker sectioning increased tissue 
integrity during slide mounting and allowed more tissue depth to obtain genetic 
material from during microdissection. Once cut, these slides were dried at room 
temperature and stored long term at -20°C.
2.5.3.3 Perfusion fixation
In order to maintain the fine morphological detail needed during SEM analysis of 
primary cilia in hepatic bile ducts, a mixture of formaldehyde and glutaraldehyde 
(PBFG) was used to quickly and efficiently cross-link mouse livers following cervical 
dislocation. Due to the small molecular size of formaldehyde, quick tissue infiltration 
was possible. This initial cross-linking was then complimented by the slower 
penetrating but more stabilising glutaraldehyde. Through the action of PBFG, hepatic 
bile ducts and the associated primary cilia were fixed in their physiological positions 
and able to withstand the chemically harsh processing needed for SEM analysis.
Following animal sacrifice, the rib cage was opened up and clamped to expose the 
heart and lungs. Dissection scissors were used to cut the right oracle and provide a 
drainage point for blood, saline and fixative pumped around the body during the 
procedure. A second incision of around 2-3mm was made on the left ventricle, 
providing an entry point for a blunted syringe needle. This was clamped in place to 
ensure a water-tight seal. A syringe with 50ml PBS was attached to the needle and 
gentle pressure was applied to flush the mouse of blood. A second syringe with 50ml 
PBFG was then pumped through the bloodstream and correct fixation was indicated 
by blanching of liver and muscle contractions of the deceased mouse. The liver was 
then removed and placed into a universal tube containing more PBFG. Following 24 
hour immersion, samples were transferred into 2.3M sucrose in TBS solution for long 
term storage at 6°C.
2.5.3.4 Haematoxylin and eosin staining
To expose often subtle kidney and liver lesions such as cysts, H&E staining was 
used. The haematoxylin colours the nuclei of cells blue, while a counterstain of eosin 
colours eosinophilic structures (including the majority of the cytoplasm) pink. Paraffin 
embedded sections were H&E stained using the following protocol: xylene (1 minute) 
x3, 100% ethanol (1 minute) x2, 70% ethanol (1 minute), Meyer’s haematoxylin (5 
minutes), running water (1 minute), eosin (2 minutes), running water (1 minute), 70% 
ethanol (1 minute), 100% ethanol (1 minute) x2, xylene (1 minute) x2. Cover slips 
and DPX were used to mount the sections and these were left to air dry in a fume- 
hood.
2.5.4 Laser capture microdissection
Laser capture microdissection allows highly selective excision of user-defined areas 
of tissue, perfect for cutting around the cysts present in our mice. Frozen tissue was 
sectioned onto poly-L-lysine and UV treated PEN membrane covered slides. 
Following a 5 minute wash in tap water, samples were treated with toluidine blue 
stain for 2 seconds and rewashed under tap water. Sections were then passed 
through 50%, 70% and 100% ethanol solutions for 15 seconds and dried on the 
bench top overnight. Slides placed under the PALM Microlaser system were cut with 
a pulsed UV laser. The focused laser beam dissects tissue without heating adjacent
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material, and leaves a defined gap between the newly isolated cyst and 
surroundings. Samples are then automatically ejected from the plane and captured 
in the oil coated cap of a microfuge tube (positioned above the slide). Through 
analysis of serial sections, cysts can be followed over several slides and multiple 
samples collected to increase the amount of genetic material obtained. Microfuge 
tubes containing sample cystic tissue were transferred to a -80°C freezer for long 
term storage.
2.5.5 Nucleic acid extraction
2.5.5.1 DNA extraction from tail tips
Routine DNA analysis was conducted on our mice in order to ascertain genotype for 
breeding and experimental purposes. The top 3mm of each mouse tail was removed 
and frozen prior to DNA extraction. After thawing, tail tips were placed in 2ml 
eppendorf tubes together with 500pl tail buffer and 20jliI proteinase K (20mg/ml) and 
incubated in a 65°C water bath overnight. The following morning, the samples were 
agitated in a bench top vortex and assessed for digestion. An extra 20jal proteinase 
K was added and vortexed if the tail was not fully digested. The resulting lysate was 
added to 250pl of 6M supersaturated NaCI (causing precipitation of proteins and 
carbohydrates but leaving DNA in solution) and vortexed until a cloudy colour was 
produced. This was centrifuged at 13,000 rpm for 10 minutes to produce a salt pellet 
and clear supernatant. The supernatant was transferred into a 1.5ml eppendorf 
along with 150pl of isopropanol and manually inverted to precipitate DNA. If a DNA 
precipitate could not be seen, tubes were left overnight at -20°C to aid the process. 
DNA was separated from the remaining solution with centrifugation at 13,000 rpm for 
5 minutes, removed and washed with 150pl of 70% ethanol. The final stage required 
the pellet to be air-dried for 15 minutes to ensure complete removal of residual 
ethanol. DNA pellets were resuspended in 30-50jnl of DNAse-free water overnight at 
35°C before storage at -20°C.
2.5.5.2 DNA extraction from laser microdissected tissue
3NA was extracted from microdissected frozen tissue (see section 2.5.4) using 
3IAamp DNA mini kits and following the manufacturers’ instructions. DNA from the 
issue is bound to a silica-gel membrane in a salt medium and through repeated
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washing with various buffers impurities are gradually removed, leaving just the DNA. 
Microdissected cysts in microfuge tube lids were left overnight at 65°C with 180pl of 
Buffer ATL and 20jul of proteinase K prior to incubation. The lysed tissue was added 
to 200jlxI of Buffer AL and incubated for 10 minutes at 70°C. This solution was 
combined with 200pl of 100% ethanol and transferred to a QIAamp silica gel based 
Spin Column and centrifuged for 1 minute at 8,000 rpm. The filtrate in the collecting 
tube was discarded and the Spin Colum was transferred to a fresh collection tube 
where 500pl of Buffer AW1 was added and the solution re-centrifuged for 1 minute at
8,000 rpm. The filtrate was discarded and a second wash was performed using 
500pl of Buffer AW2 and spinning for 3 minutes at 13,000 rpm. This was followed by 
an extra 1 minute of centrifugation to remove residual buffer from the washes. 
Finally, DNA was eluted in a variable amount of DNAse free water (ranging from 20|ul 
to 200pl for concentrated samples) by incubating the membrane at room 
temperature for 5 minutes and centrifuging at 13,000 rpm for 1 minute. The resulting 
samples were stored at -20°C.
2.5.6 Nucleic acid quantification
DNA concentrations were determined using UV spectrophotometry at wavelengths of 
260nm and 280nm. A ratio of 1.8 at 260nm:280nm implies high sample purity.
2.5.7 Oligonucleotide primer design
Web-based program Primer 3 (Rozen et al. 2000) was used to design primers 
between 18 and 23 nucleotides in length. Primers deemed to have repetitive motifs, 
a high likelihood to dimerise or form secondary structures were selected against. 
Attempts were made to represent the four bases in equal amounts, and to ensure 
melting temperatures of the primer pairs used were within 2°C of each other.
2.5.8 Polymerase chain reaction
The polymerase chain reaction, or PCR, allows selective amplification of DNA 
sequences. The procedure relies on the repetition of 20-40 thermal cycles, with each 
cycle consisting of 3 discrete stages (denaturation, annealing and elongation). The 
initial denaturation step occurs at a high temperature to separate the double helix 
template DNA into single strands. A cooler annealing step follows that allows primers
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¥to bind to complimentary DNA sequences and direct new DNA synthesis. During 
elongation, DNA polymerase synthesises a new DNA strand complementary to the 
primer bound DNA template strand by adding dNTPs.
PCR conditions for genotyping of mouse DNA were set as follows: 25ng of template 
DNA, 2pl 10x reaction buffer (100mM TrisHCI, pH8.3, 500mM KCI, 15nM MgCfe, 
0.01% w/v gelatin), 0.25mM dNTPs, 25pmol of each primer, 0.5 Units (U) of 
AmpliTaq Gold DNA Polymerase in a total reaction volume of 20pl. These amounts 
were then scaled up to a 50pl total volume and covered in a layer of mineral oil to 
insulate the reaction mixture against evaporation. Cycling temperature conditions 
were set as follows: initial denaturation at 94°C for 10-12 minutes, 35 cycles of 52°C- 
60°C (denaturation) for 1 minute, 72°C for 1-2 minutes (annealing) and 94°C for 1 
minute (extension). The PCR ends with a final elongation step for 12 minutes at 
72°C, and is then held at 4°C until the products are removed from the machine.
2.5.9 Agarose gel electrophoresis
Small and large DNA fragments will travel different distances when passing through 
an agarose gel under an electrical current. Due to the negatively-charged phosphate 
groups, DNA will migrate from the negative electrode to the positive electrode when 
in an ion solution. Agarose acts as a molecular sieve, restricting the passage of DNA 
in a size and shape dependent manner. By increasing the concentration of agarose 
present in the gel mixture, gel pore size decreases and better separation can be 
achieved in terms of small DNA fragments.
Agarose gels of 2% w/v concentration were prepared using 1x TAE buffer. To this, 
0.05pg/ml ethidium bromide was added. This dye combines with any DNA present 
on the gel and subsequently makes the nucleic acid visible under ultra-violet (UV) 
light. A plastic comb was used to create wells in the gel, and to these, 10pl of PCR 
sample mixed with 2pl of loading dye (15% w/v ficol, 10mM Tris pH 8, 1mM EDTA, 
0.2% orange G dye) was added. Fragment sizes were determined through 
comparison with a 1kb DNA fragment ladder run on the same gel in a separate well. 
Once loaded, gels were submerged in 1x TAE buffer and run at 100 volts for 
approximately an hour. Following sufficient migration of the loading dye down the
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gel, DNA was visualised through UV exposure at 300nm wavelength and images 
captured on a Gel Doc 2000 system.
2.5.10 PCR purification
PCR products destined for cyclic sequencing require purification to remove non­
incorporated dNTPs and primers from the reaction mixtures. To do this, the 
hydrolytic enzymes Exonuclease I (Exo) and Shrimp Alkaline Phosphatase (SAP) 
were used to degrade any single stranded primers and hydrolyse dNTPs 
respectively. To 15pl PCR product, 5pl Exo I and 0.5pl SAP were added and 
incubated at 37°C for 1 hour. This was followed by an 80°C denaturation step for 15 
minutes.
2.5.11 Cycle sequencing
The chain termination method of DNA sequencing was first envisaged by Sanger 
(1977), and relies on 2’, 3’ di-deoxynucleotide triphosphates (ddNTPs). These 
molecules lack the 3’ OH group found on dNTPs and cannot form phosphodiester 
bonds once incorporated into a DNA chain, leading to termination. During the 
specialised PCR reaction, DNA strands are produced by a polymerase using normal 
dNTPs and terminating ddNTPs. As the cyclic amplification continues, single 
stranded DNA fragments are formed, differing in length by one base. Since the 4 
types of ddNTP (ddATP, ddCTP, ddGTP and ddTTP) are fluorescently labelled with 
identifying colours, the sequencing reaction can take place in one tube. The ABI 
sequencer can identify the position of the labelled base by passing the DNA through 
a capillary gel. The smaller fragments in the mixture will migrate faster across the gel 
and reach the laser beam for analysis in a size dependent order. The emitted 
wavelength is detected and related to the specific ddNTP incorporated in the chain.
The Big Dye® Terminator Cycle Sequencing kit (Version 3.1 or 1.1) was used during 
sequencing reactions. To make up a total reaction volume of 10pl, 5pl of purified 
PCR product (see section 2.5.10) was added, along with 0.16pl of primers, 0.25pl of 
terminator ready reaction mix (which contained A, C, T and G dye terminators, 
dNTPs, AmpliTaq DNA polymerase FS, MgCh and Tris-HCI buffer, pH 9.0), 2pl 
BigDye® terminator sequencing 5x buffer and 2.59pl purified water. Conditions for 
sequencing were set as follows: 96°C for 1 minute followed by 25 cycles of 96°C for
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10 seconds, 50°C for 5 seconds and 60°C for 210 seconds. Montage SEQ96 
sequencing reaction clean up kits were then used to purify the cycle sequencing 
products. Twenty micro litres of injection fluid was added to the sequencing reactions 
and transferred to a micro well filter plate. The samples were drawn through the plate 
using a vacuum pump (20 inches Hg). This step was repeated with two additional 
washes of injection fluid (25pl). The purified sequencing products were re-suspended 
in 20pl of injection fluid by shaking on an orbital mixer for 10 minutes. Ten micro 
litres of sample were run on an ABI 3100 Genetic Analyser and the resulting 
sequence data viewed on Sequencher version 4.6.
2.5.12 Immunohistochemistry
Immunohistochemistry (IHC) refers to the process of localising antigens in cells of a 
tissue section through specific binding to complimentary antibodies. An avidin-biotin 
complex (ABC) method was used that exploits the very high affinity between the 
large glycoprotein avidin and the vitamin biotin. Biotin can be conjugated on to 
antibodies whilst avidin can be labelled with peroxidase or fluorescein. The ABC IHC 
method involves application of the unlabeled primary antibody, addition of a biotin- 
conjugated secondary antibody and the application of avidin-biotin peroxidase. The 
antigen-localised peroxidase is then developed using DAB to produce a colour 
change. As avidin has 4 binding sites for biotin, the signal produced is amplified 
significantly.
Slides containing paraffin embedded 5 micron thick sections of kidneys and livers 
were deparaffinised and rehydrated by immersing in xylene x2, 100% ethanol x2, 
70% ethanol, 50% ethanol and water for 5 minutes per wash. For antigen retrieval, 
sections were placed in a plastic slide rack and boiled in 10mM citrate buffer (pH 6.0) 
for 10 minutes. Slides were cooled under running tap water for 5 minutes then 
transferred to a solution of hydrogen peroxide (0.3%) for 20 minutes to block 
endogenous peroxidase activity. Following another 5 minute wash under running tap 
water, slides were placed in 1xTBS solution for 5 minutes. The rabbit VECTASTAIN 
ELITE ABC horseradish peroxidase kit was used to immunostain paraffin sections. 
This kit contains the goat serum, rabbit secondary antibody and avidin-biotin 
complex components. A wax pen was used to circle the sections and 100pl blocking 
solution was added to each slide (7.5pl goat serum and 500pl dHzO). This was
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incubated in a humidified chamber for 20 minutes. Primary antibodies were diluted to 
optimal concentrations in 1x TBS or 1x TBS/4% BSA (depending on manufactures’ 
recommendations), applied and left overnight at 6°C. The following morning, slides 
were washed in 1xTBS for 5 minutes x2 and exposed to the biotinylated secondary 
antibody (2.5pl secondary antibody, 7.5pl goat serum, 500pl dh^O) for 30 minutes. 
After another two 5 minute washes in 1xTBS, 100pl of avidin-biotin complex was 
added to each slide and incubated for 30 minutes. After another two 5 minute 
washes in 1xTBS, sections were developed using DAB, counterstained in Gills 
haematoxylin for 1 minute and blued in tap water. The final dehydration stage 
required 5 minute immersions in 50% ethanol, 70% ethanol, 100% ethanol x2 and 
xylene x2. DPX was used to mount the slides with cover slips and these were left to 
air dry in a fume hood. An Olympus BX51 microscope was used to view the results.
2.5.13 Double immunofluorescence staining
Double immunofluorescence staining is similar to the previous protocol in section 
2.5.12. However, in order to visualise a pair of antigens in a sample, such as a 
biomarker for a specific tissue type (e.g. anti-Cytokeratin 19 for cholangiocytes) and 
a marker for a specific event (e.g. anti-phospho-histone H3 for dividing cells), certain 
modifications must be made to the standard IHC protocol. By choosing antibodies 
derived from different animals (but not mouse, as this is the target tissue), the 
reagents can be incubated as a single cocktail. Secondary antibodies are selected to 
specifically recognise these antibodies and will have conjugated fluorescent 
molecules for detection. There is no need for ABC peroxidase to visualise the 
staining, so steps involving hydrogen peroxide, ABC application and DAB can be 
omitted. However, because of the sensitive nature of the fluorescent molecules 
used, care must be taken to shield the sections from exposure to natural light. 
Overexposure during the protocol will lead to a reduction in signal intensity when the 
slides are analysed, so tin foil is used to prevent this.
Slides containing paraffin embedded 5 micron thick sections of kidneys and livers 
were deparaffinised and rehydrated by immersing in xylene x2, 100% ethanol x2, 
70% ethanol, 50% ethanol and water for 5 minutes per wash. For antigen retrieval, 
sections were placed in a plastic slide rack and boiled in 10mM citrate buffer (pH 6.0) 
for 10 minutes. Slides were cooled under running tap water for 5 minutes then
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transferred to a solution of hydrogen peroxide (0.3%) for 20 minutes to block 
endogenous peroxidase activity. Following another 5 minute wash under running tap 
water, slides were placed in 1xTBS solution for 5 minutes. Blocking was carried out 
in 2x 5 minute washes in 1xTBS/0.6% bovine serum albumin (BSA). Through-out the 
protocol, immunofluorescent staining was carried out in a humidified chamber, 
covered in tin foil and placed in a dark cupboard. This was to minimise evaporation 
from the sections, keep out light and preserve fluorescence. A wax pen was used to 
circle the sections and 100pl of antibody solution (consisting of an optimal 
concentration of antibody diluted in 1x TBS) was applied prior to overnight incubation 
at 6°C. The following morning, slides were washed twice in 1xTBS/0.6% BSA for 5 
minutes and immersed for 1 hour in fluorescent secondary antibody. A further two 5 
minute washes in 1xTBS/0.6% bovine serum albumin followed this, and then 
sections were mounted using ProLong® Gold antifade reagent with DAPI and 
allowed to cure overnight in the dark. Slides were sealed with clear nail varnish and 
examined immediately on an Olympus BX51 microscope. Slides transported in the 
light were covered with tin foil to minimise loss of fluorescent signal. For storage, 
slides were kept at 6°C in a light-proof container.
2.5.14 Scanning electron microscopy
Samples were prepared for SEM analysis according to the hexamethyldisilazane 
(HMDS) method (Nation 1983), which progressively lowers the water content of the 
tissue without shrinkage or distortion of the surface.
Tissues underwent two 10 minute washes in dH20, followed by successive washes 
for 15 minutes in 50%, 70%, 90% and twice in 100% ethanol. The samples were fully 
dehydrated by three 10 minute immersions in HMDS and transferred to a perspex 
cabinet with silica gel crystals to prevent re-hydration of the desiccated tissue during 
the final air drying stage. Carbon paint was used to mount the specimens onto 
aluminium stubs, which were transferred to an EMScope vacuum coater and sputter 
coated with gold. Sample analysis was carried out at 5kV using a JEOL 840A 
scanning electron microscope.
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CHAPTER THREE: Investigating the role of hamartin, tuberin and polycystin-1 
in cystogenesis, ciliogenesis and planar cell polarity.
3.1 Introduction
Patients with TSC often develop renal cysts and those with contiguous germline 
deletions of TSC2 and PKD1 develop severe infantile polycystic kidney disease 
(Brook-Carter et al. 1994), suggesting a functional co-operation between their gene 
products (Chapter 1, Section 1.1.10). Hamartin and tuberin function as a complex 
within the PI3K-Akt-mTOR pathway and regulate nutrient and growth factor 
signalling to mTOR (Chapter 1, Section 1.1.10). Many lesions from patients with TSC 
exhibit activation of mTOR and clinical trials are underway for the treatment of these 
tumours using mTOR inhibitors (Bissler etal. 2008, Davies etal. 2008).
The primary cilium is a microtubule based sensory organelle that receives both 
mechanical and chemical signals from other cells and the environment, and 
transmits these signals to the nucleus to elicit a cellular response (Chapter 1, 
Section 1.2.9.3.1). Primary cilia are anchored to the cell via the basal body. Hamartin 
has been localised to the basal body (Hartman et al. 2009) and tuberin interacts with 
the ADPKD1 gene product, polycystin-1 (Shillingford et al. 2006), which has been 
localised to the primary cilium (Yoder et al. 2002). Numerous other proteins 
associated with cystic kidney disease have also been localised to the renal cilium or 
basal body including the ADPKD2 protein polycystin-2 (Yoder et al. 2002, Pazour et 
al. 2002), the product of the human autosomal recessive polycystic kidney disease 
gene (PKHD1), fibrocystin (Ward et al. 2003), and polaris and cystin, which are 
mutated in two mouse models of polycystic kidney disease (Yoder et al. 2002). Mice 
with mutant polaris develop shortened cilia or no cilia in kidney epithelia (Pazour et 
al. 2000) and PCK rats (an orthologous model for PKHD1) (Ward et al. 2002) have 
cilia that are abnormal and shortened (Masyuk et al. 2003).
Renal primary cilia monitor urinary flow through kidney tubules via the 
mechanotransduction properties of polycystin-1 and polycystin-2 (Nauli et al. 2003), 
and the ciliary protein inversin acts as a molecular switch from the canonical to the 
noncanonical/planar cell polarity (PCP) Wnt signalling pathways by targeting 
cytoplasmic dishevelled (Dsh) for degradation (Simons et al. 2005) (Chapter 1,
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Section 1.3.2). Furthermore, mutations in Kif3a, Ift88 and Ofd1, that disrupt 
ciliogenesis, restricts the activity of the canonical Wnt pathway with loss of Kif3a 
causing constitutive phosphorylation of Dsh (Corbit et al. 2008). Interestingly, 
hamartin and tuberin associate with the GSK3/axin complex to promote p-catenin 
degradation and inhibit canonical Wnt-signalling (Mak et al. 2003) and tuberin also 
interacts with Dsh upon Wnt stimulation (Mak et al. 2005). The lengthening of 
developing renal tubules is associated with the mitotic orientation of cells along the 
tubule axis demonstrating intrinsic PCP (Fischer et al. 2006) and this oriented cell 
division is thought to dictate the maintenance of constant tubule diameter during 
tubular lengthening, thereby preventing renal cyst formation (Germino 2005) 
(Chapter 1, Section 1.3.4). Defects in this process have been found in mice with a 
renal-specific inactivation of Tcf2, a transcription factor essential for the expression 
of genes involved in polycystic kidney disease (Fischer et al. 2006), the PCK rat 
(Fischer et al. 2006) and Kif3a mutant mice (Patel et al. 2008).
While hepatic involvement in TSC sufferers is limited to AMLs, patients with ADPKD 
will experience progressive renal and hepatic cyst formation (Lu et al. 1999). The 
liver is analogous to the kidney in several ways (Alpini et al. 1997) that make it an 
attractive target for research. The entire organ is perfused by bile ducts, lined with 
simple epithelia or cholangiocytes that modify through a series of absorptive and 
secretory events, bile of canalicular origin before it reaches the bowel (Alpini et al. 
1997). These ducts develop in a similar manner to kidney tubules, carrying bile 
instead of urine, and are lined with primary ciliated epithelial cells as found in renal 
tissue (Huang et al. 2006). Just as renal cysts are known to arise from kidney 
tubules, the hepatic cysts seen in Pkd1 mice have been shown to develop from 
these bile ducts (Lu et al. 1999). Renal tubules demonstrate high levels of intrinsic 
cell polarity that allows intense cell proliferation during kidney development to lead to 
tubule elongation with a constant diameter (Fischer et al. 2006, Simons et al. 2006). 
Hepatic tissue must meet a similar challenge when forming the complex biliary tree 
and it is likely precise orientation of cell division is required for this process.
Here, we investigate the relationship between hamartin, tuberin and polycystin-1 
through examining Tsc1+I', Tsc2+I' and Pkd1+/' mice, and their compound 
heterozygous littermates. To understand the role these proteins play in primary cilia 
formation and cell polarity, we sought defects in these processes in our mice.
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3.2 Materials and methods
3.2.1 DNA extraction and genotyping
Following the method outlined in Chapter 2, Section 2.5.5, DNA was extracted from 
scalpel-dissected tail tips using NaCI/isopropanol. PCR amplification of wild-type or 
mutant alleles for Tsc1, Tsc2 and Pkd1 was performed using the following primers in 
a 35 cycle reaction with AmpliTaq gold DNA polymerase (Applied Biosystems): Tsc1 
wild-type, Ex8F 5 -T GCCTGGAAGCCCAGG AAGGT-3' and Ex8R 5'-
CTGCAGGGCCCATGGTGGTT-3’ (183bp product), Tsc1 mutant, TSC1HETF2 5'- 
CGTT GGCTACCCGT GATATT-3' and TSC1HETR 5'-
CCAATGGGCTCATTACTCTCA-3' (268bp product), Tsc2 wild-type, genF 5'- 
AATCGCATCCGAATGATAGG-3, and TSC2WTR 5-
GTTTAATGGGCCCTGGATCT-3, (~900bp product), Tsc2 mutant, genF and 
TSC2HETR 5 -GGAT GAT CT GGACGAAGAGC-3 ’ (658bp product), Pkd1 wild-type, 
PKD1WTF 5 -GCT CGC ACTTT C AGCAATAAGAC-3’ and PKDWTR 5’-
CAGGATTTCCACTGGGTTCT-3, (661 bp product), Pkd1 mutant, PKDNEOF 5'- 
AGCGTT GGCTACCCGT GATATT G-3' and PKDEXON21R 5'-
GTCTCCGTGATGTTCTTACGCATT-3’ (731 bp product). Products were analysed on 
2% agarose gels.
3.2.2 Animal care and husbandry
All procedures with our mice were carried out under Home Office guidelines outlined 
in Chapter 2, Section 2.5.1. Tsc1+I' (Wilson et al. 2005) and Tsc2+I' mice on a Balb/c 
background (Onda et al. 1999) were crossed with Pkd1+/' mice on a 129/Sv 
background (Boulter et al. 2001) to produce Tsc1+/', Tsc2+/~, Pkd1+I', Tsc1+/~Pkct'' 
and Tsc2+/'Pkd1+l' mice, as well as wild-type littermates. Livers from 10 day old mice, 
and kidneys from 48 hour and 10 day old mice, were removed following cervical 
dislocation and processed into paraffin wax for sectioning at 4pm. Livers and kidneys 
from 3 month old mice were removed, fixed in PBFG overnight and set aside for 
examination by SEM. Livers and kidneys from 15-18 month old mice were processed 
into paraffin wax for sectioning and lesion analysis. 20 month old mice were 
investigated for large hepatic cysts, and these were taken for SEM processing.
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3.2.3 Immunohistochemistry
Five 4|jm thick sections of paraffin embedded renal and hepatic tissue were cut from 
9-12 month (kidney) or 15-18 month (liver) old wild-type, Tsc1+/', Tsc2+/', Pkd1+,' t 
Tsc1*/~PkcT,~ and Tsc2+/~Pkd1+l' mice as described in Chapter 2, Section 2.5.12. A 
section was taken every 200pm from the samples to provide a representation of the 
respective organ. Slides were H&E stained to reveal lesions and evaluated under 
blind conditions. Analyses of hepatic tissues were led by myself and analyses of 
renal tissue were led by Dr. Cleo Bonnet in our laboratory.
3.2.4 Scanning electron microscopy
At least five mice of each genotype were culled and perfused transcardially with 
40ml of phosphate buffered saline (PBS) at pH 7.4 followed by 50ml of phosphate 
buffered 4% formaldehyde / 0.2% gluteraldehyde (PBFG). The kidneys and liver 
were removed, bisected longitudinally, post-fixed for 24hrs in PBFG and infiltrated 
with 2.3M sucrose in tris buffered saline (TBS). Kidneys and livers were frozen and 
the tubule lumens and bile ducts exposed by sectioning with a freezing stage sledge 
microtome. All specimens were then dehydrated using the hexamethyldisilazane 
method (Nation 1983), mounted on aluminium stubs using carbon paint, sputter 
coated with gold using an EMscope vacuum coater and viewed at 5kV in a JEOL 
840A SEM. Primary cilia lengths were measured using analysis software by an 
observer blinded to genotype and exported as Microsoft excel tables.
3.2.5 Orientation of cell division
Kidney sections from mice at 48 hrs and 10 days of age and liver sections from mice 
at 10 days of age were stained with anti-phospho-histone H3 (Ser10) antibody (anti- 
H3pS10) (1:50 dilution) to label the chromosomes of dividing cells in late anaphase 
and telophase. Rehydrated 4pm kidney and liver sections were boiled in 10mM 
citrate buffer (pH 6.0) for 10 minutes and incubated overnight at 4°C with anti- 
H3pS10 and further incubated for 30 minutes at room temperature (RT) in the dark 
with tetramethyl rhodamine isothiocyanate (TRITC) conjugated goat anti-rabbit IgG 
(H+L) (1:300 dilution). Sections were counterstained with either fluorescein
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isothiocyanate (FITC) Lotus tetragonolobus lectin (LTL) (1:100 dilution) for the 
proximal kidney tubule, FITC Dolichos biflorus agglutinin (DBA) (1:100 dilution) for 
the collecting duct or immune-stained overnight at 4°C with Tamm-Horsfall 
glycoprotein (THP) (1:150 dilution) for the thick limb of the loop of Henle/distal 
convoluted tubule or cytokeratin 19 (CK19) (1:100 dilution) for cholangiocytes lining 
the bile duct, followed by FITC conjugated chicken anti-goat IgG (H+L) (1:200 
dilution). All staining with fluorescent labelled reagents was performed in the dark for 
30 minutes at RT. Slides were mounted with ProLong® Gold antifade reagent with 
DAPI and examined using an Olympus BX51 microscope. Images were acquired 
using a Zeiss Axiocam digital camera and analysed with AxioVision software. The 
orientation of cell division was determined by measuring the angle between the 
mitotic spindles of dividing cells and the longitudinal axis of the kidney tubules or bile 
ducts, using five mice per genotype for the kidneys and 8 mice per genotype for the 
livers. Metaphase chromosomes were ignored to avoid the measurement of spindles 
that had not yet reached their definitive orientation. Image acquisition and angle 
measurement were carried out by an observer blinded to genotype.
3.2.6 Statistical analyses
Lesion counts were compared using the Mann-Whitney U test. Primary cilia lengths 
were compared using the 2-sample T-test for parametrically distributed 
measurements, and the Mann-Whitney U test for non-parametric data. The chi- 
squared test was used to compare distributions of mitotic angles between 
genotypes.
3.3 Results
3.3.1 Renal and hepatic pathology
Several groups have previously published studies of the renal pathology seen in 
T s c t1' (Wilson et al. 2005, Wilson et al. 2006), Tsc2*'- (Onda et al. 1999) and Pkdl*1' 
(Boulter et al. 2001) mice. Tsrf*1' and Tsc2*'' mice experience a renal cystic 
phenotype in an age-dependent manner. By the age of 15-18 months, the majority of 
Tsc1+I' animals will have developed some form of renal lesion (Wilson et al. 2005),
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while all Tsc2+I’ mice will display renal cysts and cystadenomas by 15 months of age 
(Onda et al. 1999). Tsc1+I' mice occasionally develop small renal cysts by the age of 
3 months. Renal lesions in these Tsc1+I' and Tsc2+I' animals ranged from simple 
cysts, with a single epithelial cell lining, branching cysts, cystadenomas (cysts with 
papillae projections into the lumen) and renal cell carcinomas (Figure 3.1). Simple 
cysts are smaller and more numerous than cystadenomas and RCCs, suggesting 
these lesions progress from cysts to cystadenomas to RCCs (Wilson et al. 2006). 
Pkd1+I' mice experience a milder renal phenotype, with microscopic cysts observed 
in approximately half of mice analysed at 9 months of age (Boulter et al. 2001). 
These cysts were noted to arise throughout the nephron and be present in mice as 
young as 3 months old. All three mouse models (T s c 1 T s c Z 1' and Pkd1'A) have 
been observed to die in utero with a homozygous genotype.
3.3.1.1 Renal lesion analysis
Here, we examined the functional relationship between hamartin, tuberin and 
polycystin-1 by crossing Tsc1+A and Tsc2+/' mice with Pkd1+A mice to produce 
compound heterozygotes. We found that Tsc1+APkd1+A mice had significantly more 
renal lesions (an average of 33.2 microscopic lesions per mouse) as compared to 
either Pkd1*A (5.2 lesions per mouse, P=0.01) or Tsc1+A (10 lesions per mouse, 
P=0.01) mice at 9-12 months. In terms of the type of lesion, Tsc1+A Pkd1+A mice had 
significantly more cysts and cystadenomas as compared to either Pkd1+A (P= 0.02 
and P<0.01, respectively) or Tsc1+A (P= 0.01 and P=0.009, respectively) mice. We 
also found that Tsc2+A Pkd1+A mice had more renal lesions (228.8 lesions per 
mouse), that were more advanced, as compared to Tsc2+A mice (152 lesions per 
mouse) at 15-18 months (P= 0.03). While lesions from our Tsc1+A and Tsc2+A mice 
became more advanced with time, our Pkd1+A mice showed no evidence of lesion 
progression towards cystadenomas or RCCs at 9-12 months of age. No renal cysts 
or dilated renal tubules were found in wild-type littermates at the age of 18 months.
3.3.1.2 Hepatic lesion analysis
Under H&E analysis, no hepatic cysts were observed in our Tsc1+I' or Tsc2+I' mice at 
15-18 months of age (N=5), nor were any hepatic cysts or dilated bile ducts found in 
wild-type littermates up to 15 months (N=12). In the Pkd1+/~ mice, hepatic cysts were 
rare, occurring in 27% (2/7) of 15-18 month old animals, with an average of 2.7 
hepatic cysts per mouse. Tsc1+/'Pkd1+/' mice more frequently developed more 
hepatic cysts, occurring in 75% (3/4) of animals at 15-18 months, with an average of 
2.25 cysts per mouse. Tsc2+/'Pkd1+l' mice developed hepatic cysts in 50% (3/6) of 
animals studied at 15-18 months, with an average of 1.7 cysts per mouse. Cysts 
ranged in size from under a millimetre (Figure 3.2), several millimetres (Figure 3.3) 
and up to 2-3cm, and had a similar appearance -  a single epithelial cell lining with no 
papillary projections. These lesions were commonly found in clusters or foci. The 
majority of the very large cysts were recovered from the livers of >20 month old 
mice. Haemangiomas were not identified on any of the sections analysed. Neither 
liver cyst incidence nor liver cyst number was significantly different between 
genotypes.
3.3.2 Investigating the role of hamartin, tuberin and polycystin-1 in ciliogenesis
3.3.2.11nvestigating the relationship between cell size and cilia length
To ensure that cilia measurements taken from cholangiocytes were not related to the 
size of the cell analysed, cell size (largest diameter of the ciliated cell) and their 
projecting cilia were measured from SEM micrographs and tested for correlation. 
Table 3.1 provides a summary of the data and reveals no significant association 
across the genotypes between cell size and cilium length. These results imply cell 
size is not a factor that needs to be considered when assessing cilium length.
3.3.2.2 Investigating the relationship between age and cilia length
To test the effect of age on cilia length, bile duct primary cilia from 3 month and 11 
month old mice were measured. Cholangiocyte cilia from 3 month old wild-type mice 
had a mean length of 7.34pm (SD=1.4) (72 measurements, median=6.98pm, 4 
mice), while those from 11 month old mice had a mean of 6.99pm (SD=1.3) (120
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Pkd1+I- Tsc1+I
Figure 3.1 Microscopic analyses of H&E stained renal lesions from 9-12 month old 
Pkd1+/~, Tsc1+/' and Tsc2+/' mice. Examples are included of a simple cyst (A), a 
branching lesion (B), a cystadenoma (C) and a renal cell carcinoma (D).
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Figure 3.2 Microscopic analysis of small H&E stained hepatic lesions from (A-B) 
multi-cystic regions found in the liver of Pkd1+I’ (C-D), Tsc1+l'Pkd1+l' and (E-F) 
Tsc2+l~Pkd1+l' mice at 15-18 months of age.
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Figure 3.3 Microscopic analysis of large H&E stained hepatic lesions from (A-B) 
Pkd1*'-(C) Tsc1*'~Pkd1*''and (D) Tsc2+' Pkd1 mice at 15-18 months of age.
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measurements, median = 6.86|jm, 3 mice), a difference of 4.77%. The non- 
parametric data was compared with a two-tailed Mann-Whitney test. No significant 
difference was found between the medians (P=0.242). Care must be taken when 
interpreting this result, as stronger tests that require normality and equal variance 
were not available. Statistically, it may not be necessary to age match mice when 
comparing cilium lengths, but given the difference of 4.77% between the two ages 
we selected to age match all mice in subsequent studies.
3.3.2.3 Primary cilia in pre-cystic renal tubules
We studied the lengths of primary cilia in pre-cystic renal collecting tubule cells from 
3 month old Tsc1+/', 7sc2+/' and Pkd1+,~ m ice by scanning electron microscopy 
(SEM). We found that the lengths of primary cilia from Pkd1+/' mice were ~5% longer 
than those found in wild-type animals (mean 2.333pm compared to 2.233pm, 
P= 0.02). Interestingly, Tsc1+/' and Tsc2+/' animals had mean cilium lengths of 
2.122pm and 2.016pm, measurements that were -5% and ~10% shorter 
respectively than those from age-matched wild-type littermates (P=0.016 and 
P<0.001, respectively) (Table 3.2). The lengths of primary cilia from pre-cystic 
collecting tubule cells from Tsc1+/' Pkd1+/' (2.389pm) and Tsc2+/' Pkd1+/' (2.356pm) 
mice were significantly longer than found in Tsc1+/' and Tsc2+/' mice (P<0.001 for 
both) and were of a similar length to those found in Pkd1+/' mice (Table 3.2).
3.3.2.4 Primary cilia in pre-cystic liver cholangiocytes
We examined cholangiocyte primary cilia, which project into the lumen of bile ducts 
throughout the liver. Bile ducts have a distinct morphology and are commonly 
adjacent to hepatic vasculature. The epithelial cells lining these ducts have defined 
boundaries and are fairly uniform in size. It has previously been established (Huang 
et al. 2006) that bile duct diameter correlates with cilia length, with large bile ducts 
having cilia up to two times the size seen in small ones (<15pm). During this study, 
bile duct diameter was determined before cilium measurements, to ensure only large 
(diameter between 15pm and 100pm) bile ducts were used.
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Genotype N
Cell size 
(mean 
largest 
diameter) 
(±SD)
Pearson
correlation
(r)
Spearman’s 
rank 
correlation (rs)
P
value
Critical
value Result
Wild type 86 6.14pm(±1.6) 0.117 0.282 0.207
No Significant 
Association
Tsc1+I- 91 5.86pm(±1.1) 0.023 0.207
No Significant 
Association
Tsc2+I- 68 6.38pm (±1.4) 0.178 0.146 0.235
No Significant 
Association
Pkd1+I' 86 5.76pm(±1.0) 0.167 0.207
No Significant 
Association
sc1+l'Pkd1+l' 97 6.552pm (±1.4) 0.174 0.089 0.197
No Significant 
Association
sc2+l'Pkd1+l~ 65 6.61pm(±1.5) 0.133 0.290 0.235
No Significant 
Association
Table 3.1 The relationship between cholangiocyte cell size (measured by taking the 
maximum cell diameter) and primary cilium length in Tsc1+I~, Tsc2+I', Pkd1+,~, Tsc1+I~ 
Pkd1+I' and Tsc2+l~Pkd1+l' mice. Association was tested in normally distributed data 
(as confirmed by the Anderson-Darling test) with Pearson’s correlation coefficient 
(where no association is indicated when P>0.05 and when the calculated correlation 
coefficient is less than the associated critical value at that particular N value). Non- 
parametric data was ranked and analysed with Spearman’s rank correlation 
coefficient. No significant correlation in this test is indicated by the rs value being less 
than the critical value at P=0.05. All critical values taken from Minitab 14.
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Genotype N
Average renal tubule 
primary cilium length 
(pm) (±SD)
Percentage change from wild type (%) 
(P value if significantly different)
Wild type 205 2.233pm (±0.45) n/a
T s c f1' 126 2.122pm (±0.54) -4.97% (P=0.016)
Tsc2*'- 255 2.016pm (±0.41) -9.72%(P<0.001)
Pkd1H' 285 2.333pm (±0.40) +4.48% (P=0.02)
Tsc1
Pkd1*'~
269 2.389pm (±0.46) +6.99% (P<0.001)
Tsc2*'-
Pkd1H'
261 2.356pm (±0.59) +5.51% (P=0.043)
Table 3.2 Primary cilium lengths from pre-cystic renal tubule cells. N value denotes 
the number of primary cilia measured from 5 mice of each genotype. P values refer 
to associated genotype primary cilium length compared to wild type cilia length.
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Primary cilia from pre-cystic 3 month old bile ducts showed no abnormal morphology 
and were uniformly present as single projections, with no evidence of multiple cilia 
per cell (Figure 3.4). Cholangiocyte primary cilia from wild-type mice had a mean 
length of 7.34pm (SD=1.4), and were several times longer than primary cilia found 
lining kidney tubules in age matched mice from the same strain (mean 2.233pm, 
SD=0.45). Cholangiocyte primary cilia from Tsc1+'\ Tsc2+I’ and Pkd1+/’ mice were 
significantly shorter compared to cilia measurements from wild-type littermates 
matched for age (-15.8%, -12.8% and -17.6% respectively, P<0.001). Double 
heterozygote mice revealed significant shortening compared to wild-type 
measurements by comparable amounts (Tsc1+l'Pkd1+l' were shorter by -18.1% and 
Tsc2+/~Pkd1+l' by -17.3%, P<0.001) (Table 3.3 and Figure 3.5). All measurements 
were taken from bile ducts of equivalent size.
3.3.3 Primary cilia in hepatic cyst epithelia
Hepatic cyst sections were dissected from 20 month old Pkd1+I\  Tsc1+l'Pkd1+l~ and 
Tsc2+/'Pkd1+l' mice and analysed via SEM. Many measurements were possible as 
cilia carpeted the cyst lumen, with clubbed cilia commonly occurring (Figure 3.6). In 
all three genotypes, cyst primary cilia showed a large amount of variability in length 
compared to pre-cystic bile duct cilia. Despite containing occasional extremely long 
primary cilia, the mean lengths of primary cilia from epithelial cells lining cysts in 
Pkd1*'~ (5.56MIT1, SD=2.8), Tscf'-Pkd1+/' (4.29Mm, SD=1.6) and Tsc2*l'Pkd1*1' 
(4.05pm, SD=1.9) mice were all significantly shorter than measurements from the 
bile ducts of 3 month old wild-type mice (P<0.001) (Table 3.4). All of these data 
(Sections 3.3.1.1, 3.3.1.3, 3.3.2.3, 3.3.2.4 and 3.3.3) support a functional relationship 
between polycystin-1 and hamartin / tuberin that affects primary cilium length.
Tsc1+I-
Pkd1H
Tsc1+/-Pkd1+'- Tsc2+/-Pkd1+I
Figure 3.4 Scanning electron micrographs of cholangiocyte primary cilia in pre-cystic 
hepatic bile ducts (A-G). Panel A: overall morphology of a typical mouse bile duct at 
3 months of age. Panels B-G: Magnified micrographs of cholangiocyte primary cilia. 
Hepatic primary cilia are indicated with arrow heads. Scale bars: 5pm.
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Genotype
Sample
number
Pre-cystic cholangiocyte 
primary cilia mean length 
(pm) (with SD)
Percentage shorter than 
average wild-type cilium
Wild-type 72 7.34(1.4) n/a
Tsc1*'- 87 6.18(1.5) -15.8% (P<0.001)
Tsc2+A 94 6.4(1.4) -12.8% (P<0.001)
Pkd1*A 102 6.05(1.5) -17.6% (P<0.001)
Tsrt^Pkdl*'- 134 6.01 (1.2) -18.1% (P<0.001)
Tsc2*'-Pkd1*'- 92 6.07(1.8) -17.3% (P<0.001)
Table 3.3 Measurements of primary cilia length (pm) from pre-cystic hepatic bile 
ducts, matched for age and duct diameter.
8 .0 0  -I
7 .5 0  -
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Wild-type Tsc1+'- Tsc2+I’ Pkd1+I~ Tsc1+lPkd1 Tsc2+lPkd1+l’
I_________________________________________________________________ __ _____________
Figure 3.5 Graph showing distribution of mean primary cilia lengths (pm) from pre- 
cystic hepatic bile ducts, matched for age and duct diameter. A significant shortening 
of the primary cilia is seen across pre-cystic haploinsufficient cells (P<0.001) 
compared to wild-type. Standard error bars are included.
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Genotype
Sam ple
num ber
Epithelial cells lining cysts primary 
cilia m ean length (pm) (with SD)
Percentage shorter than 
average wild-type cilium
Wild-type 72 7 .3 4 (1 .4 ) n/a
Ts c 1*a n/a n/a n/a
Tsc2*a n/a n/a n/a
Pkd1*A 1932 5.56 (2 .8) -24 .3%  (P <0.001)
Tsc1*/mPkd1*/' 623 4 .2 9 (1 .6 ) -41 .6%  (P <0 .001)
Tsc2*/ Pkd1+/- 3818 4 .0 5 (1 .9 ) -4 4 .8 %  (P <0 .001)
Table 3.4 M easurem ents of primary cilia length (pm ) from epithelial cells lining liver 
cysts in 20 month old mice. Sam ple numbers indicate the total num ber of primary 
cilia m easured from 3 mice in each genotype. Tsc1 +/' an d Tsc2+I' mice do not 
experience hepatic cystogenesis.
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Figure 3.6 Main Panel: Scanning electron micrograph of the luminal surface of a 
liver cyst from a 20 month old Tsc2+/~Pkd1+/~ mouse. Inset: An enlarged area of the 
micrograph showing the occasional presence of extremely long (>10pm ) and 
abnormally clubbed primary cilia.
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3.3.4 Investigating the role of hamartin, tuberin and polycystin-1 in cell polarity
3.3.4.1 Pre-cystic renal tubules
We sought defects in cell polarity in our mice by assessing the mitotic orientations of 
dividing pre-cystic cells from the renal proximal tubule, collecting duct and loop of 
Henle/distal convoluted tubule from mice at 48 hrs of age. For wild-type mice, we 
found that 78% of dividing cells from the proximal tubule, 82% from the collecting 
duct and 78% from the loop of Henle/distal convoluted tubule divided within 10° of 
the longitudinal axis, demonstrating that, in agreement with others (Fischer et al. 
2006), oriented cell division is tightly regulated during tubule lengthening. In contrast, 
we found significant defects in the mitotic orientations of dividing cells from Tsc1+/', 
Tsc2+/' and Pkd1+/' mice. For Tsc1w' mice, we found that 41% of dividing cells from 
the proximal tubule, 45% from the collecting duct and 53% from the loop of 
Henle/distal convoluted tubule divided within 10° of the longitudinal axis (P=0.002, 
0.003 and 0.039, respectively, compared to wild-type), for Tsc2+A mice, we found 
that 46% of dividing cells from the proximal tubule, 27% from the collecting duct and 
44% from the loop of Henle/distal convoluted tubule divided within 10° of the 
longitudinal axis (P=0.003, <0.001 and 0.009, respectively, compared to wild-type) 
and for Pkd1+A mice, we found that 61% of dividing cells from the proximal tubule, 
47% from the collecting duct and 44% from the loop of Henle/distal convoluted 
tubule divided within 10° of the longitudinal axis (P=0.133, 0.001 and 0.002, 
respectively, compared to wild-type). We also studied dividing cells from mice at 10 
days of age and observed identical results to our studies at 48 hrs of age.
3.3.4.2 Pre-cystic hepatic bile ducts
We addressed whether defects in cell polarity were present in hepatic tissues from 
our mouse models. We assessed the mitotic orientations of dividing pre-cystic cells 
from the hepatic bile ducts of mice at 10 days of age. For wild-type mice, we found 
that 94% (16/17) of cells from the bile duct divided within 10° of the longitudinal axis, 
demonstrating that, similar to the developing renal tubule, orientated cell division is 
tightly regulated during bile duct lengthening (Figure 3.7). Consistent with the 
abnormalities that we detected in renal tubules, we found significant defects in the
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mitotic orientations of dividing hepatic cells from Tsc1+/', Tsc2+/' and Pkd1+/' mice. 
For Tsc1+/' mice, we found that 33% (7/21) of cells divided within 10° of the 
longitudinal axis, for Tsc2+/' mice, we found that 29% (6/21) of cells divided within 
10° of the longitudinal axis and for Pkd1+/' mice, we found that 45% (9/20) of cells 
divided within 10° of the longitudinal axis (P<0.001 for all, compared to wild-type).
We also observed that in Tsc1+I' mice, 28% of dividing cells from hepatic bile ducts 
showed an ‘extreme’ dysregulation of mitotic orientation (with divisions between 60° 
and 90° to the duct axis) and similarly, in Tsc2+/' mice, 38.1% of dividing cells 
displayed this severe phenotype. Such dysregulation was observed less frequently in 
dividing cells from Pkd1+I' mice (15%) and was not observed in wild-type littermates.
3.3.4.3 Genotype and aberrant polarity
In the kidney, we found no difference between Tsc1- and Tsc2-associated polarity 
defects. As expected, we did find significant differences in the orientations of dividing 
cells from Tsc1+/ Pkd1+/' and Tsc2+/' Pkd1+/' mice as compared to their wild-type 
littermates, but did not observe any differences between Tsc1+/ Pkd1+/' and Tsc2+/ 
Pkd1+/' mice, or their corresponding single heterozygote littermates (all were similarly 
misorientated). In the liver, no significant difference was found between the Tsc1-, 
Tsc2- and Pkd1-associated polarity defects, implying all genotypes had bile duct 
cells that were similarly misorientated during mitosis.
3.4 Discussion
3.4.1 A genetic interaction between Tsc1, Tsc2 and Pkd1
A genetic interaction between TSC2 and PKD1 is implied by the severe early onset 
cystic kidney phenotype seen in patients with a contiguous deletion of TSC2 and the 
adjacent PKD1 gene (Brook-Carter et ai 1994, Sampson et al. 2997). In an attempt 
to recapitulate this phenotype, we bred Tsc2+I~ mice with Pkd1+I' mice and analysed 
renal and hepatic lesions at 9 -12 months of age. While more renal lesions were
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Figure 3.7 Mitotic orientations of dividing pre-cystic hepatic bile duct cells from 10 day old mice. Graph showing distribution of mitotic 
angles of division in relation to longitudinal bile duct plane from wild-type, Tsc1+I~, Tsc2+I~ and Pkd1+I' mice (A). Fluorescent 
micrographs showing examples of mitotic orientation in wild-type (B), Tsc1+I~ (C), Tsc2+I' (D) and Pkd1+I' (E) mice stained for dividing 
chromosomes (red) with anti-H3pS10, DAPI for nuclear staining (blue) and cholangiocytes (green) with anti-CK19. Scale bars: 10pm.
found in our Tsc2+l'Pkd1+l' crosses when compared to single heterozygous Tsc2+I' or 
Pkd1+I' animals, the results seen were not on the same scale as the human 
contiguous deletion syndrome. Rather than massive cystogenesis across newborn 
kidneys leading to early kidney failure, our compound heterozygote mice presented 
with moderately increased levels of simple cysts, as well as more advanced lesions, 
such as cystadenomas and RCCs.
Because tuberin and hamartin have been shown to physically interact and form a 
tumour suppressor complex (van Slegtenhorst et al. 1998, Tee et al. 2003), we also 
investigated the effects of a compound Tsc1+l'Pkd1+l' phenotype in our mice. No 
severe early onset cystogenesis was seen in our animals, although significantly 
more renal lesions (cyst, cystadenomas and RCCs) were observed in these mice 
compared to single heterozygote littermates.
Mice deficient in hamartin or tuberin did not experience any hepatic phenotype at 15- 
18 months of age. The Pkd1+I' mice and associated crosses (Tsc1+/'Pkd1+l~ and 
Tsc2+l'Pkd1+l') developed liver cysts at an incidence of -30-75%. Renal cysts are 
known to occur in both the Pkd1 and the Tsc animals. This would suggest a 
polycystin-1 deficiency is required for the appearance of cysts in the liver. The 
appearance of a hepatic cystic phenotype in our Pkd1+/' mice at 15-18 months is a 
rare event, but is slightly increased in frequency under compound Tsc1 or Tsc2 
mutation. However, average hepatic lesion number was not significantly different 
between Pkd1+/', Tsc1+l'Pkd1+l' and Tsc2+l'Pkd1+l' mice.
Several reasons may underlie the modulation of the renal phenotype. A compound 
heterozygote (such as Tsc1+l'Pkd1+l') has two genes mutated at a germline level, 
leaving the possibility of a second somatic hit in either gene more likely than in a 
single heterozygote animal. This second hit to completely remove gene function is 
likely to exacerbate the cellular phenotype seen with haploinsufficient protein levels 
and may drive such a cell towards cystogenesis. If such a relationship was a
113
straightforward link between germline gene mutation and cyst incidence, one would 
expect an additive increase in lesion number rather than the more complex pattern 
seen in our animals. Furthermore, several studies (Wilson et al. 2006, Onda et al. 
1999, Koptides et al. 2000) have also found that second hits are not always 
observable in TSC and ADPKD-associated lesions.
Tissue specific factors are relevant in the interpretation of our results, as a 
compound heterozygous mouse will experience a greatly exaggerated renal 
phenotype but only a marginally raised incidence of hepatic cysts. A functional 
interaction between tuberin, hamartin and polycystin-1 has been suggested in the 
kidney to account for such a large increase in lesion burden, but the data is not so 
compelling in hepatic samples. Tuberin and polycystin-1 have been shown to 
functionally and physically interact, with the TSC2 product trafficking polycystin-1 to 
the cell membrane from the Golgi (Kleymenova et al. 2001). At this point, other 
groups (Shillingford et al. 2006, Mostov et al. 2006) have suggested that the 
cytoplasmic C-terminal tail of polycystin-1 mediates assembly into a complex with 
tuberin and mTOR. This high level of co-dependency and functional interaction may 
explain the renal cystic phenotype seen in our compound heterozygous mice but it is 
likely that additional layers of complexity exist in cholangiocytes, such as alternative 
signalling pathways, a different cellular signalling environment and a reduction in 
cellular requirement for hamartin/tuberin/polycystin-1 interaction.
The histological appearance of the liver lesions was similar across all genotypes -  
focal growths dispersed across the organ, with a single epithelial cell lining and no 
papillae projections. Size did vary from under a millimetre to several centimetres, 
with a tendency for larger cysts to be discovered in older animals. This is different to 
the situation in kidneys, where advanced cysts developed papillae projections and 
progress towards a cystadenoma. Foci of cystic growth are uncommon in renal 
samples, while it is a normal finding in the liver. This is likely due to tissue specific 
differences. For example, under histological examination, hepatic tissue is tightly 
packed and therefore restrictive to cyst expansion. Cysts in the liver may naturally
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expand to fill available space I areas of reduced compaction, in much the same 
manner as a balloon expanding in a complex 3D shape might. The resultant cyst foci 
seen in hepatic tissue may be the result of a cross section through this complex 
shape. Kidney tissue (which certainly appears more spacious under a microscope) 
may not be so restrictive to cyst expansion, and allow a lesion to expand in a roughly 
circular shape, compressing the surrounding tissue.
The overall picture appears to suggest that kidneys are much more susceptible to 
cystic growth and progression compared to livers. An additional Pkd1+I' mutation is 
required to drive any sort of hepatic phenotype in our Tsc animals. The resulting 
compound heterozygotes have a slightly raised risk of hepatic cyst incidence but 
nowhere near the levels seen in kidneys from these same animals. The liver cysts do 
not progress towards a cancerous phenotype (as seen in kidneys) demonstrating a 
possible resistance to cyst progression. However, hepatic cysts are much rarer than 
kidney cysts and may require more time to form in sufficient numbers before 
advanced lesions may emerge.
3.4.2 Differences between the Pkd1*,m mouse models and humans with ADPKD
Humans with ADPKD are subject to a progressive formation of bilateral, multiple 
renal cysts. In around 70% of patients, cysts will also occur in the liver (Yoder et al. 
2006). In our Pkd1*'~ mouse model, renal cyst incidence has been placed at 50% of 9 
month old animals (Boulter etal. 2001), with liver cysts occurring in 29% (2/7) of 15- 
18 month olds. The cystic kidney phenotype seen in Pkd1+I' animals appears less 
pronounced than in human counterparts. Additionally, the incidence of hepatic 
cystogenesis is reduced in the mouse model, although similarities exist in the origins 
of cyst development -  both appear to arise from epithelial cells contained in the 
biliary tree (Lu et al. 1999). Although several groups (Lu et al. 1999) have underlined 
the importance of the Pkd1+I~ mouse model in recapitulating human ADPKD in terms 
of renal and hepatic cystogenesis, there is a need to appreciate differences exist in 
cystic kidney disease between humans and mice (specifically with regards to onset 
and severity).
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3.4.3 Mice from Tsc2f/‘ and Pkdl*1' crosses occasionally experience a severe 
early onset kidney disease
As discussed previously (Chapter 1), humans born with a contiguous deletion of 
TSC2 and the adjacent PKD1 gene experience a severe infantile polycystic kidney 
syndrome. Interestingly, lesion studies in our Tsc1+,'Pkd1+,~ and Tsc2+l'Pkd1+l' mice 
failed to find a similar gross cystic phenotype. Mice experiencing severe renal cystic 
disease may have died before 9-12 months of age, so a breeding programme was 
set up by our lab as part of a separate study, to examine mice at weaning (3-4 
weeks old). Although extremely rare, from over 200 mice born through Tsc2+I' and 
Pkd1+I' crosses, we found three animals with a severe polycystic renal phenotype 
(no cysts in extra renal tissues were observed). Two of these mice were 
characterised as Tsc2+/'Pkd1+l+ and one was a Tsc2+l'Pkd1+l'. No mice generated 
from over 200 crosses of Tsc1+/' and Pkd1+/' animals were found to have a severe 
early onset cystic disease.
In all three mice with early onset polycystic kidney disease, the cystogenesis was 
unilateral, with one normal kidney and one enlarged cystic kidney. Upon longitudinal 
bisection, microscopic cysts (ranging in size between 1mm and 5mm) were found to 
be distributed homogenously across the cortical and medullary regions. Despite the 
young age of the mice, evidence of lesion progression (in the form of cystadenomas) 
was found in the 7sc2+/'mouse kidney. The cysts examined in the kidneys of the 
Tsc2+,'Pkd1+l' mice resembled cysts found in later Pkd1+/' animals. Similar to our 
findings, Cai et al. (2003) have found three young Eker rats (>3 months of age) with 
severe polycystic kidney disease. They found cysts, cystadenomas and RCCs in 
these animals to be present across the cortex and medulla, but the cystogenesis 
seen was bilateral, not unilateral as in our mice. Cai et al. also noted extra-renal 
lesions in the spleen and uterus, while no evidence of this was found in our early 
onset animals. Molecular analysis revealed renal cells had lost their functional copy 
of Tsc2, and the authors attributed this to a mutational event during embryogenesis 
(probably chromosomal nondisjunction). Thus the affected animals were mosaics for 
loss of Tsc2 gene function. A similar event may have occurred in our mice, 
accounting the rarity of this early onset phenotype. The fact that our mice displayed
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unilateral cystogenesis while the Eker model produced bilateral cysts implies that 
loss of the wild-type allele occurred later in embryogenesis. This is supported by the 
lack of extra-renal lesions in our mice, compared to the wider cystic phenotype seen 
in the early onset Eker rats.
It is likely that somatic genetic differences account for the discrepancy between 
contiguous TSC2/PKD1 syndrome patients and our Tsc2+l'Pkd1+l' mouse lines. In 
humans, TSC2 and PKD1 lie adjacent on chromosome 16. In our mice, Tsc2 and 
Pkd1 are adjacent on chromosome 17, but the gene targeting constructs will lie on 
different alleles in compound heterozygote animals. The result of this makes biallelic 
inactivation of the remaining wild-type TSC2 and PKD1 genes much more likely in 
humans (through a single large deletion mutation) than in mice, which would require 
two further mutational events to completely remove Tsc2 and Pkd1 gene function.
3.4.4 Hamartin, tuberin and polycystin-1 play a role in renal and hepatic 
ciliogenesis
Following SEM measurement of primary cilia in renal tubules and bile ducts, we 
found hamartin, tuberin and polycystin-1 play a role in maintaining the length of 
these organelles in pre-cystic cells. In cholangiocytes, there was a significant 
decrease in length in all mutant genotypes when compared to wild-type littermates, 
matched for age and bile duct size. Renal tubule cells experienced disruption in their 
primary cilia too, with shortening in Tsc1+I' and Tsc2+I' animals, and lengthening in 
Pkd1+I' mice. These measurements support a role for these proteins in renal and 
hepatic ciliogenesis, and suggest that a deficiency in hamartin, tuberin or polycystin- 
1 can lead to haploinsufficient ciliary abnormalities that pre-date cyst development. 
Clearly ciliogenesis is perturbed in both tissues but the effect of polycystin-1 
deficiency appears to vary with tissue type.
Work done by Hartman et al. (2009) found that in Tsc1 and Tsc2 null mouse 
embryonic fibroblasts (MEFs) there was a 17-27% increase in primary cilia length 
when compared to wild-type cells. This would be at odds with our in vivo hepatic and 
renal data but several factors may account for this difference. The MEFs used were
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immortalised, through spontaneous means (TscV1') or through a targeted p53 
knockout (T s c Z Either way, there is potential for other pathways to disrupted, any 
of which may have a bearing on the ciliary phenotype. The experiments were also 
conducted under conditions that are removed from liver or kidney physiological 
conditions and with tubular / ductal flow removed from the ciliated cell environment. 
While an underlying ciliary disruption may well be present in these cell lines, there is 
perhaps an issue with recapitulating the physiological setting that a primary cilium 
would experience in vivo, and so caution must be exercised when drawing 
comparisons.
Primary cilia lengths from epithelial cells lining hepatic cysts from Pkd1+,\  Tsc1+I' 
Pkd1+I' and Tsc2+l~Pkd1+,~ lesions echoed the shortening seen in pre-cystic lesions, 
although to a greater degree. The primary cilia projecting into the cyst lumen of our 
20 month old mice were visibly malformed and significantly shorter than primary cilia 
in the bile ducts of our 3 month old wild-type mice. One standout feature of the cyst 
cilia data was the massive range of lengths found. While pre-cystic cilia from across 
the genotypes occasionally reached 10pm, several Pkd1+I' and Tsc2+,'Pkd1+l' cyst 
cilia reached sizes exceeding 18pm, with the longest reaching 20pm (almost 3 times 
the size of a wild-type cilium). This was accompanied by a large number of 
foreshortened cilia, leading to an overall low average length and large range. 
Interestingly, this variability was not seen in Tsc1+,'Pkd1+l' mice although smaller 
cysts were used and less measurements taken. The massive variation indicates an 
extreme loss of control over cilia structure, and additional defects such as clubbing 
and multi-ciliated cells would support this. Large differences in cilium lengths have 
previously been observed in renal cysts from these same mice (Bonnet et al. 2009). 
There, a 200% increase in renal cilia length was reported in Tsc1+I' and Tsc2+I' mice, 
changing from a relatively modest 5-10% difference in pre-cystic cells. Taken 
together with the liver data, we see an extreme loss of length control when moving 
from a pre-cystic to cystic setting. This may be accounted for by the acquisition of 
additional mutations during cystogenesis. As these cysts progress, second hits may 
occur in the remaining Tsc1, Tsc2 or Pkd1 genes, compounding any effects seen 
and amplifying the phenotype. Ciliary clubbing seen in the liver was not found in the 
kidney studies and may well be another tissue specific difference.
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Interestingly, Pkd1+,~ in the kidney appears to play a different modifying role, by 
causing an increase in primary cilium length when compared to the wild-type 
measurements. This may be another example of tissue specific differences in the 
roles of primary ciliary proteins and cilium length maintenance, but could also 
suggest an underlying inconsistency in the ciliogenesis and imply defects seen in 
this organelle are simply a symptom of disrupted polarity (discussed later).
3.4.5 A physiological consequence to abnormal primary cilia?
The ciliary membrane is rich in receptors, ion channels and signalling proteins, with 
the potential for activation by mechanical or chemical means (Rosenbaum et al. 
2002). Consistent with the loss of such a high concentration of signal transducing 
proteins, cells lacking primary cilia experience negative cellular effects, such as 
reduced sensitivity to fluid flow mediated calcium influx (Nauli et al. 2003, Praetorius 
et al. 2003, Lin et al. 2003). Our mice have disrupted renal tubule and cholangiocyte 
primary cilia, but it is unclear if a modest reduction in length of ~10-20% can exert 
similar a pathophysiological effect on pre-cystic cells. Work using the orpk mouse 
model of autosomal recessive polycystic kidney disease looked at a similar situation 
in renal tubules (Brown et al. 2003). It was found that while the observed correlation 
between reduction in cilia length and formation of renal cysts in orpk mutants might 
indicate a link between reduced ciliogenesis and cystic disease, this hypothesis was 
not borne out through additional analysis of orpk and knockout rescue models. 
These rescue models revealed discrepancies between levels of ciliogenesis and 
cystogenesis, implying the two may well be separate processes and not intrinsically 
linked.
More recent work by Verghese et al. (2008) has shown renal cells to alter primary 
cilia lengths as a cellular response to ischemic renal injury. An initial ciliary 
shortening was observed following loss of blood flow to the proximal tubule but this 
was proceeded by lengthening of cilia in several regions of the kidney tubule 
network. It was suggested that this lengthening was a cellular attempt to increase 
sensitivity to fluid flow and maintain an epithelial phenotype in the face of hostile 
factors promoting desensitisation and dedifferentiation. This theory would explain the
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accentuated phenotype seen in cystic cell cilium lengths. The cyst has been 
described as a hostile environment and as such, cellular stresses may be indicated 
through drastic lengthening and shortening of primary cilia.
Taken together, these observations imply foreshortening of renal and cholangiocyte 
primary cilia may be a symptom or compounding factor of perturbed cellular 
signalling and not a direct cause of pathophysiological effects. Uncertainty arises 
through the reciprocal relationship between primary cilia and cell signalling. For 
example, defects in primary cilia structure and function have been shown to affect 
Wnt signalling, but conversely, Wnt pathway proteins are responsible for ciliary 
formation (Simons et al. 2005, Corbit et al. 2008).
3.4.6 Role of hamartin, tuberin and polycystin-1 in bile duct and renal tubule 
cell polarity
In the livers of our mice, wild-type bile duct cholangiocytes behave similarly to renal 
tubule cells and divide in a tightly controlled manner. Pre-cystic 10 day old mutant 
mice were then assessed to measure duct polarity during biliary tree development. 
Significantly less cell divisions in Tsc1+I', Tsc2+I' and Pkd1+I' mice occurred inside 
10° to the axis of the bile duct. Additionally, while no wild-type cell divisions occurred 
at an extreme angle to the plane, it was found significant levels of Tsc1+,\  Tsc2+I' 
and Pkd1+/' duct cells divided at an angle greater than 60°.
It is important to note that crucial differences exists between the liver and kidney -  a 
bisected kidney will reveal thousands of tubule cells, many of which are likely to be in 
the correct plane for measurement if dividing. A dissected liver will unfortunately not. 
Chance plays a large part in catching a bile duct in the correct orientation with 
dividing cells, and combined with the small numbers of ducts present on a section, 
this results in a much smaller number of cells being counted. Every effort was made 
to obtain sufficient numbers of cell divisions to give an overview of polarity in the liver 
and the picture that has emerged appears to mirror the situation that occurs in the 
much more extensively measured kidney.
It has been suggested that it may be appropriate to generate more comprehensive, 
three dimensional images of aberrant mitotic orientations in renal tubules and bile
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ducts to ensure divisions that appear in or outside the tissue plane are not 
artefactual. Using confocal microscopy, work in the kidney has found similar results 
using fluorescent staining and 3D techniques, implying the method used here is 
reliable (Bonnet et al. 2009).
On the basis of these results, our data show for the first time that hamartin, tuberin 
and polycystin-1 have a role to play in bile duct and renal tubule cell polarity. Mice 
that have reduced levels of these proteins in their cholangiocytes or tubule cells have 
a deficiency in controlling the orientation of their cell divisions that, alongside the 
altered lengths of the primary cilia, are abnormal changes that pre-date hepatic and 
renal cystogenesis.
Potential reasons behind this disruption in polarity are numerous. All three proteins 
have strong links to the primary cilium, and are known to cause abnormalities in cilia 
length when levels are diminished through germline mutation (as previously 
discussed). The primary cilium is thought to modulate planar cell polarity (PCP) 
(Simons et al. 2005) and so a poorly formed organelle may translate to reduced 
control over mitotic divisions. As an alternative to a cilium-led hypothesis, it is also 
possible that defective cellular polarity has caused the abnormality in primary cilia 
lengths (which are polar structures and require functional polarity to form). In this 
instance, the malformed organelles would be a symptom of an underlying defect 
(caused directly by a reduction in one of the three proteins) and is therefore a 
passenger, rather than driver, factor in cystogenesis. To support this hypothesis, 
several lines of evidence link the ciliary proteins directly to cell polarity signalling. 
Work by Massey-Harroche et al. (2007) using a two-hybrid assay has shown a 
molecular interaction between the C-terminal domain of tuberin and PDZ 2 and 3 of 
PATJ. PATJ is a scaffold member of the Crumbs 3 complex in mammalian epithelial 
cells and is required for normal polarity. Overexpression of the Crumbs 3 complex or 
knockdown of PATJ (Shin et al. 2005) results in polarity defects and a delay in apical 
morphogenesis in MDCK cells (Roh et al. 2003, Lemmers et al. 2004). Another 
group has demonstrated in cell line work that the C-terminal tail of polycystin-1 is 
able to undergo cleavage, localise and bind to p-catenin in the nucleus. It is thought 
this binding inhibits p-catenin-dependent Wnt signalling and TCF-dependent gene 
transcription. Disrupted levels of Pkd1 expression may therefore activate canonical
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Wnt signalling (Lai et al. 2008), and dysregulate planar cell polarity (which requires 
precise switching between canonical and non-canonical Wnt signalling).
These defects in cell polarity are likely to be occurring as a result of 
haploinsufficiency rather than as a consequence of secondary somatic mutations. 
The mitotic misorientations took place in very young mice (2 and 10 days old) and at 
this age it is unlikely that second hits will have occurred in the bile ducts or renal 
tubules to give rise to such widespread defective polarity. Additional work in the brain 
provides an interesting parallel, where haploinsufficient levels of hamartin or tuberin 
appear to dysregulate polarity. Polarisation of neurons is crucial for correct formation 
of axons and dendrites, and proteins called SAD (synapses of amphids defective)- A 
and B were found to play a key role in this process in mice (Kishi et al. 2005). 
Inactivation of Tsc1/2 was shown to promote axonal growth via upregulation of SAD- 
A, a protein noted to be elevated in the cortical tubers of a TSC patient (Choi et al. 
2008). LOH of wild-type TSC1 or TSC2 in cortical tubers is thought to be a rare 
event (Henske et al. 1996, Niida et al. 2001) and so one defective copy may be 
enough to induce signalling effects (such as upregulation of SAD-A) and promote 
dysregulation of polarity.
3.4.7 Planar cell polarity or apical/basal polarity?
To perform many of their functions, epithelial cells (such as renal tubule cells or bile 
duct cholangiocytes) need to be polarised within the plane of the epithelium, and this 
is termed PCP (Jenny et al. 2006). Apical-basolateral (A/B) polarity is perpendicular 
to the plane of the epithelial sheet and allows cells to directionally transport 
molecules across a cell layer and selectively excrete extracellular matrix components 
to form a basal lamina (Eaton et al. 1995). PCP is known to be important in formation 
of the vertebrate inner ear (specifically the orientation of stereociliary bundles in the 
organ of Corti) and convergent extension during gastrulation and neurulation 
(Wallingford et al. 2002, Keller et al. 2002).
Close examination of misorientated bile duct and renal tubule cells revealed that a 
significant proportion of these cells were dividing in a plane perpendicular to the 
epithelial sheet, consistent with defects in PCP (which would be a failure to polarise
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cells in the plane of the epithelium). However, further work on our mice examining 
the organ of Corti failed to find evidence of defective polarity in the stereociliary 
bundles (Bonnet et al. 2009). As previously mentioned, these are orientated through 
PCP, implying either the PCP defects seen are tissue specific, or it is A/B polarity 
that has been affected. No defects in gastrulation have been reported either. Finally, 
primary cilia are the most apical structures in the cholangiocytes and defects seen 
there could well be accounted for by aberrant A/B polarity. These pieces of data 
would suggest A/B polarity and not PCP has been affected in our mice. However, 
evidence for a direct link between A/B polarity and PCP has been shown in recent 
research. The drosophila PATJ equivalent, dPatj, is known to play a key role in A/B 
polarity, and binds to the cytoplasmic tail of Frizzled (Fz1) which recruits aPKC, and 
in turn phosphorylates and inhibits Fz1-dependant PCP, thereby providing a direct 
link between A/B polarity and PCP (Djiane et al. 2005). Hence, defects in one 
signalling pathway, such as PCP and misaligned cell division, may spill over and 
affect A/B polarity in certain tissues, for example by foreshortening primary cilia. The 
literature on cell signalling would place Tsc2 at the heart of this switching mechanism 
and may explain why aspects of both polarity pathways appear to be involved.
3.4.8 Wild-type misorientated cell division
Data from wild-type renal tubules suggests 78% of dividing cells in the proximal 
tubule, 82% from the collecting duct and 78% from the Loop of Henle/distal 
convoluted tubule divided within 10° of the longitudinal axis. While this demonstrates 
tight orientation of cell division, it is important to note the system is not perfect. 
Several divisions are occurring outside the tubule plane in non-mutant, wild-type 
mice. Similarly, in liver bile ducts, an instance of wild-type cell division occurring at 
an angle outside 10° was found. Taken together, this data implies wild-type cells do 
occasionally experience misorientated cell divisions, but are found at a much lower 
level than in our mutant mice. Because tubule and duct architecture is maintained in 
wild-type animals, this would indicate a mechanism exists to remove the occasional 
misorientated cell from the liver or kidney.
123
CHAPTER FOUR: Defective apoptosis may promote TSC-associated renal
cystogenesis.
4.1 Introduction
The TSC proteins function as negative regulators in the mTOR signalling pathway. 
Many lesions from TSC patients and animal models stain positively for activation of 
mTOR, and clinical trials to treat advanced tumours with mTOR inhibitors such as 
Rapamycin have been conducted with reasonable success (Bissler et al. 2008, 
Davies et al. 2008). A study by Kenerson et al. (2005) in the Eker rat model of TSC 
highlighted a subset of smaller lesions that were unresponsive to Rapamycin 
treatment and lacked evidence of apoptosis. Additionally, when looking at mTOR 
inhibition in preventing renal lesion development, it was found that Rapamycin 
reduced the progression but not incidence of precursor lesions. Further work in a 
Tsc2+I' mouse model suggested CCI-779 (a Rapamycin analogue) treatment could 
cause regression of later lesions but found no effect on the appearance of early 
kidney lesions (Messina et al. 2007). Clearly, mTOR activation is an important part of 
kidney lesion progression (as illustrated by the effects of mTOR inhibition on tumour 
volume and advancement), but other factors may influence the formation of a new 
cyst.
We have demonstrated that primary cilia and cell polarity are perturbed in renal 
tubule cells from 2- and 10-day old Tsc1+I' and Tsc2+I~ mice (Chapter 3), but what is 
unclear is why these early pre-cystic changes do not manifest as widespread tubule 
dilation and cystogenesis until around 3-6 months of age (Wilson et al. 2005). The 
simple cysts that eventually arise commonly do not stain positive for mTOR 
activation, implying alternative signalling pathways may contribute to the initiation of 
TSC-associated cystogenesis in renal tissue.
It has been suggested in other tissues (such as the mammary gland) that apoptosis 
can act as an important level of control in maintaining epithelial cell structures, in a 
process suppressed by contact with the extracellular matrix (Frisch et al. 1997, 
Pullan et al. 1996). In a similar fashion, a misorientated renal tubule cell division at 
an extreme angle to the plane of the tubule may result in a daughter cell displaced
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from the basement membrane, isolated in terms of cell-cell contact and further 
removed from pro-survival signals. Apoptosis is known to play an important role in 
normal tubule development (Igarashi 1994) but we sought to ascertain if the process 
could be triggered in misorientated renal tubules as a rescue mechanism.
Here, we studied developing renal tubules from Tsc1+I', Tsc2+I' and Pkd1+I' mice and 
wild-type littermates, stained for a marker of apoptosis to assess the role this 
process may play in rescuing a defective polarity phenotype. Furthermore, we 
studied the nature of TSC-associated mTOR-independent renal cystogenesis 
through the examination of lesions from Tsc1+I' (Wilson et al. 2005) and Tsc2+I' 
(Onda et al. 1999) mice. Apoptosis in these lesions was evaluated to test for a 
correlation between mTOR status and programmed cell death.,
4.2 Materials and methods
4.2.1 Animal care, genotyping and tissue preparation
All matters relating to animal husbandry, care and genotyping were carried out as 
previously described. Tsc1+I~, Tsc2+I' and Pkd1+I' mice were obtained along with wild- 
type littermates for control purposes. Four mice from each genotype (Tsc1+I~ and 
Tsc2+I') were sacrificed at 9-12 months and dissected to obtain paraffin-embedded 
kidneys as previously described. Two day old kidneys, required for tubule apoptosis 
counts, were removed from Tsc1+I\  Tsc2+I~ and Pkd1+/' mice and wild-type 
littermates. These were embedded in paraffin wax as previously described.
4.2.2 Immunohistochemistry
Paraffin-embedded kidneys from 2 day old wild-type (N=6), Tsc1+I~ (N=6), Tsc2+I' 
(N=6) and Pkd1+/' (N=5) mice were serially sectioned at 5pm and renal tubules were 
stained for apoptosis (active caspase-3) as previously described. Slides were 
counterstained with haematoxylin to reveal tubule cell morphology and analysed 
under an Olympus BX51 light microscope at x100 magnification. Levels of apoptosis 
taking place in pre-cystic renal tubules from these animals were based on the 
amount of positively stained tubule cells compared to the number of tubule cells
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counted. A counter was used to manually record tubule (collecting duct, proximal 
tubule and Loop of Henle/ distal convoluted tubule) cell numbers from representative 
sections of the young kidneys. Stain grading was performed by an observer blinded 
to genotype.
Whole kidneys from 9-12 month Tsc1+'~ (N=4) and Tsc2+I' (N=4) mice were serially 
sectioned at 5pm onto clear Superfrost Plus slides. The resulting bank of kidney 
tissue was then assessed for Tsc-associated lesions though staining every 6th slide 
with H&E (to reveal abnormal tissue architecture). Following identification of a lesion, 
further IHC stains were carried out on adjacent slides known to contain the same 
cyst. A marker of mTOR activation, anti-phospho-S6 ribosomal protein (Ser240'244), 
and a marker of active apoptosis, anti-cleaved caspase-3 (Asp175) were used to 
categorise the cysts. Simple cysts were defined as cysts having a single epithelial 
cell boundary, with no evidence of multicellular projections (Wilson et al. 2006). 
Cysts with multicellular projections, branching lesions, cyst adenomas and renal cell 
carcinomas were classified as advanced lesions. Following ABC peroxidase 
treatment as previously described, slides were graded on stain intensity to assess 
the mTOR and apoptotic status of the cyst. Lesion analysis was performed by an 
observer blinded to genotype.
4.2.3 Cell size measurement
As previously discussed, serial sections of kidneys were obtained from Tsc1+I' and 
Tsc2+I' mice, stained for pS6 and caspase-3, and categorised into simple cysts (96 
cysts) and advanced lesions (111 lesions). These were analysed under a light 
microscope, photographed and measured with AxioVision software. Cross sectional 
area (in pm2) was assessed by measuring all available sections containing a cyst, 
and taking the largest single area (rather than an average) to represent that lesion. 
Data was then tested for normality with an Anderson-Darling test and compared 
using the Mann-Whitney test for non-parametric data.
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4.2.4 Statistics
Cyst staining data was compared using Fisher’s exact test with contingency tables. 
Larger samples (N>6 in all categories) were analysed with a Chi-squared test. To 
analyse the levels of apoptosis in 2 day old renal tubules, Chi-squared contingency 
tables were used, as the data was categorical and non-parametric. Cell sizes were 
compared with Mann-Whitney test.
4.3 Results
4.3.1 Apoptosis in developing mouse renal tubules
To test the hypothesis that apoptosis could be triggered to destroy misaligned tubule 
cells in Tsc1+I\  Tsc2+I' and Pkd1H' mice, we stained developing renal tubules from 2 
day old mice for cleaved Caspase-3 (a marker of apoptosis). Tubule polarity defects 
have previously been established in these mice (see Chapter 3). We found that 11.6 
x 10-4 (76/65337) and 11.8 x 10'4 (53/44963) tubule cells from Tsc1 and Tsc2 mice, 
respectively, were undergoing apoptosis which was ~1.5 fold higher than found in 
wild type littermates (7.8 x 10*4 [50/64246] tubule cells; P=0.026 and P=0.034, 
respectively). Pkd1+/' mice demonstrated similar levels of elevated renal tubule 
apoptosis when compared to wild-type littermates (14.9 x 10"4 [69/46322] tubule 
cells, P<0.001) (Figure 4.1, Table 4.1).
4.3.2 mTOR activation in TSC-associated renal lesions
We stained 41 simple cysts, defined as having no multicellular projections or 
branches into the lumen and 40 advanced lesions (branching cysts, cystadenomas 
and RCCs) from Tsc1+I' mice (N=4) and 55 simple cysts and 71 advanced lesions 
from Tsc2+/' mice (N=4) for phospho-S6, a marker of mTOR activation. In agreement 
with our previous studies (Wilson et al. 2006), we found that mTOR was not active in 
39% (16/41) and 40% (22/55) of simple cysts from Tsc1 and Tsc2 mice, respectively, 
whereas almost all advanced lesions from these mice were mTOR-active (40/40, 
100% for Tsc1 and 70/71, 98.6% for Tsc2, P<0.005 for both as compared to cysts) 
(Figure 4.2). No significant difference was found between Tsc1 and Tsc2 simple 
cysts in terms of mTOR activation.
127
4.3.3 Caspase-3 and mTOR activation in TSC lesions
We stained simple kidney cysts from 9-12 month-old Tsc1+I~ (N=4) and Tsc2+I' mice 
(N=4) with caspase-3 and, on adjacent serial sections, pS6. We found that 17/41 
(41.5%) and 18/55 (32.7%) of cysts from Tsc1+I’ and Tsc2+I' mice, respectively, 
stained for caspase-3. In the context of mTOR activity, almost all cysts without 
mTOR activation did not have caspase-3 activation (36/38, 94.7%), whereas many 
cysts with mTOR activation also had caspase-3 activation (25/58, 43%; P<0.001 as 
compared to mTOR-inactive cysts) (Figure 4.3, Table 4.2 and 4.3).
4.3.4 Cyst size investigation
As previously discussed, simple and advanced lesions from 9-12 month-old Tsc1*'~ 
(N=4) and Tsc2+I' mice (N=4) were defined on the basis of H&E stained sections and 
categorised on levels of phospho-S6 and cleaved caspase-3 staining. To further 
characterise the cystogenesis seen in our Tsc mouse models, these lesions were 
measured under an Olympus BX51 light microscope with AxioVision software. In the 
207 lesions found in our 8 mice (111 advanced lesions, 96 simple cysts), the 
variability in size was considerable, with the smallest cyst measuring 362pm2 and the 
largest being 1,688,362pm2. No significant difference was found between the sizes 
of our mTOR positive and negative simple cysts (P=0.7502), although both mTOR 
positive and negative simple cysts were significantly smaller than mTOR active 
advanced lesions (P<0.0001 and P=0.0002 respectively). No significant difference 
was detected between the sizes of Tsc1+I~ and Tsc2+I' simple cysts (P>0.05). No 
significant difference was detected between the sizes of Tsc1+/' and Tsc2+I' 
advanced lesions (P>0.05). In simple cysts, mTOR activation (pS6+/C3- compared 
to pS6-/C3-) does not significantly alter cyst size (P=0.1894). However, active 
apoptosis (pS6+/C3+ compared to pS6+/C3-) correlated with a significantly larger 
average cyst size (P=0.0247). Simple cysts with no mTOR activation and no 
apoptosis were found to contain both the smallest and the largest recorded cyst 
sizes in all 96 simple cysts (362pm2 and 400,000pm2, respectively). Advanced 
lesions were nearly all mTOR active, but when compared for size in the context of 
caspase-3 staining (pS6+/C3+ compared to pS6+/C3-), it was found cysts with 
inactive apoptosis were significantly smaller (Figure 4.4, Table 4.4).
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Figure 4.1 Apoptosis in 2-day old mouse renal tubules. Panel A: Haematoxylin and 
cleaved-caspase 3 stained mouse renal tubules. Cell counts were made from all 
sections of the kidney (collecting duct, proximal tubule and Loop of Henle/ distal 
convoluted tubule). Panel B: 100x magnification images of apoptotic events taking 
place in Tsc1+I' and Tsc2+I' mouse renal tubules. Panel C: Apoptosis taking place in 
the lining of cyst epithelium (from 9-12 month old mice). Occasionally, sloughing-off 
may be seen, when a recently deceased cyst cell is forced into the cyst lumen, 
leading to the collection of apoptotic bodies in the central vacuation.
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Genotype
Number 
of slides 
used
Number
of
apoptotic
events
Apoptotic 
events 
per slide
Projected 
number of 
tubule 
cells
Percentage  
of tubule 
cells 
undergoing 
apoptosis
Percentage 
increase 
compared 
to wild-type
Wild-type 34 50 1.47 64246 0.078 n/a
Tscl*1' 25 76 3.04 65337
0.117  
(P =0.026)
+33%
Tsc2 28 53 1.89 44963
0.118  
(P =0.034)
+34%
Pkd1*'- 25 69 2.76 46322
0.149
(P <0.001)
+48%
0.16
!§ .  o |
I fc 
3 0)J2
8 |
E o2 >(0
o '?  0.06
<d  cnj 
r a -
-£ w 0.04
0.14
0.12
0.1
0.08
d) Q.
CL o  0.02 
aj
P <0.05
Tscf 7sc2 PkdfWild-type
Table 4.1 Levels of apoptosis in the developing renal tubules of Tsc1+/~, Tsc2+/', 
Pkd1+/' and wild-type mice at 2 days of age. An average of 6 mice was used in each 
genotype, with tubule counts performed on representative kidney sections. Apoptotic 
lesions found across these slides were expressed as a percentage of total tubule 
cells, calculated from the representative sections. No significant difference was 
found in the levels of apoptosis between Tsc1 or Tsc2 mice and Pkd1 mice. All three 
mutant mouse lines had significantly more renal tubule apoptosis compared to wild- 
type littermates (P =0.026 Tsc1+I'. P=0.034 Tsc2+I~ and P<0.001 Pkd1+,~).
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Tsc1*'-
Simple Cysts Advanced Lesions
38/96 mTOR negative
(39.6%)
1/111 mTOR negative 
(0.9%)
Tsc1H-
Tsc2H-
Total
*
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Figure 4.2 Many simple cysts (A) do not stain positive for m TOR activity (indicated by the absence of a strong brown stain), while later and 
more advanced lesions (B and C) commonly do (P<0.005). Simple cysts are defined as having a single epithelial cell boundary, with no 
evidence of multicellular projections. Photos were taken from the serial sectioned kidneys of 9-12 month old Tsc1+/' and Tsc2+/' mice.
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Figure 4.3 Apoptotic and m TO R status of early and late lesions in Tsc cystogenesis. Serially 
sectioned kidneys from Tsc1+I' and Tsc2+I' w ere stained for m TOR and apoptosis. Panel A: 
Many simple cysts do not demonstrate m TO R  activation, and these particular lesions are also 
negative for apoptosis. Panel B: Advanced lesions commonly stain strongly for both markers.
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Simple cysts
Mouse ID Genotype
N e g a tiv e  
pS6 /  
N e g a tiv e  
caspase-3
N e g a tiv e  
pS6 /
Positive
caspase-3
Positive 
pS6 /  
N e g a tiv e  
caspase-3
Positive 
pS6 /  
Positive 
caspase-3
Total
6448A 12 Tsc1*'- 6 0 4 1
41
6439624 Tstf*1' 3 0 0 3
64493A B Tsd*'- 6 0 2 7
64387E 7 Tsrf*1' 0 1 3 5
B659B634 Tsc2*‘- 3 0 3 3
55
B 6596E10 Tsc2*h 7 0 6 9
B659B336 Tsc2*'~ 2 1 3 3
B659F8FA Tsc2H' 9 0 4 2
36 2 25 33 96
Apoptotic Status
caspase-3
positive
caspase-3
n eg a tive
m TOR
status
pS6
positive
33/58 (56.9% ) 25/58  (43.1% )
pS6
n eg a tive
2/38 (5 .3% ) 36/38 (94.7% )
Table 4.2 Apoptotic and m TO R status of simple cysts in Tsc-associated renal 
cystogenesis. Eight mouse kidneys, four from each genotype, were serially sectioned 
and stained for m TO R and apoptotic status. Cysts were split into four subgroups, where 
it was found the m TO R negative subgroup were highly likely to contain cysts that did not 
stain for active apoptosis (P<0.001).
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Advanced lesions
Mouse ID Genotype
N eg a tive  
pS6 /  
N eg a tive  
caspase-3
N eg a tive  
pS6 /
Positive
caspase-3
Positive 
pS6 /  
N e g a tiv e  
caspase-3
Positive 
pS6 /  
Positive 
caspase-3
Total
6448A 12 Tsc1*'~ 0 0 7 10
40
6439624 Tsc1*'~ 0 0 7 3
64493AB Tsc1*'~ 0 0 6 3
6 4 3 8 7 E7 Tsc1*‘- 0 0 3 1
B659B634 Tsc2*‘- 0 0 5 10
71
B 6596E10 Tsc2H' 0 0 3 20
B659B336 Tsc2*h 0 0 8 12
B659F8FA Tsc2*!~ 0 1 5 7
0 1 44 66 111
Apoptotic Status
caspase-3
positive
caspase-3
neg ative
m TO R
status
pS6
positive
6 6 /1 1 0 (6 0 % ) 4 4 /1 1 0 (4 0 % )
pS6
n eg a tive
1/1 0/1
Table 4.3 Apoptotic and m TO R status of advanced lesions in Tsc-associated renal 
cystogenesis. Eight mouse kidneys, four from each genotype, were serially sectioned 
and stained for m TO R and apoptosis. Cysts were split into four subgroups, where it was 
found the vast majority of advanced lesions were positive for m TOR signalling but were 
equally likely to be positive or negative for apoptosis.
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Advanced
lesions
Simple
cysts
Simple cysts Advanced lesions
N = 96
Mean cyst size = 3 1 ,513pm 2 
Median cyst size = 12 ,234pm 2 
Sm allest cyst = 362pm 2 
Largest cyst = 400,000pm 2
N = 111
Mean cyst size = 102,850pm 2 
Median cyst size = 4 1 ,862pm 2 
Sm allest cyst = 4 ,052pm 2 
Largest cyst = 1 ,688,362pm2
95%  Confidence Intervals
pS6 active / caspase inactive
pS6 active / caspase active 
P=0.0001 t o t a l  pS6 active
-§-------- 1 pS6 active / caspase inactive
-------------- § ----------------- 1 pS6 active / caspase active
P=0.0247
TOTAL pS6 active 
 •----- -| pS6 inactive / caspase inactive------
-  |—# - |  pS6 inactive / caspase active
P=0.2526
TOTAL pS6 inactive
P=0.7502
n i i i I i i i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— | i i i i I r
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Figure 4.4 The effect of m TO R  activation and apoptosis on lesion size. Lesions from Tsc1+I' and Tsc2+I' mice at 9 -12  months w ere categorised as simple or 
advanced, measured (cross sectional area, pm 2) and com pared. Simple cysts with m TO R  activation w ere significantly larger with active apoptosis than 
those without (P =0 .0247). No significant difference w as found between sizes of simple cysts from T s c l*1' and Tsc2+I' mice.
Lesion
classification
mTOR
status
caspase-3 negative 
(N= number of 
individual cysts used)
caspase-3 positive 
(N= number of 
individual cysts used)
Mean lesion size based on 
pS6 status (N= number of 
individual cysts used)
Simple cysts
pS6
negative
49,682|jm 2 (N=36) 7,130pm2 (N=2) 47,443pm2 (N=38)
pS6
positive
14,692|jm 2(N=25) 25,913pm 2 (N=33) 21,976pm2 (N=58)
Advanced
lesions
pS6
negative
n/a (N=0) 70,208pm 2 (N=1) 70,208pm2 (N=1)
pS6
positive
72,015pm2 (N=44) 123,900pm2 (N=66) 103,146pm2 (ISM 10)
Table 4.4 The effect of mTOR and apoptotic status on lesion size in Tsc1+I' and 
Tsc2+I' mice. Lesion size was categorised into advanced lesions and simple cysts. 
The sizes were then broken down according to mTOR status. Finally, lesions were 
assessed on their apoptotic status. All statistical comparisons were carried out with 
the Mann-Whitney test for non-parametric data. Perhaps not surprisingly, advanced 
lesions with mTOR activation were significantly larger than both simple cysts with 
mTOR activation (P<0.0001) and without mTOR activation (P=0.0002). In advanced 
lesions with mTOR activation, active apoptosis correlated with a larger cross 
sectional area (P=0.0001). No significant difference was found between the mTOR 
positive and negative simple cysts (P=0.7502). In simple cysts with mTOR activation, 
apoptosis activation was associated with larger cyst sizes (P=0.0247). No significant 
difference was found in mTOR negative simple cyst sizes when compared in the 
context of apoptosis activation (P=0.2526),
136
4.4 Discussion
4.4.1 Latency in TSC-associated cystogenesis
The Tsc1+I' and Tsc2+I' mice used in our study develop renal lesions in an age- 
dependent manner. New born mice will have no lesions, 3-6 month old mice may 
have a low number of simple cysts, 9-12 month old mice commonly have a range of 
cysts and cystadenomas, while older mice (18 months up) start to develop a 
significant amount of renal cell carcinomas (Wilson et al. 2005, Onda et al. 1999). A 
clear latency period exists where renal tissue from mice heterozygous for hamartin 
or tuberin is indistinguishable to wild-type littermates. This latency period has 
previously been cited as the time needed to provided a somatic mutation in the 
remaining Tsc1 or Tsc2 allele and induce cyst formation through loss of control over 
the mTOR pathway. This would follow the classic progression of TSG loss of 
function outlined by Knudson, but data from Wilson et al. (2006) in our Tsc1+I' mice 
suggests many of the earliest lesions do not stain for mTOR activation. Furthermore, 
we have discovered subtle but significant changes in the renal tubules and hepatic 
bile ducts of 2- and 10-day old Tsc1+I' and Tsc2+I' mice that predate cystogenesis 
(Chapter 3). These changes in primary cilium lengths and cell polarity are likely to 
occur in the absence of secondary hits in the TSC genes, given the early time scales 
involved and lack of cyst formation apparent at this age. Therefore, what we are 
seeing in our mice may not be a simple waiting period for a second hit in the mTOR 
pathway.
4.4.2 A significant proportion of Tsc-associated simple cysts do not stain for 
mTOR activation
Since the discovery that the TSC1 and TSC2 gene products inhibit mTOR activity 
through modulation of Rheb GTP levels (Inoki et al. 2002, Tee et al. 2002), the 
majority of TSC research has centred on the mTOR pathway. Interestingly, in 
kidneys from our 9-12 month old Tsc1+I' and Tsc2+I' mice, we have found many 
simple cysts do not stain for pS6 (a marker of mTOR activity), while many later 
lesions do. This supports and builds upon previous work from our group that 
analysed Tsc1+I' mice to show 37% (20/54) of cysts showed little or no mTOR
137
activity, compared with 7% (7/98) of advanced lesions (P<0.001) (Wilson et al. 
2006). Cysts were stained across several sections where possible, and in all cases, 
pS6 staining was consistent across all lesions.
Data present here, along with similar studies by Kenerson et al. (2005) and Messina 
et al. (2007), suggest cysts associated with TSC can develop without activation of 
the mTOR pathway.
4.4.3 Advanced lesions are highly likely to be positive for mTOR activation
Nearly all later lesions (cystadenomas and RCCs) were found to be positive for 
mTOR signalling, which suggests that dysregulation of this pathway is something 
acquired as cysts progress and become more advanced. Downstream targets of 
active mTOR signalling involve stimulation of transcription, translation, cell growth 
and proliferation. These are all outcomes that may promote cystogenesis and lesion 
progression, perhaps explaining why mTOR activation is so commonly seen in 
advanced lesions.
4.4.4 Apoptosis is elevated in developing renal tubules with defective polarity
It was found that apoptosis was elevated in the renal tubules of our 2-day old Tsc1+,~, 
Tsc2+I' and Pkd1+/' mice when compared to wild-type littermates. This is another 
subtle, pre-cystic change that occurs alongside primary cilia defects and aberrant 
polarity. Since epithelial cells displaced from the extracellular matrix are subject to 
apoptotic cell death (Frisch et al. 1997), we suggest that apoptosis is acting as a 
rescue mechanism in renal tubules to prevent aberrant cell divisions from surviving. 
Under this hypothesis, the elevated levels of apoptosis seen in our mutant kidneys is 
an outward sign of the mechanism clearing misaligned cells from the developing 
renal tubules. Tubules with evidence of misorientated cell divisions (previously 
demonstrated in Tsc1+I', Tsc2+I' and Pkd1+I' mice) are therefore likely to have raised 
levels of apoptosis to cope with this challenge to tubule architecture. In addition to 
elevated cell death in the lining of the 2-day old tubules, apoptotic bodies were also 
found in the tubule lumen, suggesting recently killed cells are sloughed off from the
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tubule lining and enter the adjacent fluid to be cleared from the tissue. Because 
apoptotic cell death is a quick process (Green 2005), and the products of this 
process seem to be removed with efficient sloughing-off, IHC analysis of a kidney 
will detect a reduced portion of the total apoptotic events taking place. This highly 
efficient induction and clearance may explain why under widespread defective 
polarity conditions, levels of tubule apoptosis appear elevated only ~1.5 times in our 
Tsc1+I', Tsc2+I' and Pkd1+I' mice compared to wild-types.
4.4.5 Apoptosis is important in wild-type kidney development
While apoptosis may be acting as a rescue mechanism in the renal tubules of mice 
with defective polarity (Tsc1+I', Tsc2+I' and Pkd1+I'), the process is clearly important 
in normal tissue development too. This is illustrated by the presence of apoptotic 
cells in the lining of wild-type renal tubules. Our lab has shown cell orientation in 
wild-type mice to be a tightly controlled process, but the occasional division does 
take place outside the plane of the renal tubule. Some of the apoptosis seen in renal 
tubules from wild-type mice may be accounted for by the occasional cell that has 
mis-divided and become removed from cell-cell contacts and the basement 
membrane. Aside from this, wild-type tubule cells could be stimulated to die for a 
range of physiological reasons, such as occurrence of spontaneous mutations, DNA 
damage, the need to control cell numbers or simply in the process of sculpting the 
renal architecture (Brill etal. 1999).
4.4.6 Simple cysts that are negative for activation of the mTOR pathway are not 
likely to display apoptosis
Following the identification of apoptosis as a potential rescue mechanism in kidneys 
with defective polarity, we then analysed simple cysts for signs of apoptosis. Simple 
cysts which did not demonstrate mTOR activity were highly likely to be negative for 
caspase-3 activity. This result implies a strong correlation between cyst 
development, lack of mTOR activation and lack of apoptosis. It may be defects in 
misaligned cell removal, such as through inappropriate survival may eventually
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produce a cyst through mTOR-independent means. Mutations that render a 
progenitor cyst cell to be unresponsive to death cues following an aberrant division 
are likely to persist through to the eventual cyst as our Tsc lesions are clonal. The 
higher levels of apoptosis seen in advanced lesions may be explained by the cyst 
environment itself, which has previously been noted to be hostile, hypoxic and 
nutrient deprived. mTOR activation is present in the majority of these advanced 
lesions, and the elevated apoptosis rates could also be due to consequences of 
dysregulated mTOR signalling.
4.4.7 Caspase and mTOR activation modulate cyst size
Renal lesions were assessed for cell size in the context of mTOR activation and 
apoptotic status. The subset of simple cysts that were negative for mTOR and 
apoptosis contained the largest and smallest of all simple cysts measured. Between 
these two extremes, huge variability was seen in cyst size in mice from the same 
age group. Without loss of mTOR control to drive cyst size, an observer may expect 
mTOR negative cysts to remain relatively small, but this evidently not always the 
case. Cyst size is therefore influenced by more factors than mTOR status alone, 
although this is clearly important given mTOR’s cellular functions and the role of 
hamartin and tuberin in its repression. Cysts that are developing without functional 
apoptotic machinery (contained within the caspase-3 inactive subset) may not be 
subject to the growth restriction experienced by other caspase-3 active cysts. 
Factors such as contact-inhibition of growth and self-limiting cell proliferation may 
restrict the expansion of other cysts (even though they may have more cellular 
stimuli driving their enlargement).
In the mTOR active simple and advanced lesions, we found that absence of caspase 
staining correlated strongly with a smaller average lesion size. This may seem 
counter-intuitive, because a lack of apoptosis should lead to more cells being 
present in the lesion, and therefore a larger lesion size. However, mTOR active 
lesions are likely to be highly proliferative (for reasons outlined above, and in 
Chapter 1, Section 1.3.6) and may be able to offset the cells lost though apoptosis to 
an overall net gain in lesion size. Similarly, mTOR active lesions without caspase 
staining may be weakly proliferative, so as to not trigger cell cycle-induced
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apoptosis. It may be possible that apoptosis is a marker for cysts and lesions with 
the capacity to become large and progressive. This is because apoptosis is so 
closely linked to cell proliferation, a key determinant of overall lesion size.
Perhaps not surprisingly, it was found mTOR active advanced lesions had a 
significantly larger cross sectional area compared to mTOR active, and mTOR 
inactive simple cysts in the same Tsc1+I' and Tsc2+I' mice. Between the simple cysts, 
mTOR activation was not found to modify lesion size. The mTOR pathway has well 
characterised roles in cell growth and proliferation, explaining why mTOR positive 
advanced lesions tend to be larger than mTOR negative simple cysts. The cells that 
compose the lesion will be more proliferative and larger than cyst cells that can 
control mTOR signalling. Because these advanced lesions are also larger than 
mTOR positive simple cysts, it may be reasonable to assume a certain level of 
progression is required for lesion size to increase under dysregulated mTOR 
signalling. All these lesions have come from the same group of 9-12 month old mice, 
but lesions may develop at different rates and at different starting points. For a cyst 
to become advanced and far removed from normal renal tissue, various mutations 
are likely to be collected on the way towards a lesion with multiple papillae 
projections or a solid carcinoma centre. Therefore, by selecting for a comparison 
between advanced lesions and simple cysts, we are comparing the relative purity of 
a fresh lesion to the genetic chaos present in a progressive renal tumour. The 
advanced lesion may have acquired numerous mutations outside the mTOR 
pathway, some of which could pertain to overall lesion size (through changes to 
genes that alter the cellular response to growth factors, vascularisation factors or 
nutrient uptake, for example).
Finally, it is important to note that the absence of a caspase stain in a cyst does not 
necessarily mean that the lesion does not contain functional apoptotic machinery. It 
simply means that when the IHC stain was performed, no apoptosis was taking 
place. This could be due to a defect, lack of pro-death stimulation or strong pro­
survival signalling.
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CHAPTER FIVE: Activation of the Jak/Stat signalling pathway in Tsc-
associated cystogenesis
5.1 1ntroduction
Previous work has revealed widespread polarity defects in both renal and hepatic 
tissue from Tsc mice (see Chapter 3). While polarity has been strongly linked to 
cystogenesis (Bissler et al. 2005), there is a significant delay between widespread 
misaligned cell divisions taking place (2 and 10-day old mice) and disruption of renal 
architecture with tubule dilation and cystogenesis (around 6 months). Work in 
developing renal tubules suggest that apoptosis may be acting as a rescue 
mechanism to clear aberrant cell divisions from the organ, as cleaved caspase-3 
levels are elevated in mice with defective polarity compared to wild-type littermates 
(see Chapter 4). Further data in simple cysts has highlighted a subset of lesions that 
have developed without mTOR activation and are also negative for a marker of 
active apoptosis (see Chapter 4). A failure to initiate apoptosis in response to a 
misaligned cell division may be the first step towards the formation of some TSC- 
associated cysts.
How could a misguided cell division be selected for apoptotic cell death in a renal 
tubule or hepatic bile duct? The working hypothesis put forward by our lab is that a 
misorientated cell division at an extreme angle to the plane of the tubule or duct will 
result in a daughter cell a) more distant from the tubule basement membrane b) 
more isolated in terms of cell / cell contact and c) further removed from pro-survival 
signals. Indeed, it has been shown in mammary glands (Pullen et al. 1996) that cells 
require survival signals from the basement membrane to prevent the engagement of 
apoptosis, and that this survival is enhanced by cell-cell contact.
Aberrantly divided cells may well lack tight junctions with adjacent tubule cells, 
leading to isolation and loss of cellular communication (both associated with 
apoptosis). Cells in these tubules that are dividing incorrectly may be subject to this 
level of intrinsic control and will undergo apoptotic death and slough-off into the flow 
of the adjacent lumen. It may be through this control that aberrantly divided cells are 
prevented from dilating the tubule and leading the organ towards cyst formation.
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As reviewed in Chapter 1 (Section 1.3.6), apoptosis is controlled cell death through 
two general routes. Internal apoptosis involves a signalling phase (such as a toxic 
insult, cell injury, DNA damage or removal of survival signals) to stimulate a shift in 
the internal balance of Bcl2 family members towards mitochondrial membrane 
permeablisation and cytochrome c release. External apoptosis is characterised by a 
different signalling phase, and involves the stimulation of specific cell surface 
receptors by cell death associated ligands. Both forms of apoptosis proceed to an 
execution phase that involves the activation of caspases, which mediate the 
cleavage of key structures and bring about characteristic morphological changes. 
This includes chromatin fragmentation, membrane blebbing (surface changes) and 
the eventual formation of apoptotic bodies. These are commonly sloughed-off from 
surrounding, healthy cells and subjected to phagocytosis. Apoptosis is thought to be 
the consequence of an intricate balancing act by the cell, with factors supporting and 
inhibiting the process. It is crucial for maintaining appropriate cell numbers and 
tissue organisation, and is also implicated in many pathogenic conditions. In cyst 
formation specifically, several animal models with aberrant apoptosis experience a 
renal cystic phenotype (reviewed in Chapter 1, Section 1.3.6.2). Gene mutation 
involved in removal of this apoptotic control is more likely to be a single gain-of- 
function mutation (the activation of a proto-oncogene) rather than two separate hits 
to remove a tumour suppressor gene function.
Anoikis (reviewed in Gilmore 2005 and Zhan et al. 2004) is defined as a subset of 
apoptotic cell death arising through inadequate or inappropriate cell-matrix 
interactions. It is commonly called anchorage-related apoptosis. Examples of anoikis 
include the apoptosis after detachment and shedding of terminally differentiated 
colon epithelial cells into the lumen (Strateref al. 199 6), and the apoptosis of 
mammary epithelial cells upon regression of the mammary gland (Lund et al. 1996). 
It has also been observed in kidney epithelial cells (Frisch et al. 1994) where the 
term anoikis was first coined. Communication exists between cells and their 
surroundings, such as specific interactions with the extracellular matrix (ECM) and 
also neighbouring cells. A removal or disruption of either of these interactions can be 
sufficient to induce anoikis in a cell. Several groups have published data showing 
how cells deprived of ECM contact undergo classical apoptosis (Frisch et al. 1994, 
Meredith et al. 1993). A crucial finding in these papers was that anoikis was inhibited
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by overexpression of Bc/2 indicating apoptosis was taking place through the intrinsic, 
mitochondrial route. They also noted that not all cell types are equally sensitive to 
anoikis, with epithelial cells (such as the ones lining kidney tubules) being more 
sensitive than fibroblasts. Oncogenic transformation (conferred by mutations in cell­
cell adhesion molecules, integrins, integrin-associated signalling molecules or 
apoptotic regulators) can cause these epithelial cells to become anoikis insensitive. 
Many of these cellular interactions are mediated by adhesion receptors, which 
function in an analogous way to growth factor receptors (GFRs) and activate many of 
the same downstream pathways (Gilmore 2005). Indeed, GFRs themselves can 
relay important spatial information to a newly divided cell, as distance to the 
basement membrane (and pro-survival GFs) is a function of the cell’s position. 
Incorrect attachment by the cell to the immediate environment is conveyed by 
integrins and growth factors to result in suppression of pro-survival signalling (such 
as through PI3K and ERK pathways) and activation of pro-apoptotic signalling (for 
example through p53 induction and modulation of the Bc/2 family of genes).
It is important to note that correct attachment to the environment is not sufficient on 
its own to provide a survival signal. Cell spreading and shape can profoundly 
influence phenotype, with the role played by the cytoskeleton in these aspects of 
adhesion signalling being critical. Additionally, integrins crosstalk directly with GFRs 
to permit cells to fully respond to growth factor signalling when correctly orientated in 
their surroundings (Gilmore 2005).
While strong evidence exists to support this form of cell death occurring through the 
intrinsic route (Frisch et al. 1996, llic et al. 1998), some studies suggest the external 
route of apoptosis can be involved too. Epithelial cells overexpressing a dominant- 
negative form of FADD (which blocks caspase-8 recruitment to the DISC) inhibits 
anoikis (Frisch et al. 1999, Rytomaa et al. 1999). This implicates both types of 
apoptosis in controlling the correct position of cells within tissues.
We hypothesised that our cysts that have arisen without mTOR activation may have 
done so through gain-of-function mutations in pro-survival signalling pathways. We 
therefore stained our cysts for a variety of markers to provide information on the 
pathways activated and repressed. Because the library of cysts constructed in 
Chapter 4 was a scarce resource, it was important to identify the key regulatory
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proteins in cell survival signalling that could lead to defective apoptosis in renal 
tubules. Figure 5.1 reviews the apoptotic and anoikis signalling network and 
highlights important proteins in the pathways.
Bcl2 is an integral outer mitochondrial membrane protein which regulates cell death 
by controlling permeability of this membrane to cytochrome c. It is a member of a 
large family of both pro- (Bid, Bak, Bax, Puma and Noxa) and anti- (Bcl2 and BclxL) 
apoptotic factors. While many of these family members differ in specific protein 
domains, most will contain a C-terminal transmembrane domain that targets these 
proteins to the outer mitochondrial membrane. Once released through the action of 
pro-apoptotic factors, cytochrome c will induce apoptosis by activating caspase-9 
and subsequently, caspase-3. Bcl2 exerts its anti-apoptotic function in two ways, 
firstly by preventing the activation of caspases by inhibiting the release of 
cytochrome c from mitochondria, and secondly by binding to the apoptosis activating 
factor (APAF1). Previous work has suggested that expression levels of Bcl2 family 
members may determine the sensitivity of a cell to anoikis (Strasser et al. 2000), and 
overexpression of this protein may protect cells from anchorage-mediated death 
(Frisch et al. 1996). We therefore selected to stain for elevated Bcl2 in our cohort of 
cysts.
Stat3, also called Acute Phase Response Factor (APRF), is a member of the STAT 
(signal transducers and activators of transcription) family. It is activated as a result of 
signalling by a variety of cytokines, growth factors and other stimuli. It has been 
suggested to play both a pro-apoptotic role (for example, during mammary gland 
involution) and a pro-survival role (in numerous human and mouse malignancies) 
(Yu et al. 2009). Tyrosine phosphorylation at a single site near the carboxyl-terminus 
of Stat3 (Tyr705) is required for dimerisation, nuclear translocation and DNA binding 
(Lo et al. 2003). However, full transcriptional activity of the Tyr705 homodimer is only 
achieved through further phosphorylation at a site within the transactivation domain 
(Ser727). JAKs phosphorylate Stat3 at Tyr705, while Ser727 can be phosphorylated by 
several means, discussed later. We opted to stain for the Tyr705 form of the protein.
JAK2 is widely expressed member of the Janus family of tyrosine kinases and its 
importance is highlighted by its susceptibility to mutational activation which leads to 
cell transformation (Kurzer et al. 2006). Commonly, JAK signalling is induced by
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interaction of an internal FERM domain with activated cytokine receptors. While 
these receptors have no intrinsic catalytic ability, binding of cytokines (such as 
erythropoietin, interleukins and interferons) to the receptor leads to recruitment and 
activation of JAK tyrosine kinases. The JAK/STAT axis is of interest to our studies 
because it is a key mediator of cell survival. Furthermore, it is constitutively activated 
in a number of human diseases, such as RCCs (Wu et al. 2007) and various other 
inflammatory diseases and cancers (Yu et al. 2009). Activation of JAK2 has been 
strongly correlated with elevated STAT3 signalling in human diseases such as 
polycythemia vera and essential thrombocythemia (Constantinescu et al. 2007). It 
has two sites that are associated with kinase activity, Tyr1007 and Tyr1008 (with Tyr1007 
likely to be more important) and we opted to use an antibody that recognised this 
double phosphorylated, active form of Jak2 (Feng etal. 1997).
NF-kB is a protein complex that controls transcription of DNA. It is found in most 
cells and is activated in response to cell stress, cytokine signalling and bacterial / 
viral antigens (providing a link to the immune system). NF-kB is a heterodimer of 
subunits that translocate to the nucleus upon activation to modulate a wide variety of 
genes (Baldwin 1996, May et al. 1997). These subunits have two general classes; 
Class I, which includes p100 and p105 (these are large precursors and are 
processed to p52 and p50 respectively) and Class II, which includes p65 (also called 
RelA). NF-kB is not considered a strong activator of transcription unless the 
signalling complex includes p65. This subunit is phosphorylated by protein kinase A 
(PKA) on serine 726 to activate signalling (Zhong et al. 1998), and it is this form of 
p65 that we opted to stain for in our simple cysts. Because NF-kB does not require 
new protein synthesis to be activated it is an extremely fast acting transcription factor 
signalling pathway and a first responder to harmful cellular stimuli. It is a widely 
expressed regulator of genes that control cell proliferation and survival, and as such, 
is frequently constitutively activated in disease (Karin 2006). Cancers such as 
pancreatic and breast have been found to have upregulated NF-kB signalling 
(reviewed in Rayet et al. 1999, Cascinu et al. 2007). Chronic inflammation has been 
linked to cystogenesis in renal tissue in conditions such as ADPKD, and NF-kB 
signalling is known to be activated by pro-inflammatory cytokines such as IFNa. 
Because of these numerous links to proliferation, survival and responses to
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cytokines and inflammatory signalling molecules, we opted to stain for 
transcriptionally active NF-kB in our cysts.
HGF is known to be mitogenic and anti-apoptotic in renal tubule cells (Horie et 
al. 1994) and a mouse model that overexpresses HGF experiences a renal cystic 
disease similar to our Tsc mice, with tubular cystic dilation (Takayama et al. 1997). It 
is known HGF signalling leads to inhibition of Anoikis in cancerous cell lines, via 
PI3K/Akt activation and MAPK pathways (Xiao et al. 2001). This has obvious 
interesting implications for our mice as it may well be that disruption of cell-cell 
interactions / removal of ECM survival signals is pushing a misdivided cell to 
undergo apoptosis. We opted to stain for the activated form of the high affinity HGF 
receptor, c-Met, to ensure stains were tightly localised to the cystic epithelia, rather 
than diffuse across the tissue section (as may be the case with a soluble GF).
Akt, also called Protein Kinase B (PKB), is Serine/Threonine kinase. Its principle role 
in the cell is to promote growth factor mediated cell survival and to block apoptotic 
cell death. To be fully activated, it requires phosphorylation at two regulatory 
residues, Threonine 308 (by PDK1) (Alessi et al. 1996) and Serine 473 (by 
mTORC2) (Sarbassov et al. 2005). The initial phosphorylation event (Thr308) appears 
to ‘prime’ the kinase, while the additional phosphorylation (Ser473) enhances activity 
(Pommier et al. 2004). We used an antibody that recognises the Ser473 form of Akt, 
the enhanced form of the activated kinase, used in many publications for a similar 
purpose (Engelman et al. 2008, Allard et al. 2008, Segrelles et al. 2008). The kinase 
has many links to inappropriate cell survival in human and mouse cancers, with 
interestingly links to the mTOR axis. Although we are primarily looking for activation 
of pathways outside the mTOR axis, Akt is an important staining target because it 
has been shown to be activated in other TSC lesions (Han et al. 2004).
Finally, p53 is the most commonly mutated gene in human cancers (Cheah et al. 
2001), and this reflects its role as a cell cycle regulator and mediator of apoptosis. It 
is normally kept at low levels through continuous degradation, but is increased and 
activated under periods of cell stress. In contrast to most other proteins, it is 
regulated through protein modification rather than transcriptional or translational 
upregulation. It is primarily through interaction with its regulatory binding partner, 
Mdm2 that mediates this control through targeting the heterodimer for ubiquination
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and proteasome degradation. Phosphorylation of p53 at the N-terminus interrupts 
this interaction and leads to elevated p53 in the cytosol and the nucleus (due to a 
nuclear localisation domain). Further modification of p53 can then enhance 
specificity for binding elements of downstream genes that control cycle progression 
and cell survival. Mutations in p53 that arise in cancer commonly occur in the DNA 
binding domain of the protein, rendering it unable to modulate gene function in the 
face of cellular stress. Because cysts are known to be highly hostile environments 
and may display dysregulated cell proliferation and apoptosis, we therefore opted to 
stain for elevated p53 in our cohort of cysts.
Here, we investigate if pathways that are generally outside the mTOR/TSC axis are 
dysregulated and contributing to inappropriate cell survival in early cystogenesis. To 
do this, the panel of 96 simple cysts previously assessed for mTOR activity (positive 
or negative for pS6) and apoptotic activity (positive or negative for cleaved caspase- 
3) (see Chapter 4) were screened for a variety of markers of cell survival. The 
selection of staining targets for this investigation was the result of careful analysis of 
current literature, pathways and animal models. These proteins were finalised as the 
following: Bcl2, Stat3, p65, c-Met, Akt, p53 and Jak2.
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Figure 5.1 Identification of key proteins within anoikis and apoptosis signalling. Panel A: Cell 
contact with the ECM  or other cells promotes cell survival. It does this through many of the same 
pathways as G FR signalling. The ECM  is also a source of survival signals that stimulate GFRs. 
Panel B: Loss of cell anchorage leads to upregulation of pro-apoptotic Bcl2 family members and 
cell death. Panel C: The Bcl2 family of proteins regulate apoptosis by controlling mitochondrial 
permeability. Anti-apoptotic Bcl2 and BclxL are located on the outer mitochondrial membrane, 
where they inhibit cytochrome c release. Pro-apoptotic family members such as Bad, Bak, Bax and 
Bim are cytosolic until activated by death signalling. The ultimate release of cytochrome c and 
resultant apoptosis is the result of a precise interplay between many cellular proteins (which centre 
on activation / repression of the Bcl2 family). Yellow colour indicates a protein analysed in our 
study.
149
5.2 Materials and methods
5.2.1 Animal care, genotyping and tissue preparation
All matters relating to animal husbandry, care and genotyping were carried out as 
previously described. Tsc1+I‘ and Tsc2+,~ mice were obtained at 9-12 months. Four 
mice from each genotype were sacrificed and dissected to obtain paraffin-embedded 
kidneys as previously described.
5.2.2 Immunohistochemistry
Whole kidneys were serially sectioned at 5pm onto clear Superfrost Plus slides. The 
resulting bank of kidney tissue was then assessed for Tsc-associated lesions though 
staining every 6th slide with H&E (to reveal abnormal tissue architecture). Following 
identification of a lesion, further IHC stains were carried out on adjacent slides 
known to contain the same cyst. A marker of mTOR activation and a marker of active 
apoptosis were used to categorise the bank of cysts as previously discussed 
(Chapter 4). Further staining was then carried out on the remaining serial slides 
using the following antibodies: anti-phospho-Stat3 (Tyr705) (1:100), anti-phospho- 
Jak2 (Tyr1007/1008) (1:50), anti-phospho-Akt (Ser473) (1:100), anti-phospho-p65 
(Ser276) (1:50), anti-phospho-Met (Tyr1234/1235) (1:150), anti-Bcl2 (1:100) and 
anti-p53 (1:100). Simple cysts were defined as cysts having a single epithelial cell 
boundary, with no evidence of multicellular projections (Wilson et al. 2006). 
Following ABC peroxidase treatment as previously described, slides were assessed 
under blinded conditions. A grading system was used to differentiate the staining, 
ranging from GO (no staining) to G4 (heavy, dark brown staining); G3/4 was 
considered positive and compared to GO-2.
5.2.3 Statistical analysis
Cyst staining data was compared using Fisher’s exact test with contingency tables. 
Larger samples (N>6 in all categories) were analysed with a Chi-squared test.
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5.3 Results
5.3.1 Delineating the pro-survival mechanism in mTOR-inactive simple cysts
from Tsc1+/' and Tsc2+/' mice
In cysts without mTOR activation and that were not undergoing apoptosis, we did not 
find activation of c-Met (Y1234/Y1235) (0/12 cysts stained strongly), Akt (S473) (0/14 
cysts stained strongly) or p65 (NF-kB) (S726) (0/11 cysts stained strongly) (Table 
5.1) (Figure 5.2). In contrast, we did observe activation of Jak2 (Y1007/Y1008) 
(10/12 cysts stained strongly) and its downstream targets Stat3 (Y705) (9/10 cysts 
stained strongly) and Bcl2 (7/13 cysts stained strongly) (Figures 5.3, 5.4 and 5.5 
respectively). As expected, activation of the Jak2-Stat3-Bcl2 pathway was 
significantly less frequent in cysts with mTOR activation and that were undergoing 
apoptosis (phospho-Jak2 4/14 cysts stained, P^O.008; phospho-Stat3 3/12 cysts, 
P=0.004; Bcl2 1/12 cysts, P=0.030) (Table 5.1 and 5.2). No mice had germline 
variants in the regulatory region of the Jak2 gene (discussed in full in Chapter 6).
To determine whether activation of the Jak2/Stat3 pathway was occurring in an 
mTOR-independent manner, we analysed cysts that showed activation of mTOR but 
that were not undergoing apoptosis. We found significantly less of these cysts 
stained for activated Jak2 (Y1007/Y1008) (5/15 cysts, P=0.019) and Stat3 (Y705) 
(4/14 cysts, P=0.005) as compared to the mTOR-inactive, caspase-3 negative, cysts. 
Interestingly, Bcl2 was elevated in similar proportions of mTOR-active (6/13 cysts 
stained) and mTOR-inactive (7/13 cysts) cysts that were not undergoing apoptosis.
We also stained for levels of p53 to determine if this pro-apoptotic protein was 
elevated in our simple cysts (Table 5.1, 5.2 and Figure 5.6). We found 4/15 cysts 
that were mTOR inactive and caspase-3 inactive stained strongly for p53. However, 
no significant difference was found between the levels of strong p53 staining when 
this was compared to mTOR active / caspase-3 inactive cysts (1/9 cysts, P= 0.615) or 
mTOR active / caspase-3 active cysts (1/10 cysts, P=0.615).
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mTOR inactive / mTOR active / mTOR active /
caspase-3 inactive caspase-3 inactive caspase-3 active
phospho-Mef (Y1234/Y1235) 0/12 0/9 (P=1.000) 0/9 (P=1.000)
phospho-Ja/c2 (Y1007/Y1008) 10/12 5/15 (P=0.019) 4/14 (P=0.008)
phospho-/\W (S473) 0/14 0/12 (P=1.000) 0/12 (P=1.000)
phospho-Sfaf3 (Y705) 9/10 4/14 (P=0.005) 3/12 (P=0.004)
phospho-p65 (S276) 0/11 2/11 (P=0.476) 1/10 (P=0.476)
fic/2 7/13 6/13 (P=0.695) 1/12 (P=0.030)
p53 4/15 1/9 (P=0.615) 1/10 (P=0.615)
Table 5.1 Simple cysts staining strongly (G3/4) for phospho-Met, phospho-Jak2, phospho-Akt, phospho-Stat3, phospho-p65, Bcl2 
and p53. Results are categorised by their mTOR and caspase-3 activity. All P values are in comparison to strong staining events 
in mTOR inactive / caspase-3 inactive simple cysts.
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Figure 5.2 m TO R  inactive /  caspase-3 inactive simple cysts do not show activation 
of Akt, c-Met or p65. Panel A: phopsho-p65 w eak and strong staining in m TOR  
inactive (left) and active (right) cysts. Panel B: no simple cysts stained strongly for 
phospho-Akt, regardless of m TO R /  apoptotic status. Panel C: no simple cysts 
stained strongly for phospho-Met, regardless of m TO R / apoptotic status
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phospho-Jak2 staining
Figure 5.3 Activation of Jak2 in simple cysts from Tsc1+I~ and Tsc2+I' mice, with 
examples of w eak (Panel A) and strong (Panels B and C) staining. Jak2 was found 
activated in significantly more m TO R inactive / caspase-3 inactive lesions compared 
to m TOR active /  caspase-3 inactive and m TO R active /  caspase-3 active cysts.
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Figure 5.4 Activation of Stat3 in simple cysts from Tsc1+I' and Tsc2+/' mice, with 
examples of weak (Panel A) and strong (Panels B and C) staining. Stat3 was found 
activated in significantly more m TO R inactive / caspase-3 inactive lesions compared 
to m TO R active / caspase-3 inactive and m TO R active /  caspase-3 active cysts.
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Figure 5.5 Upregulation of Bcl2 in caspase-3 inactive simple cysts from Tsc1+I' and 
Tsc2+,~ mice, with exam ples of w eak (Panel A) and strong (Panels B and C) 
staining. Bcl2 was found upregulated in significantly more caspase-3 inactive lesions 
compared to cysts undergoing apoptosis. No significant difference was found 
between the frequency of strong staining events in m TO R active / caspase-3 inactive 
and m TO R  inactive /  caspase-3 inactive cysts.
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Figure 5.6 Upregulation of p53 is seen in a selection of lesions from Tsc1+I' and 
Tsc2+I~ mice. Panel A and B: W eak and strong staining (respectively) for p53 in 
simple cysts with inactive m TO R  and inactive caspase-3 from Tsc1+I~ and Tsc2+I' 
mice. Panel C: A  cyst from a Tsc2+I~ mouse with active m TO R and caspase-3 
signalling, displaying strong p53 staining.
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Figure 5.7 Columns 1-3: Serial m TO R  inactive /  caspase-3 inactive (1), m TO R  
active /  caspase-3 inactive (2), m TO R  active /  caspase-3 active (3) simple cyst 
sections stained for m TO R , caspase-3, Bcl2, phospho-Stat3, phospho-Jak2, 
phospho-Akt and phospho-p65. Column 4: Serial sections of a multicellular 
projection from an advanced lesion stained for the sam e markers.
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mTOR inactive / caspase-3 inactive cysts
Pro-survival
signalling
3 7 31 36 49 50 51 55 64 85 103 105 108 110 112 115 117 121 123 126 145 152 164 170 177 180 183 193
phospho-Akt (S473)
phospho-p65(S276)
P53 ■
phospho-Met (Y1234/Y1235)
phospho-Stat3 (Y705)
phospho-Jak2 (Y1007/Y1008)
Bel 2 u ■1
mTOR active / caspase-3 inactive cysts
Ol
CO Pro-survival
signalling
6 12 14 34 35 44 47 58 60 62 69 77 84 94 107 128 129 136 142 182 191 211 216 222 226
phospho-Akt (S473)
phospho-p65(S276)
P53
phospho-Met (Y1234/Y1235)
phospho-Stat3 (Y705)
phospho-Jak2 (Y1007/Y1008)
Bel 2 1
mTOR active / caspase-3 active cysts
No activation 
of pro-survival 
signalling
2 11 20 33 38j 43 46 52 59 65 66 67 73 86 96 98 114 122 137 163 175 176 187 198 199 200 204 205 206 209 210 214 220
phospho-Akt (S473) i
phospho-p65 (S276) p
P53
phospho-Met (Y1234/Y1235)
phospho-Stat3 (Y705)
phospho-Jak2 (Y1007/Y1008)
Bel 2
Table 5.2 Patterns of activation in simple cysts stained for activation of Akt, p65, p53, c-Met, Stat3, Jak2 and Bcl2, assessed with regards 
to m TO R and caspase-3 activation status. Green: strong staining (G 3/4) Red: weak staining (GO-2). Numbers across the table refer to 
individual cysts, followed across serial sections and stained for activation of specific pathways.
5.4 Discussion
5.4.1 The pro-survival signalling in our simple cysts deficient in apoptosis 
appears to be Bcl2 mediated
We sought to determine the basis of cell survival in our cysts and analysed levels of 
Bcl2, a common mediator of inappropriate cell survival. We found expression levels 
of Bcl2 to be significantly elevated in the caspase-3 negative subsets of our simple 
cysts when compared to the cysts actively undergoing apoptosis, implying that this 
was mediating the cell survival. Because no difference was found between mTOR 
active / caspase-3 inactive and mTOR inactive / caspase-3 inactive cysts, we 
suggest that Bcl2 induction may be a general mediator of cell survival in cysts and 
not specific to mTOR positive or negative pathways. In this way, Bcl2 induction 
represents a point for signalling pathways to converge on, and this is in agreement 
with current literature (Tsujimoto 2001).
Previous work in Tsc2+I' mice has shown these animals develop tumours and cysts 
that express gelsolin (Onda et al. 1999). Interestingly, gelsolin is a known repressor 
of apoptosis (Ohtsu et al. 1997), a function it mediates through its ability to prevent 
apoptotic changes of mitochondria (Koya et al. 2000). Taken with the Bcl2 data, we 
suggest that the mitochondrial cell death pathway is exploited during cystogenesis.
5.4.2 Simple cysts that do not display apoptosis or mTOR activation are likely 
to have increased levels of activated Stat3 and Jak2
Following confirmation of elevated Bcl2 in our simple cysts with no apoptosis, we 
then sought to ascertain the cause of the pro-survival signalling. We stained our 
panel of early cysts for activated Stat3 (a known regulatory of the Bcl2 family) and 
activated Jak2 (a pro-survival signalling molecule and activator of the STAT 
pathway).
Stat3 has previously been shown to mediate cell survival by inducing anti-apoptotic 
genes like Bcl2 (Bhattacharya et al. 2005) and BclxL (Lu et al. 2006). In our simple 
cysts, we found activated Stat3 (indicated by strong staining [G3-4]) in significantly
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more mTOR inactive cysts than equivalent mTOR active lesions, in an expression 
pattern that correlated with Bcl2 elevation. This implies phospho-Stat3 signalling may 
mediate the high levels of Bcl2 seen in our mTOR inactive category of cysts. 
Activated phospho-Stat3 was seen in both mTOR active / caspase-3 inactive and 
mTOR inactive / caspase-3 inactive cysts. This suggests a correlation with 
repression of apoptosis, but the association was only significant in the mTOR 
inactive category (implying this effect is mTOR independent). Our observations of 
Stat3 activation in Tsc1+I' and Tsc2+I' cysts is in agreement with current literature, 
where elevated pSTAT3 Tyr705 levels have been reported in Tsc2 null 
neuroepithelial progenitor cells (Onda et al. 2002), Tsc1 and Tsc2 null MEFs (El- 
Hashemite et al. 2004), TSC-associated LAM (El-Hashemite et al. 2005) and renal 
AMLs (El-Hashemite et al. 2005). This elevated Stat3 signalling has previously been 
linked to Bcl2 mediated resistance to apoptosis (El-Hashemite et al. 2004). What 
may be contentious however, is whether Stat3 can be activated in the absence of 
mTOR signalling (as observed in our simple cysts). This is discussed later on.
In human cancers, no STAT3 gain-of-function mutations have been reported 
(Constantinescu et al. 2007). However, STAT3 is frequently activated in a variety of 
cancers (Calo et al. 2003), so commonly a cell will have dysregulation of upstream 
STAT activators. We sought these mTOR-independent defects by examining several 
Stat3 activators, including Jak2.
We found phospho-Jak2 to be activated in significantly more mTOR inactive / 
caspase-3 inactive simple cysts than mTOR active / caspase-3 inactive and mTOR 
active / caspase-3 active cysts. When plotted for activation of Jak2, along with the 
other staining targets in the context of mTOR and caspase-3 status, we saw a strong 
correlation with the expression profiles of Jak2, Bcl2 and phospho-Stat3 in these 
mTOR inactive / caspase-3 inactive cysts. While the Bcl2 elevation appears to be 
independent of mTOR status (suggesting a convergence point), phopsho-Stat3 and 
phospho-Jak2 are activated in cysts without mTOR signalling, providing an 
alternative means of cyst initiation.
Interestingly, a steady flow over endothelial cells in culture has been found by Ni et 
al. (2004) to suppress Jak2/Stat3 signalling induced by IL-6 signalling. This may 
have implications in our Tsc mice because the renal cysts they experience will likely
161
repress fluid flow in two ways -  firstly through expansion and occlusion of nearby 
tubules, and secondly through blockage and distortion of cystic tubules. 
Furthermore, haploinsufficiency in the Tsc proteins has previously been shown to 
produce structural abnormalities in primary cilia (see Chapter 3) and these are key 
mechanosensors of fluid flow in the kidney. The defects produced by a Tsc1+I' or 
Tsc2+,~ genotype may be sufficient to reduce responsiveness to fluid flow in renal 
tubules and activate the Jak2/Stat3 signalling pathway in an mTOR-independent 
manner. Similarly, Gatsios etal. (1998) published that renal cell injury through 
hyperosmolarity resulted in Jak2 phosphorylation and induction of Stat3 following cell 
shrinkage. Whether the cyst cells we see in Tsc are osmotically abnormal remains to 
be discovered. Renal injury, which has been proposed as a mechanism for 
precipitating cystogenesis in TSC kidneys, was shown by Kuratsune et al. (2007) to 
lead to six times the endogenous level of phospho-Stat3 in rat renal tubules.
The SOCS proteins play an inhibitory role in JAK/STAT signalling (Constantinescu et 
al. 2007) and inactivating mutations in the SOCS genes are known to cause 
dysregulation of STAT signalling in human cancers such as B cell lymphomas 
(Melzner et al. 2005), hepatocellular carcinoma (Ogata et al. 2006) and Hodgkin’s 
lymphoma (Weniger et al. 2006). Mutations in these SOCS proteins would be 
another mTOR-independent route of Stat3 / Bcl2 activation, although the high levels 
of phospho-Jak2 staining in our cysts would suggest this is not the main route for 
Stat3 activation.
5.4.3 Activation of Stat3 can be mTOR-dependent or independent
Stat3 is a member of the STAT family and contains multiple phosphorylation sites 
that are crucial for its activation and signalling function. As previously discussed, 
phosphorylation at Tyr705 leads to monomer dimerisation, nuclear localisation and 
DNA binding. Further phosphorylation at Tyr727 is required for maximal transcriptional 
activity. Separate kinases are thought to be responsible for these phosphorylation 
events, with Jak1 / 2 acting at Tyr705 and a variety of kinases acting Tyr727. Kinases 
linked to this site include JNK-1 (Lim et al. 1999), MEKK1 (Lim et al. 2001), ERK 
(Kuroki et al. 1999), Protein Kinase C (Gartsbein et al. 2006, Jain et al. 1999) and 
mTOR (Kim et al. 2008, Yokogami et al. 2000). While the Y727 site is important, as 
illustrated by the defective embryonic development and elevated apoptosis seen in
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mouse lines lacking a 727 tyrosine residue (Shen et al. 2004), we have opted to look 
at the Tyr705 form of phospho-Stat3. This is because we are interested in mTOR 
independent signalling pathways that may lead to cystogenesis. Although our results 
refer to the mTOR-independent form of activated Stat3, it is important to remember 
that further activation events will come in downstream to maximise the transcriptional 
response of this transcription factor. Hence, while levels of active phospho-Stat3 
(Tyr705) may be mTOR-independent, ultimate Stat3-lead transcription may not be. 
However, other kinases apart from mTOR have been shown to carry out this 
secondary phosphorylation event, and so the whole pro-survival pathway could be 
outside the mTOR axis. Cell line work done by Chung et al. (1997) suggests 
activation at Tyr727 may negatively feedback to repress Tyr705 phosphorylation, 
providing another point that mTOR could impact upon activation of Stat3. Our 
phospho-Stat3 data in simple cysts suggests mTOR activity is not required for 
phosphorylation of Stat3 at Tyr705, in agreement with current literature. mTOR 
positive cysts had markedly reduced levels of phospho-Tyr705, which may be 
explained by the feedback mechanism proposed by Chung et al. (1997).
5.4.4 ADPKD and JAK21 STAT3
Work by Talbot et al. (2011) has found membrane-bound polycystin-1 is able 
activate STAT3 in a JAK2-dependent manner, leading to tyrosine phosphorylation 
and transcriptional activity. Furthermore, it is thought polycystin-1 can also activate 
STAT 1, -3 and -6 following cleavage and nuclear translocation of its cytosollic tail. In 
ADPKD kidneys, polycystin-1 tail fragments are overexpressed. Interestingly, STAT3 
was found to be activated in human ADPKD renal cysts by the same group, 
suggesting this cellular interaction carries over to the cystic phenotype. HGF, an 
activator of JAK2, has been found in cystic fluids in ADPKD (Horie et al. 1994), while 
transgenic mice overexpressing HGF develop renal cysts (Takayama et al. 1997). 
The previous work in ADPKD goes some way to validate the observations we have 
made in our Tsc-kidneys. Activation of the JAK2/STAT3 signalling pathway is 
associated with cystogenesis in humans and mice with dysregulated polycystin-1 tail 
signalling, and we have now shown similar Jak2-mediated activation of Stat3 is 
associated with a cystic phenotype in our Tsc1+I' and Tsc2+I' mice.
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5.4.5 NF-kB is not activated in simple cysts from our Tsc1+I' and Tsc2+I' mice
We found that phospho-p65 was rarely activated (IHC stain of G3-4) in our simple 
cysts. The only cysts found to contain active NF-kB signalling were also positive for 
mTOR activation, although some had evidence of apoptosis and some did not. This 
implies NF-kB signalling is not significantly involved in early cystogenesis, either in 
concert with mTOR signalling or as an alternative route of cell proliferation and 
survival. The lack of correlation between strong NF-kB staining and apoptotic status 
indicates that this pathway is probably not involved in mediating any effects on cyst 
apoptosis. Active NF-kB signalling is able to induce the release of cytokines which 
can then activate the JAK/STAT signalling pathway (Ward 2002), but this is unlikely 
to be the means of Jak2/Stat3 activation in our cohort of cysts because of the low 
levels of NF-kB activation.
The lack of NF-kB activation in our cysts is an interesting result because this 
pathway is known to be upregulated in other cystic disorders. It is widely used by 
eukaryotic cells as a regulator of genes that control survival and proliferation. 
Following stimulation of NF-kB signalling by cytokines, cell stress and growth factors 
(Baldwin 2001), the pathway can be active within minutes. A study by Konda et al. 
(2008) found weak phospho-p65 in normal tissue and upregulation of NF-kB 
signalling in the tubules and cysts of renal samples from patients with acquired cystic 
disease of the kidney. These cysts develop papillae projections and progress to RCC 
(as in TSC), and active NF-kB was found elevated in these tumours too. The 
researchers concluded that activated NF-kB signalling may drive the progression of 
a simple cyst towards epithelial hyperplasia and eventually to RCC. NF-kB is also 
known to be induced by hypoxic renal injury (Melvin et al. 2011), a factor that has 
been implicated in early cystogenesis (Pollard et al. 2007, Konda et al. 2008, Belebi 
et al. 2011). Because NF-kB is such a quickly induced signalling pathway, it may be 
that this pathway is activated in our young mice following renal injury, stimulates 
cystogenesis through tubule hyperproliferation and inappropriate survival, and then 
quickly returns to normal levels as other pathways like mTOR or Jak/Stat signalling 
take over. The simple cysts we are looking at may miss this narrow window. Finally, 
the strong links between NF-kB and cytokine / growth factor signalling and the lack
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of activation seen in this pathway imply that our cysts may not be initiated by 
external signalling events and could be arising through internal malfunctions.
5.4.6 HGF signalling is not activated in simple cysts from our Tstf*1' and 
Tsc2+I~ mice
Hepatocyte growth factor (HGF) is a secreted GF that acts on responsive cells via a 
high affinity cell surface c-Met receptor. We decided to stain our cysts for the 
activated form of the HGF receptor, phospho-c-Met, to ensure positive stains would 
be localised to the cyst lumen and not dispersed across the kidney (as HGF is a 
soluble GF). The antibody we used stains c-Met when phosphorylated at Tyr1234 
and Tyr1235 - this selects for the receptor activated by HGF signalling. HGF induces 
STAT3 during tubule development, and both the GF and its receptor have been 
shown to be overexpressed in many human cancers, including RCC (Zhang et al.
2004). In humans with ADPKD and simple renal cysts, studies have found elevated 
HGF in the cell walls of many lesions studied (Horie et al. 1994). Furthermore, cyst 
fluid from another disease, acquired renal cystic disease (a disorder that progresses 
to RCC in a similar manner to TSC) has been found to contain high levels of the 
soluble GF, suggesting it may play a role in promoting cyst progression (Konda et al.
2004).
Despite an animal model that experiences renal cysts with HGF overexpression, 
links to cystic progression and a clear anti-apoptotic role, we failed to find HGF / c- 
Met signalling elevated in any of our simple cysts. It may be that HGF signalling 
becomes an important factor later on in cyst progression but does not have a bearing 
on the early events in cystogenesis. However, the dilated tubules and cysts 
experienced by HGF overexpression suggest it can be activated to initiate cyst 
formation. In these mice with aberrant HGF signalling, it is possible that they have 
defective apoptosis, and therefore, a misdivided cell in these tubules (which we have 
suggested can happen in wild-type mice, see Chapter 3), would persist and 
constitute the first step towards tubule dilation and cyst formation. The fact that we 
did not observe any abnormal HGF activation perhaps suggests this is a rare 
occurrence in a mouse kidney, and something that only takes place as a lesion 
progresses and becomes more genetically unstable.
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5.4.7 Akt signalling is not activated in simple cysts from our Tsc1*,m and Tsc2+I'
mice
Activation of PI3K stimulates cell growth, proliferation and survival primarily through 
Akt-directed phosphorylation (Manning et al. 2005). It is this PI3K-Akt axis that 
stimulates mTOR under growth factor signalling, whereby the main mechanism of 
activation appears to be phosphorylation and inhibition of TSC2 (Inoki et al. 2002, 
Manning et al. 2002). Interestingly, it has been noted that homozygous loss of Tsc1 
or Tsc2 in MEFs and Drosophila results in strong inhibition of PI3K signalling 
(Radimerski et al. 2002, Zhang et al. 2003, Harrington et al. 2004). Manning et al. 
(2005) carried out further work in Tsc2+I~ and Pten+I~ mice and suggested that loss of 
Tsc2 expression in developing tumours triggers an upregulation of mTOR activation 
and a subsequent feedback inhibition of Akt signalling. It is this feedback inhibition 
that may limit the growth of TSC-related tumours and account for the benign nature 
of many of the tumours that arise in the disease. The same feedback inhibition could 
cause the absence of strong active Akt staining in our mTOR active cysts. We also 
saw no strong staining in our mTOR inactive / caspase-3 inactive cysts, implying Akt 
has not become activated in these lesions either. This would suggest these early 
cysts are developing without strong GF stimulation (which can be important in other 
renal cystic diseases), because this would be likely to feed in through the PI3K-Akt 
pathway. It may be possible that crosstalk from other mTORCI-independent 
signalling pathways is acting to repress activation of Akt, such as via ER stress 
(Chen et al. 2011), or PTEN signalling. PTEN is a major negative regulator of the 
PI3K/Akt pathway (Cantley et al. 1999) and is controlled by phosphorylation and 
cellular localisation (Meili et al. 2005). The small G protein Rho has been implicated 
in this activation (Meili et al. 2005) and both TSC1 (Lamb et al. 2000) and TSC2 
(Goncharova et al. 2004) have been shown to activate Rho. Hence, in a cyst with 
functional TSC proteins (in which mTOR is inactive) there could be activated Rho, 
and consequently PTEN signalling may be elevated and repressing activation of Akt. 
While good antibodies exist for the detection of activated Rho and PTEN, constraints 
on the amount of cysts available for our IHC studies has lead this particular line of 
research to be left for future work. Furthermore, while activated Akt signalling is 
associated with resistance to apoptosis and inappropriate cell survival in other 
conditions, such as breast cancer (Bose et al. 2006), we can confirm it does not
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appear activated in our simple cysts, irrespective of whether the cyst is displaying 
apoptosis or not.
5.4.8 p53 in cystogenesis
Our IHC analysis showed p53 was strongly activated in several cysts, both positive 
and negative for mTOR activation. The p53 transcription factor is known to sense a 
variety of cell stress signals which may reduce the fidelity of cell growth and division. 
It also can prevent misdirected growth in endothelial cell culture assays. Its role is 
therefore to initiate cell cycle arrest, senescence or apoptosis. While strong 
activation of p53 is perhaps not surprising considering the high rates of cell stress 
and proliferation in a developing cyst, it appears mTOR activation status does not 
definitively correlate with p53 levels in a Tsc lesion. Several groups have previously 
examined the links between mTOR and p53. TSC2 has been shown to be a p53- 
regulated target gene, with levels of tuberin rising following p53 induction in cell line 
work and p53 binding elements found in the TSC2 gene (Feng et al. 2005, Feng et 
al. 2007). This suggests that p53 signalling may downregulate the mTOR pathway 
as tuberin is a negative regulator of mTOR signalling. Furthermore, p53 is also 
known to upregulate PTEN (Stambolic et al. 2001), a phosphatase upstream from 
the mTOR complex and generally associated with mTOR repression. Although high 
levels of p53 should correlate with low levels of mTOR signalling, this is not the case 
in our cysts, where both mTOR active and inactive simple cysts stained strongly for 
p53. It is important to note that this strong staining was a rare event when compared 
to the total number of cysts stained. This implies many levels of complexity exist 
between p53 induction, target gene modulation and overall effects on mTOR 
signalling. Similarly, although p53 is linked to apoptosis induction, strong staining 
was witnessed in caspase 3 active and inactive cysts. It is likely that many factors 
play a modulating role in the final outcome of cell death, and upregulated p53 is 
clearly not a precise marker for apoptosis. Indeed, p53 activation alone may not be 
sufficient for induction of apoptosis, and Weber et al. (2003) have shown it may take 
a coordination of several factors to illicit a death response. A marker such as cleaved 
caspase-3 is much better for finding cells undergoing apoptosis because it is directly 
involved in the cell death pathway as one of the terminal effectors of this process. It 
is one of the last caspases to become activated, by which point, cells are wholly 
committed to fuliment apoptosis.
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5.4.9 Activation of pro-survival signalling in simple cysts without mTOR 
dysregulation
In conclusion, we have found simple cysts that did not stain for caspase-3, were 
significantly more likely to stain strongly for Bcl2 when compared to cysts that were 
undergoing apoptosis. This induction of Bcl2 was seen in both mTOR active and 
inactive lesions, implying the pro-survival protein is a general mediator of anti- 
apoptotic signalling in our Tsc cysts and may represent a convergence point for 
mTOR-mediated and mTOR -independent cell survival. Furthermore, we have 
shown that active phospho-Jak2 and phospho-Stat3 correlate strongly with this 
induction of Bcl2 in our mTOR inactive cysts that are not undergoing apoptosis. This 
pathway does not appear to be activated in mTOR active cysts that are non- 
apoptotic. We therefore suggest that inappropriate cell survival (mediated by Jak2- 
Stat3-Bcl2 signalling) can lead to the development of dilated tubules and simple 
cysts in Tsc1+I~ and Tsc2+I' mice, when placed in the context of widespread defective 
renal tubule polarity (previously discussed in Chapter 3). This mechanism of cyst 
formation appears to be mTOR-independent and represents an important step 
towards fully understanding the processes behind the formation of a Tsc renal lesion. 
To confirm our IHC findings, evidence of gain-of-function mutations in Jak2 were 
sought from a panel of Tsc1+/' and Tsc2+I~ simple cysts (discussed in Chapter 6).
168
CHAPTER SIX: Oncogenic somatic Jak2 mutations may promote TSC-
associated renal cystogenesis
6.1 Introduction
We have shown for the first time that the majority of mTOR-inactive simple cysts 
from Tsc murine models do not show signs of apoptosis, suggesting that they have 
somatically activated a pro-survival pathway. In support of this, we found strong 
activation of Jak2 and its downstream target, Stat3, in the majority of these cysts 
(Chapter 5).
JAK2 is a member of the Janus family of non-receptor protein tyrosine kinases, 
which also includes JAK1, JAK3 and TYK2 (Zou et al. 2011). The kinase is widely 
expressed and found in virtually all cell types (Sayyah et al. 2009). The JAK-STAT 
pathway mediates signalling by cytokines, which control cell survival, proliferation 
and differentiation of many cell types. Based on their primary structure, members of 
the JAK family are characterised by the presence of seven regions of conserved 
homology, denoted JAK homology (JH) domains 1-7 (Harpur et al. 1992). A somatic 
JAK2 mutation, V617F, in the JH2 domain is present in the majority of patients with 
myeloproliferative neoplasms (MPNs) including polycythemia vera (PV). The 
mutation leads to constitutive kinase activity (Zhao et al. 2005), which activates the 
JAK2 signalling pathway in a cytokine-independent manner and is believed to be a 
critical driver of excess proliferation. Other neoplastic conditions that display 
constitutive JAK2 or its downstream target, STAT3 activation include RCCs 
(Horiguchi et al. 2010), melanomas (Kong et al. 2008), and other cancers of the 
breast, neck, ovaries, lung and prostate (Yu et al. 2004). Many of the gain-of- 
function JAK2 mutations are contained within the same region of the protein, a 
section called the pseudokinase domain (JH2), which has basic structural features of 
a kinase domain but no catalytic activity. It is involved in the autoregulation of the 
adjacent kinase domain, and amino acid substitutions have been shown to produce 
conformational changes that disrupt the inhibitory function of this region (Zhao et al.
2005). While the JAK2 gene in humans and mice spans 24 exons, many gain-of- 
function mutations occur within the JH2 domain (exons 11-17), providing a suitable 
target for molecular analysis in our simple cysts.
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We have previously shown that the Jak2-Stat3-Bcl2 signalling pathway is 
upregulated in our mTOR inactive cysts, and that growth factor / cytokine signalling 
is unlikely to drive initiation of these lesions (as indicated by weak staining for active 
c-Met, Akt or NF-kB) (Chapter 5). We therefore sought evidence of activating 
mutations in Jak2 in Tsc-associated cysts to support our IHC findings.
6.2 Materials and methods 
6.2.1 Animal care, genotyping and tissue preparation
All matters relating to animal husbandry, care and genotyping were carried out as 
previously described. Tsc1+I' (N=10) and Tsc2+/' (N=11) mice were obtained at 11-12 
months along with wild-type littermates. Following cervical dislocation and dissection, 
kidneys were bisected longitudinally and snap frozen in OCT as previously 
described. Kidneys for lesion progression analysis were taken from Tsc2+I' mice, 
while wild-type mice were used for a separate cyst incidence study. Kidneys from 
both studies were matched for age and formalin fixed / paraffin embedded as 
previously described.
6.2.2 DNA isolation from simple cysts
Snap frozen kidneys were serial sectioned at 10pm onto 1.0 PEN membrane PALM 
slides using a freezing-stage microtome, and stained with toluidine blue dye. This 
stain was used to reveal lesions for microdissection. Samples were viewed and cysts 
dissected on a PALM Microlaser system. Great care was taken not to include any 
surrounding tissue in the areas selected for dissection, and cysts were dissected 
over several sequential slides where possible to maximise the amount of DNA 
captured. DNA was extracted from cysts using QIAamp DNA mini-kits, re-suspended 
in distilled water, and stored at -20°C. A total of 71 simple cysts were identified and 
DNA extracted.
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6.2.3 Jak2 sequencing
Primers were designed using Primer3 (Rozen et al. 2000) to amplify exons 11-17 of 
the murine Jak2 gene (Gene ID: 16452): 11F 5’-AGTTTTGCTGTGCTTTGCTT-3\
11R S’-GACACTGCTTTAAAGGGACAAA-S’; 12F 5-
CATTTTTGTCATTGAATATGTTTCC-3’, 12R 5’-TCT C AC AT GC AT CTAAT GTGC-3’; 
13F 5’-CAGGGGTAT CTTT CT GAGTT CT G-3’, 13R 5’-
TCCAAGGTTTTGCTGACACC-3’; 14F 5’-TTGCCTGTTGTATCCACAAGT-3’, 14R 
5’-TCCTTCTGGTTGCCAGGTTA-3’; 15F 5’-ATCTGTACTGTAGTTTTGGGCATA-3,> 
15R S’-CAGCAATAAACTAGAATGAAAGGAA-S’; 16F 5’-
CAAGTAAGTTTGGAACTCTTCACA-3’, 16R 5’-TAGAAGGGCCAGGAACACAC-3’; 
17F 5’-CCTGGCCCTTCTAATTGTGA-3’, 17R 5’-
GACTGTCTCAGATGGAGCTAAAAA-3’. PCR products were purified with 
Exonuclease I and Shrimp Alkaline Phosphatase and Sanger sequenced using the 
BigDye Terminator Cycle Sequencing kit (Version 1.1 and 3.1) on an ABI 3100 
Genetic Analyser.
6.2.4 Cyst progression in Tsc2*,m mice with and without germline Jak2 changes
To study the effects that germline Jak2 changes at K575E and G614G have on 
lesion progression, we sequenced exons 12 and 13 of Jak2 using tail DNA from a 
cohort of Tsc2+I' mice. We assembled the mice into groups matched for age and 
background (at 7-12 months [N=22] and 17-23 months [N=8]) and cut 5 
representative slides at 5pm (taken at 200pm intervals) from across the kidney. 
Slides were stained with H&E to reveal the lesions, and counted by an observer 
blinded to the Jak2 status of the mice. Renal abnormalities were mapped throughout 
the kidney to ensure the same lesion was not counted multiple times.
6.2.5 Cyst analysis in wild-type mice with and without germline Jak2 changes
To study the effects that germline Jak2 changes at K575E and G614G had on cyst 
initiation in mice, we sequenced exons 12 and 13 of Jak2 using tail DNA from a 
cohort of wild-type mice. We assembled the mice into groups matched for age and 
background (10-16 months [N=11]). The first 150pm of each kidney was serial 
sectioned at 5pm and stained with H&E. Slides were analysed under a Motic B3 
professional series light microscope and assessed for the presence of lesions by an
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observer blinded to the germline Jak2 status of the mice. Lesions were mapped 
throughout the kidney to ensure the same cyst was not counted multiple times.
6.2.6 SNP severity prediction
We used a web-based algorithm to anticipate how amino acid substitutions would 
affect Jak2 protein function. AlignGVGD, (http://aqvqd.iarc.fr/aavad input.php) 
makes predictions based on sequence homology and the biophysical properties of 
an amino acid. Sequence homology between species was ascertained 
usingClustalW2 (http://www.ebi.ac. uk/Tools/msa/clustalw2). which is a general 
purpose multi-sequence alignment program for DNA. Accession numbers for the 
protein sequence of Jak2 in humans (Homo Sapiens) (NP_004963.1), orang-utan 
(Pongo Albeii) (NP_001125600.1), mouse (Mus Muscularis) (NP_001041642.1), rat 
(Rattus Novegicus) (NP_113702.1), chicken (Gallus Gallus) (NP_001025709.1) and 
zebrafish (Danio Reno) (NP_571168.1) were taken from NCBI.
6.2.7 Statistical analysis
Frequencies of renal cyst formation in wild-type mice (with and without germline 
changes in Jak2) were compared using Fisher’s exact test. Comparisons between 
frequencies of renal cystogenesis in Tsc2+I' mice with and without germline Jak2 
mutations were compared using the Mann-Whitney test for non-parametric data.
6.3 Results
6.3.1 Germline Jak2 variations are present in our T s c 1 and Tsc2+,m mice
Here, we analysed DNA from 71 simple cysts from 11-12 month old Tsc1+I' (N=10) 
and Tsc2+I' (N=11) mice to test for activating mutations in the regulatory domain 
(exons 11-17) of Jak2. We identified six single base changes in this pseudokinase 
domain, four of which were somatically acquired (discussed in Section 6.3.2) and 
two which were present in all 9 cysts removed from the same Tsc2+I' mouse. Upon
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testing the tail DNA from this same animal, we confirmed that the two variants were 
germline changes. These were K575E (exon 12) and G614G (exon13), and both 
have been previously characterised (rs37008700 and rs13483586, respectively) 
(Figure 6.1).
6.3.2 Somatic Jak2 mutations are present in the cysts of our Tstf*1' and Tsc2+I' 
mice
Four variants were detected during our sequencing of the regulatory region of Jak2 
in the cyst DNA of our Tsc1+I' and Tsc2+I' mice (Figure 6.2). These were all somatic 
mutations, confirmed by sequencing of tail DNA to prove the absence of the 
mutation. Each somatic mutation was identified just once. In DNA extracted from a 
Tsc2+,~ simple cyst, we found an I522T mutation in exon 11 of Jak2, which is a non- 
conservative change from Isoleucine (hydrophobic) to Threonine (hydrophilic). The 
intronic region downstream of Jak2 exon 11 was found to contain a base substitution 
in DNA from a Tsc2+I~ simple cyst, 12 bases away from codon 547 (termed 
c547+12T>C). In DNA extracted from a Tsc2+/~ simple cyst, we found a single 
incidence of a V617A change in exon 13 of Jak2, a conservative substitution but at a 
key position. Finally, DNA from a Tsc1+I' simple cyst was found to contain a single 
base mutation in exon 16 of Jak2, N726N, which did not lead to a change in the 
amino acid encoded (Asparagine).
6.3.3 Jak2 mutation analysis
6.3.3.1 Evolutionary conservation
We sought to determine the fidelity of this regulatory region and the mutations 
contained within it by aligning the murine Jak2 sequence with that of JAK2 in 
humans, orang-utan, rat, chicken and zebrafish (Figure 6.3). The alignment revealed 
a high level of conservation at V617, implying this is an important residue in the 
function of Jak2. Across the species, the I522 and K575 residues are not found to be 
conserved, indicating these amino acids may not be so crucial to the properties of 
the kinase.
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6.3.3.2 Severity of residue change
Finally, an in silico analysis was performed to test the consequences of our non- 
synonymous SNPs on the function of Jak2. AlignGVGD revealed I522T and V617A 
were ‘very likely’ to interfere with Jak2 function (C65), while K575E was predicted to 
be ‘likely’ to interfere (C55).
6.3.4 Germline variants in Jak2 at K575E and G614G may modulate cyst 
burden in Tsc2H' animals
We observed that the 12 month old Tsc2+I~ mouse with germline K575E and G614G 
variants in Jak2 experienced an unusually large number of cysts across its kidneys. 
By looking at the number of cysts removed for LCM in this mouse and the other 20 
animals without Jak2 germline variants, we found it had approximately 3x as many 
lesions (22 cysts compared to an average of 8.14). We therefore sought to address 
whether the presence of these germline Jak2 variants can influence levels of 
cystogenesis in Tsc. We set up a study looking at 7sc2+/' mice at 7-12 months and at 
17-23 months of age. These were tested for the presence of the two Jak2 germline 
changes in exon 12 and 13 (hereafter termed Tsc2*l~Jak2K575EI+). Mice that tested 
positive (7sc2+/Va/c2K575E/+) were matched for age and generation with Tsc2+I' Jak2+I+ 
mice, and assessed for cyst incidence. Kidneys were embedded and sectioned as 
previously described, with one 5pm section being cut every 200pm, to obtain 5 
representative sections (H&E stained) throughout the organ.
As expected, we found an increase in all types of lesion with age. The younger age 
group, 7-12 months, contained 10 7sc2+/Vak2K575E/+ mice and 12 Tsc2+l'Jak2+l+ mice. 
No significant difference was found between the number of simple cysts (2.9 per 
animal compared to 2.5, respectively [P=0.59]), the number of branching cysts (1.3 
per animal compared to 0.7, respectively [P=0.24]), the number of cystadenomas 
(0.5 per animal compared to 1.2, respectively [P=0.30]) or the number of RCCs (0.4 
compared to 0.2 per animal, respectively [P=0.78]). Total lesion incidence was 5.1 
lesions per 7sc2+/'Ja/c2K575E/+ animal compared to 4.5 lesions per Tsc2+l~Jak2+l+ 
animal (P=0.59), an increase of 1.13 fold.
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Exon 12 K575E
Cyst
DNA
Tail
DNA
Exon 13 G614G
Leu His 
5 ’-C T G C A C
Leu His 
5 ’-C T G C A C
Lys
Ka a
Giu
GAA
Thr Glu 
A C G G A A -3 ’
Thr Glu 
A C G G A A -3 ’
Asn Tyr 
5 ’-AATTAT
Asn Tyr 
5 ’-AATTAT
Gly
GGT
Gly
GGC
Val Cys 
G T C T G T -3 ’
Val Cys 
G T C T G T -3 ’
Cyst
DNA
Tail
DNA
Figure 6.1 Germline changes in Jak 2were found in all 9 simple cysts taken from 
one of our Tsc2*'mice. Sequencing of tail DNA confirmed the changes were present 
in the germline. The mutation at K575E is a non-conservative change from a 
positively charge amino acid to a negatively charged residue. The change at G614G 
does not alter the amino acid encoded.
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Figure 6.2 Som atic changes in Jak2 w ere found in four separate cysts from Tsc1+I' 
and Tsc2+/~ mice. T h e  som atic status of these mutations was confirmed through 
sequencing of tail D N A  from the sam e animal.
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Exon 11 -  I522T
Homo Sapiens ppkpkdksnllvfrtngvsdvptsptlqrpthmnqmvfhkirnedlifne 549
PongoAlbeii ppkpkdksnllvfrtngvsdvptsptlqrpthmnqhvfhkirnedlifne 549
Mus Muscularis ppkpkdksnllvfrtngisdvqisptlqrhnnvnqmvfhkirnedlifne 549
Rattus Norvegicus ppkpkdksnllvfrtngvsdvqlsptlqrhnnvnqmvfhkirnedlifne 549
Gallus Gallus PPKPKDKSNLLVFRSNSVSDVPSSPTLQRHN-VSQMVFHKIRNEDLIFEE 546
Danio Reno sprpkekssllvcrshrglevplssslqrhn-isqhvfhkikkedlelge 532
. * ; * * ; * * . * * *  * ; .  . *  * > : * * *   ^ ; #* * * * * * * ; ; * * *  ; *
Exon 12 -K 575E
Homo Sapiens 
PongoAlbeii 
Mus Muscularis 
Rattus Norvegicus 
Gallus Gallus 
Danio Rerio
S L GQGTF TKIF KGVRREVGD YGQL HE TE VL L KVL D K AHRNYS E S F F E A AS 599 
S L GQGTF TKIF KGVRRE VGD Y GQL HE TE VL L KVL D K AHRNYS E S F F E A AS 599 
S L GQGTF TK IF KGVRRE V GD YGQL HKTE VL L KVL D K AHRNYS ESFFEAAS 599 
S L GQGTF TK IF KGVRREVGD YGQL HE TE VL L KVL D K AHRNYS E S F F E A AS 599 
S L GQGTF TK IF KG IRKE V GD YGQL HQTE VL L KVL D KVHRN YS ESFFEAAS 596 
S QGQGTF TK IF KG I RKE QGD YGE THKTEVIVKVL D K AHRNYS E S F F E A AS 582
*  * * * * * * * * * * * * * * *  * * * * ***** *************
Exon 13 -  V617A
Homo Sapiens mhsklshkhlvlnygvcvcgdenilvqefvkfgsldtylkknkn— cini 647
Pongo A Ibeii mms kl s hkhlvlnygvcvc gd en i lvqe fvkf gs l d tyl kknkn- - c in i 647
Mus Muscularis MMSQLSHKHLVLNYGVCVCGEENILVQEFVKFGSLDTYLKKNKN—  SINI 647
Rattus Norvegicus mmsqlshkhlvlnygvcvcgeenilvqefvkfgsldtylkknkn— sini 647
Gallus Gallus MMSQLSYKHLVLNYGVCVCGEENILVQEYVKFGSLDTYLKKNKN— VINI 644
Danio Rerio mhsqlthkhlvltygicvcgdenimvqeyvkfgsldtylkknkssvsvni 632
* * * ; * •  • * * * * * _  * * ;  * * * * ;  * * * ;  * * * ;  * * * * * * * * * * * * * * _  ; * *
Figure 6.3 Hum an (Homo Sapiens), orang-utan (Pongo Albeii), mouse (Mus 
Muscularis), rat (Rattus Novegicus), chicken (Gallus Gallus) and zebrafish (Danio 
Rerio) Jak2 alignment, highlighting the positions of the variants found in our cysts. 
No symbol: poorly conserved, Single dot: weakly conserved, Double dot: Strongly 
conserved, Star: 100%  conservation.
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The older age group, 17-23 months, included 4 Tsc2+l~Jak2K575EI+ mice and 4 Tsc2+I' 
Jak2+I+ mice. No significant difference was found between the number of simple 
cysts (6.0 per animal compared to 4.75, respectively [P=0.37]), the number of 
branching cysts (5.0 per animal compared to 4.75, respectively [P=0.89]), the 
number of cystadenomas (4.5 per animal compared to 1.75, respectively [P=0.24]) or 
the number of RCCs (3.0 compared to 0.75 per animal, respectively [P=0.23]). Total 
lesion incidence was 18.5 lesions per 7sc2+/Va/c2K675E/+ animal compared to 12.0 
lesions per Tsc2+l~Jak2+l+ animal (P= 0.25), which is a modest increase of 
approximate 1.5 fold (Table 6.1, Figure 6.4).
6.3.5 Wild-type mice with germline variants in Jak2 at K575E and G614G 
experience a low level of renal cystogenesis
We then investigated the effect of the Jak2 germline variants on cystogenesis in 
wild-type mice. We selected animals previously genotyped as wild-type for Tsc1, 
Tsc2 and Pkd1 and tested for the presence of the K575E and G614G germline Jak2 
variants. We found 8 wild-type mice with the Jak2 variants between the ages of 10- 
11 months of age where tissue was available for sectioning. These kidneys were 
serial sectioned for 150pm and assessed for the presence of cysts. We found a low 
level of cystogenesis occurring in these animals, with the maximum number of cysts 
found in one mouse being 6. However, several had no lesions, and the overall 
average was 2.38 cysts per mouse (Figure 6.5). All lesions found were small simple 
cysts, with evidence of dilated renal tubules in many of the kidneys. Two 13 month 
old wild-type mice with no Jak2 germline variants were used as controls, and no 
evidence of dilated tubules or cysts were found in their kidneys. In addition, previous 
studies have reproduced the finding that no wild-type mice at 15 months get renal 
cysts on a range of genetic backgrounds (Wilson et al. 2006, Bonnet et al. 2009), All 
mice used in this study were genotyped multiple times to ensure they carried no 
germline mutations in Tsc1, Tsc2 or Pkd1.
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Figure 6.4 Germline changes in Jak2 at K575E and G 614G  may modestly affect 
lesion incidence in Tsc2+I' mice. A  1.13 fold increase in total lesions per mouse was 
observed at 7-12 months in the kidneys of our 7sc2+/Va/c2K575E/+ mice compared to 
Tsc2+l~Jak2+l+ animals (5.1 average lesions per mouse compared to 4.5, 
respectively). W hen examined at 17-23 months of age, this difference between 
Tsc2+l'Jak2^575E/+ and Tsc2+l~Jak2+l+ animals had increased to 1.54 fold (18.5  
average lesions per mouse compared to 12, respectively). Neither increase was 
statistically significant.
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00
Wild-type/Ja/c2 K575E/+ Wild-type/Ja/c2
ga
■V
M K V r *S«tf f  H
Wild-type/ Jak2 K575E/+ r V
Jf&li*/»***
Mouse ID Age
(months)
Cyst count Germline 
Jak2 SNP?
A66D645B 13 0 No
A642C850 13 0 No
Z6349BB5 11 3 Yes
Z61FC7BE 10 4 Yes
Z6440CBD 11 0 Yes
N643EBFA 11 0 Yes
N643809A 11 0 Yes
N659B84D 11 6 Yes
Z64315EB 11 2 Yes
N63BF2B7 11 4 Yes
Sample Genotype
Controls
Pkd1+/-Pkd1+/+
Tsc2+/- Tsc2+/+
Z6349BB5 A66D645B
Figure 6.5 Germline changes in Jak2 at K575E and G 614G  may cause wild-type ( Tsc1+I+ and Tsc2+,+) mice to develop renal cysts. Several 
examples of renal cystogenesis were observed in mice that were confirmed as definitely negative for mutations in Tsc1, Tsc2 and Pkd1. The  
presence of a Jak2 germline change was confirmed by sequencing tail DNA from the animal. No cysts were seen in our wild-type controls, nor 
have any been reported by other groups using the sam e mouse lines.
6.4 Discussion
6.4.1 Jak2 mutations in Tscl*1' and Tsc2*,m simple cysts
The JAK2 locus has previously been reported to be susceptible to point mutations, 
rearrangements or deletions (Sayyah et al. 2009), and we have found a range of 
Jak2 mutations in the renal cysts of our Tsc1+I~ and Tsc2+/' mice. Despite being a mix 
of exonic / intronic, synonymous / non-synonymous and conservative / non­
conservative changes, we found all four somatic mutations were T to C transitions. It 
is perhaps not surprising that all the changes found were base substitutions, as 
these are among the most common mutations observed in mice and humans. In 
finding evidence of Jak2 mutations in the DNA extracted from simple cysts in our 
Tsc1+I' and Tsc2+I' mice, we have strengthened the IHC observations in Chapter 5 
and demonstrated a possible mechanism of pro-survival signalling taking place. This 
is the first time that mutations outside the mTOR pathway have been indentified in 
simple Tsc cysts.
6.4.2 Somatic Jak2 mutations in Tsc-associated renal cysts
In total, we found three exonic somatic mutations in our cysts, I522T, V617A and 
N726N. We found a further intronic somatic mutation 12 base pairs downstream from 
the 3’ end of exon 11 (termed c547+12T>C). These were all separately confirmed to 
be true somatic events through sequencing matched tail DNA.
The I522T variant is a non-conservative substitution from a hydrophobic amino acid 
(Isoleucine) to a hydrophilic residue (Threonine). Sequence alignments revealed the 
I522 position to be poorly conserved, indicating a substitution here may not lead to 
drastic effects on protein function. The human and orang-utan forms of Jak2 actually 
have a Threonine at this position in place of Isoleucine. However, in silico analysis 
with GVGD software suggests an I522T mutation was very likely to alter protein 
function.
The c547+12T>C variant was detected between exon 11 and exon 12 of Jak2. 
Although it does not lead to a coding change, the variant may still be of interest
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because of its proximity to the end of exon 11. The area adjacent to the end of an 
exon is often conserved to facilitate complex gene splicing, and non-coding 
mutations such as c547+12T>C may disrupt this and lead to protein abnormalities. 
Disruption in a 5’ donor splice site can lead to exclusion of exonic coding sequence 
in the mature mRNA (Bateman et al. 1994) and work by Saharinen et al. (2000) has 
shown deletions within the pseudokinase domain of Jak2 to lead to constitutive 
activation of the tyrosine kinase and induction of Stat transcription factors. However, 
the base pair involved is just outside the region covered by the characterised 
consensus sequence (which normally extends ~6 bases into the intron from the 5’ 
splice site) and therefore may not affect the splicing of Jak2. Outside of this 5’ donor 
site sequence, other consensus sequences are required for correct formation of the 
‘lariat’ intermediate (the ‘branch point’) and the final correctly assembled Jak2 mRNA 
(the 3’ acceptor splice site). These are unlikely to be disrupted by the c547+12T>C 
change because they lie much further downstream (the intron between exon 11 and 
12 of Jak2 is 2,365bp long, with the 3’ acceptor splice site lying adjacent to the start 
of exon 12, and the branch point commonly occurs ~25bp upstream from there). One 
more factor to be considered by intronic mutations is the possibility of disrupting an 
intronic splicing enhancer (ISE) or intronic splicing silencer (ISS). These short 
sequences can modulate splice site selection and alter the coding sequence 
included in the final mRNA transcript. Splicing defects in the regulatory domain of 
JAK2 have previously been linked to pathological conditions such as chronic 
myeloproliferative neoplasms (Ma etal. 2010).
The V617A mutation, found in exon 13 of Jak2, is the most likely to have 
pathological consequences to the regulation of Jak2 kinase function. Indeed, several 
other mutations at residue 617 (V617I, V617L, V617M, and V617W) have also been 
shown to be able to induce constitutive signalling in vitro (Dusa et al. 2008). The in 
silico analysis supports these claims, as the V617 residue is highly conserved from 
humans to zebrafish, indicating that changes here are poorly tolerated. This V617 
residue is commonly mutated in polycythemia vera (PV) as V617F (Zhao et al.
2005), where it has been shown to be present in the blood of 20 out of 24 PV 
patients. In these samples, the substitution to a phenylalanine constitutes a gain-of- 
function mutation in JAK2 and leads to unrestrained STAT3 activation. Although the 
change we have discovered in our cystic DNA is more conservative (a Valine to an
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Alanine), the position is clearly vital to the inhibitory properties of the pseudokinase 
domain. We therefore suggest that the cyst cells expressing the V617A Jak2 mutant 
are likely to have enhanced kinase activity and constitutive Stat3 activity.
Finally, the N726N variant did not lead to a change in the amino acid encoded 
(Asparagine). However, work done by Juboa et al. (2003) and Capon et al. (2004) 
suggests ‘silent’ synonymous mutations can actually impact on protein function 
through altering mRNA folding, and lead to changes in stability and levels of 
translation. In this context, the silent AAT—»AAC change may still alter the levels of 
Jak2 available for activation and Stat signalling.
6.4.3 Low levels of Jak2 mutation detection
In total, four somatic Jak2 mutations were found across exons 11-17 in cysts from 
our Tsc1+/' and Tsc2+I~ mice. Of the total 65 cysts sequenced for each exon, 37.5% 
(36/96, see Chapter 4) of these would be expected to be mTOR and caspase 
inactive. From this subset, previous work in Chapter 5 has shown ~80% (10/12, see 
Chapter 5) will show Jak2 activation. We therefore expected to find 19.5 variants in 
our cohort of mice (65 cysts x 0.375 x 0.8). This means that we are seeing fairly low 
levels of mutation in the Jak2 gene, which can be accounted for in several ways. 
Due to restrictions on cyst DNA levels, only a small portion of the total Jak2 gene 
was sequenced. When isolating advanced tumour DNA via LCM, large quantities of 
genetic material can be collected due to the solid and densely packed nature of most 
tumours. Unfortunately, cysts have a central vacuation, leaving a single cell lining to 
collect DNA from. The sequencing approach was specifically designed to make the 
most of our small amounts of DNA, and cover the areas of Jak2 most likely to 
contain gain-of-function mutations, but clearly many exons have been left out of our 
molecular analysis. This means mutations in exons 1-10 and exons 18-24 could be 
present but were not searched for in our samples. Another weakness of LCM tissue 
collection from cysts is the possibility of wild-type cells contaminating the sample and 
reducing the mutant allele frequency to a level that may not be detectable by 
standard sequencing techniques. It is also possible that some cysts that stained 
positive for phospho-Jak2 in Chapter 5 did so through normal activation or renal 
injury, not through mutation driven gain-of-function signalling. This would therefore 
reduce the expected level of Jak2 mutations. Finally, the Stat3 and Bcl2 activation
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seen in our cysts could be brought about through Ja/c2-independent means (such as 
dysregulated polycystin-1 tail signalling) further reducing the expected levels of Jak2 
mutations.
Repressors of this signalling pathway are another important consideration when 
interpreting these findings. The SOCS proteins act to negatively regulate JAK-STAT 
signalling through three distinct means -  by direct inhibition of JAKs by binding to the 
kinase activation loop (Endo et al. 1997), by competing for binding sites on the 
receptor with other molecules containing the SH2 domain (STATs) (Matsumoto et al. 
1997) and by targeting the receptor complex and associated proteins for 
proteasome-mediated degradation (Hilton et al. 1998, Zhang et al. 1999). 
Constitutive activation of the JAK-STAT pathway can be induced by mutations in the 
SOCS genes and are associated with human disease; for example, mutations in 
SOCS1 are associated with primary mediastinal B cell lymphoma (Melzner et al. 
2005), hepatocellular carcinoma (HCC) (Yoshikawa et al. 2001) and Hodgkin’s 
lymphoma (Weniger et al. 2006). Other studies have suggested promoter 
methylation may lead to silencing of the SOCS3 gene and cause persistent anti- 
apoptotic signalling under weak JAK-STAT activation (Constantinescu et al. 2007). 
This has been linked to HCC, as Ogata et al. (2006) have shown SOCS3 expression 
to be reduced in HCC areas compared to non-HCC tissue in the same patients. Liver 
specific deletion of SOCS3 enhances carcinogen-stimulated hepatic tumour 
development in mice, and correlated with increased expression of several anti- 
apoptotic genes (Ogata et al. 2006). Therefore, mutations in SOCS genes in our 
mice that reduce repression on the JAK-STAT axis may contribute to pro-survival 
signalling. However, because these proteins are acting as tumour suppressor genes, 
it is probable that two separate hits are required to remove their regulatory function. 
This is less likely than a single gain-of-function mutation occurring higher up the 
pathway in a proto-oncogene.
6.4.4 Germline Jak2 mutations
We observed two Jak2 variants (K575E and G614G) that were present in both cyst 
DNA and tail DNA of a Tsc2+'~ mouse. These were found together in exons 12 and 
13 (respectively) in all samples analysed from that mouse. Through lineage analysis, 
we traced the mutation back to a cd1/129 founder mouse, which had a homozygous
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change for GAA (and not AAA) at 575 (encoding Glutamic acid rather than Lysine), 
and GGC (and not GGT) at 614 (still encoding Glycine). Because this mouse was a 
progenitor Pkd1+/~ mouse in our colony, we then tested the germline status of Jak2 in 
all the mice used in our studies. None of the mice used in Chapters 3, 4 or 5 were 
found to contain the Jak2 K575E / G614G changes.
The K575E change occurs at a residue which is relatively strongly conserved, 
indicating its alteration may have consequences for Jak2 regulation. In silico analysis 
through GVGD software supports this suggestion by grading the change as C55 
(likely to interfere with function). Humans, Orang-utans and rats all encode a 
Glutamic acid at position 575, implying this change can be tolerated in these 
animals. However, it was noted that the Tsc2+/' mouse containing these two 
mutations was heavily burdened with cysts compared to age matched Tsc1+/' and 
Tsc2+/' littermates used in the same study. This was the impetuous for a further study 
into the effects of these germline Jak2 mutations on cystic load (see Section 6.4.5 
and 6.4.6).
6.4.5 The effects of germline changes in Jak2 on Tsc-associated renal 
cystogenesis
Due to the high number of renal cysts experience by the Tsc2+I' mouse with germline 
changes in Jak2 at K575E and G614G, we sought to address whether these variants 
could modulate cystic load. Following careful age and strain matching, we collected 
data at two different ages to provide a complete picture of lesion development in 
7sc2+/Va/c2K575E/+ and Tsc2+l~Jak2+l+ animals. We found no significant difference 
between simple cysts or more advanced lesions in 7-12 month old or 17-23 month 
old mice. However, the presence of a germline change in Jak2 did increase the 
incidence of most types of lesions in both age groups. In terms of fold difference, the 
average number of simple cysts forming in 7-12 month old mice increased by x1.2 in 
the context of a Tsc2+/"Ja/c2K575E/+ genotype compared to a Tsc2+l'Jak2+l+ animals. 
This difference increases to x1.3 in the older age category. The number of advanced 
lesions (branching cysts, cystadenomas and RCCs) also appears to be modulated 
with the germline change, with the incidence of RCCs in 17-23 month old animals
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being increased x4 under a Tsc2+l"Jak2K575EI+ genotype compared to Tsc2+l'Jak2+l+ 
animals. Perhaps the most encompassing way to compare the effects of germline 
Jak2 changes on cystogenesis is to compare total lesion counts, because advanced 
lesions have developed directly from cysts and the frequencies of both will be closely 
related. We saw a modest x1.1 fold increase in total lesions per mouse at 7-12 
months when comparing Tsc2+l~Jak2K575E,+ mice to Tsc2+l'Jak2+l+ animals. As before, 
age appears to amplify this difference, with the difference between total lesions per 
mouse increasing to x1.5 fold (comparing Tsc2+l'Jak2K575EI+ mice to Tsc2+l~Jak2+l+ 
animals) at 17-23 months of age.
These data suggest a germline Jak2 mutation may be having a subtle effect on cyst 
formation and progression. However, caution should be taken when interpreting the 
results because these changes were not statistically significant. The fact that wider 
differences are not seen may reflect the subtle nature of genetic changes to Jak2 -  
with K575E taking place at a relatively well tolerated position and G614G being a 
synonymous mutation. Any difference in cyst data being observed under these 
relatively mild Jak2 changes underlines a strong role for the Jak2/Stat3 signalling 
axis in cystogenesis.
6.4.6 Wild-type mice with germline changes in Jak2 experience a low level of 
renal cysts
To conclude our study on the effects of germline changes in Jak2 at K575E and 
G614G, we analysed kidneys from wild-type mice both with and without these 
variants. Interestingly, although previous studies have noted that our mice do not 
experience renal cysts when wild-type for Tsc1, Tsc2 or Pkd1, we discovered clear 
cut examples of cystogenesis in a selection of wild-type mice. All these mice were 
confirmed to have the germline changes in Jak2 at K575E and G614G, while control 
animals with no changes in Jak2 did not show signs of any renal cysts. Great care 
was taken with the genotyping of these animals, and it is highly unlikely that mutant 
Tsc or Pkd mice were included in our counts. Furthermore, the levels of 
cystogenesis were well below that expected in animals of the same age with Tsc1,
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Tsc2 or Pkd1 mutations, implying that what we are seeing here is independent of 
classic Tsc / Pkd cystogenesis.
Wild-type mice may experience a very mild cystic phenotype due to inappropriate 
cell survival following misorientation of a renal tubule cell division. Although cell 
polarity is not massively disrupted in these wild-type animals (Chapter 3), a 
proportion of cell divisions were found to occur outside the plane of the renal tubule 
in wild-type animals. We hypothesize that these misdivisions are normally killed off 
through activation of apoptosis, possibly via anchorage dependent cell death. Under 
inappropriate survival signalling, which may be upregulated in the renal tubules of 
our germline Jak2 mutants, some of these cells may persist, cause tubule dilation / 
pinching and constitute the first steps towards cyst formation. The dispersed and 
focal nature of the cysts suggests other factors may be required before a cyst can 
form, possibly as a result of localised renal injury or a somatic mutation in an 
unknown pathway. The germline changes found in Jak2 may be just one 
characterised example of a wide range of variants in pro-survival genes that 
cumulatively contribute towards a cystic phenotype.
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CHAPTER SEVEN: General discussion
7.1 Haploinsufficiency in TSC and ADPKD
We have observed abnormalities in renal and hepatic tissue from mice heterozygote 
for Tsc1, Tsc2 and Pkd1. Due to the young age of these animals (2 days old), it is 
unlikely that these events are mediated by a somatic removal of functional hamartin, 
tuberin or polycystin-1. The suggestion that deficiency in Tsc1, Tsc2 or Pkd1 may 
induce haploinsufficient pathological effects is supported by wide ranging studies 
from other groups.
7.1.1 Haploinsufficiency in TSC and other hamartoma syndromes
Stoyanova et al. (2004) have previously shown aberrant gene expression profiles in 
renal epithelial cells cultured from patients with a germline TSC mutation when 
compared to control cells under microarray analysis. These epithelial cells were 
reported to be microscopically normal but demonstrated upregulation of factors 
involved in protein synthesis, such as eukaryotic translation initiation factor 3 and 
several ribosomal proteins (L6, L21, S6, S25). Furthermore, TSC haploinsufficiency 
was able to increase levels of HIF1a subunit mRNA, hypoxia-inducible protein 2 and 
hypoxia-induced gene 1, all involved in cellular oxygen sensing and HIF signalling.
Uhlmann et al. (2002) found 7sc2+/' astrocytes to have reduced levels of the cell 
cycle control protein, p27-Kip1 compared to wild-type cells. This decrease was 
suggested to mediate the 1.5 fold increase in Tsc2+,~ astrocyte number (uniformly 
distributed throughout the brain) in vivo, by providing a growth advantage in 
heterozygous cells. Tsc2 heterozygosity was then coupled with mutations in other 
genes (Tsc1 and p53) to test for an additional growth advantage. Tsc1+l’Tsc2+/' mice 
displayed a cooperative astrocyte growth advantage which underlines the much 
studied functional interaction between tuberin and hamartin (van Slegtenhorst et al. 
1998, Plank et al. 1998, Nellist et al. 1999). Unlike Nf1+I'p53+I' mouse crosses (which 
do demonstrate significant genetic cooperation) (Bajenaru et al. 2001), the Tsc2+I' 
p53+l' mice showed no such effect.
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Further evidence that heterozygosity for TSC1 or TSC2 may be sufficient to trigger 
cell abnormalities has come from mutational analysis studies of brain lesions in TSC 
(Henske et al. 1996, Parry et al. 2000), where lesions do not (or rarely) demonstrate 
bi-allelic inactivation of TSC1 or TSC2. Goorden et al. (2007) reported that Tsc1+I' 
mice with no apparent cerebral pathology showed impaired learning in hippocampus- 
orientated tasks (Morris water maze trials) and abnormal social behaviour (reduced 
nest building).
A link between tuberin and DNA repair has been proposed by Habib et al. (2008), 
through using Eker rats (Tsc2+,~). Under heterozygous levels of tuberin, a decrease 
in the levels of expressed 8-oxoguanine DNA glycosylase (OGG1) was noted in the 
renal tissue of the Eker rats when compared to controls. OGG1 initiates base 
excision repair in mammalian cells and is the main defence against the mutagenic 
effects of the oxidised DNA product, 8-oxo-2’deoxyguanosine (8-oxo-dG). The 
researchers suggest that this haploinsufficiency for Tsc2 makes the Eker rats more 
susceptible to oxidative DNA damage. The kidney is known to have unusually high 
levels of oxygen metabolism and furthermore, high concentrations of urea are able to 
trigger oxidative stress in kidney cells (Audebert et al. 2000). Haploinsufficient 
defects in this pathway may have severe repercussions for the genetic integrity of 
the kidney and lead to the acquisition of further mutations.
Our laboratory has contributed to this area of TSC research by finding a lack of Tsc1 
second hits in 68.4% of renal cysts compared to ~20% of advanced lesions 
(cystadenomas and RCCs) from Tsc1+I' mice. Second hits were tested for by LOH 
analyses and direct sequencing of the entire Tsc1 ORF, and the absence of these 
events in many early lesions suggests haploinsufficiency for Tsc1 may be sufficient 
to initiate renal cystogenesis (Wilson et al. 2006). The work in this thesis adds to 
these renal findings by providing further evidence for haploinsufficient Tsc1 and Tsc2 
cystogenesis, as indicated by the finding that a significant proportion of simple cysts 
are mTOR inactive (Chapter 4). In addition, we report other subtle, pre-cystic 
changes in renal tubule cell primary cilium lengths, hepatic cholangiocyte primary 
cilium lengths and defects in mitotic orientation of tubule / duct cells in both organs 
(Chapter 3). Furthermore, apoptosis rates in developing renal tubules in our 
heterozygote mice (Tsc1+I~ and Tsc2+/') were found to be elevated when compared to
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wild-type littermates. Our findings are likely to be the earliest events in cystogenesis 
and support the theory that haploinsufficiency of Tsc1 or Tsc2 is able to instigate 
cyst formation (Figure 7.1).
Aside from TSC, there is evidence for haploinsufficient tumour initiation in several 
related hamartoma (hyperplastic disorganised growth) syndromes (such as Peutz- 
Jeghers syndrome [PJS], PTEN hamartoma syndromes and juvenile polyposis 
syndrome [JPS]) (reviewed in Santarosa et al. 2004). Data from these syndromes 
support the Tsc renal findings, where many advanced lesions will display second hits 
in their corresponding wild-type gene while earlier lesions will demonstrate 
haploinsufficiency. For example, LOH of the wild-type LKB1 gene is almost always 
found in carcinomas from PJS patients, but is only seen in 38% of benign 
hamartomatous polyps (Entius et al. 2001). Furthermore, heterozygosity for Lkb1 is 
sufficient to induce gastrointestinal polyps in Lkb1+/' mice (Miyoshi et al. 2002, Rossi 
et al. 2002, Jishage et al. 2002). Loss of wild-type Pten does not occur in the 
hyperplastic / dysplastic changes of the colon mucosa and polyps in the lower 
gastrointestinal tract in Pten+I' mice (Di Cristofano et al. 1998), and PTEN 
haploinsufficiency can induce gene expression changes in subventricular zone 
precursor cells (Li et al. 2003). Finally, LOH of the Smad4 allele (associated with 
JPS) is rare in early gastrointestinal lesions from Smad4+I' mice (Xu et al. 2000, 
Alberici et al. 2006), and data from humans with JPS suggests a similar low level 
(9%) of SMAD4 LOH in gastrointestinal polyps (Howe et al. 1998).
Due to the higher frequency of biallelic inactivation in advanced lesions when 
compared to early lesions, it is likely that one hit in Tsc1 or Tsc2 will prime cells for 
tumourigenesis and a second hit will promote tumour progression. As a lesion 
develops and becomes increasingly genetically unstable, further mutations are 
acquired and the initiating factors in tumourigenesis become masked. A cyst that has 
arisen though reductions in the cellular levels of tuberin or hamartin (but not 
complete removal, as indicated by control over the mTOR pathway) will have strong 
selection pressures for a second mutational event at the wild-type Tsc1 or Tsc2 loci 
to remove mTOR control and increase cell proliferation and translation. We suggest 
that by looking in pre-cystic cells from Tsc heterozygous mice we are observing 
effects of hamartin and tuberin haploinsufficiency (alterations of primary cilium
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lengths, aberrant cell polarity and elevated apoptosis) before confounding factors 
can obscure what is critical to lesion formation.
7.1.2 Haploinsufficiency in ADPKD
Second hits in PKD1 or PKD2 are unable to be found in a significant proportion of 
cysts from ADPKD patients (see Chapter 1, Section 1.2.8) (Jiang et al. 2006). 
Furthermore, many ADPKD cyst epithelia stain strongly for polycystin-1 and -2 (Ong 
et al. 1999a, Ong et al. 1999b), implying that complete loss of these proteins is not 
strictly required for cystogenesis in this condition. A reduced dosage of wild-type 
Pkd1 was sufficient for cyst formation in a mouse model with 15-20% normally 
spliced polycystin-1 (Lantinga-van Leeuwen et al. 2004). Jiang et al. (2006) found 
similar results in a conditional Pkd1 knockout mouse model. Ahrabi et al. (2007) 
studied a non-cystic Pkd1+I~ mouse model and found a reduction in polycystin-1 to be 
associated with a phenotype of inappropriate antidiuresis (reduction of urinary 
volume) reflecting decreased intracellular Ca2+ concentration, decreased activity of 
RhoA and abnormal expression of Arginine vasopressin in the brain. 
Haploinsufficiency has also been demonstrated in Pkd2 mice, where Chang et al. 
(2006) found Pkd2 heterozygous mice to have an elevated proliferative index in non- 
cystic renal tubules, when compared to wild-type littermates. When non-cystic 
tubules of ADPKD patients were analysed by the same group, a similar increase in 
the proliferative index was seen, implying this increase in cell proliferation is an event 
that pre-dates cystogenesis and can result from haploinsufficiency at PKD2.
In our Pkd1+/' mice, we found pre-cystic defects in the lengths of primary cilia 
projecting from renal tubule cells and cholangiocytes lining the hepatic bile ducts. We 
also observed a disruption in pre-cystic renal tubule and bile duct cell polarity, 
reflected in high levels of misaligned mitoses. Developing renal tubules in our Pkd1+I' 
mice exhibited elevated apoptosis when compared to wild-type littermates, and these 
changes, together with the above studies, make a clear case for haploinsufficiency at 
Pkd1 causing pre-cystic abnormalities.
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Figure 7.1 Consequences of haploinsufficiency in Tsc1 and Tsc2. Purple boxes: contributions to the field contained 
within this thesis.
7.2 Mechanisms of cystogenesis
, We have shown that PCP or A/B polarity is disrupted in the pre-cystic kidneys of our 
. Tsc1+I', Tsc2+I~ and Pkd1+/' mice. This dysregulation of mitotic orientation is likely to
• underlie cystic changes that occur later in the kidneys of these mice. Similar polarity 
t defects were observed in hepatic bile ducts from the same animals, although the
I
| lack of a cystic phenotype in Tsc1*'~ and Tsc2+I' mice suggests polycystin-1 plays a 
particularly important role in hepatic cystogenesis. Our data from wild-type mice 
suggest tubule and duct elongation during development is a tightly controlled 
j process, with carefully orientated cell divisions ensuring an increase in tubule / duct 
length but maintenance of a constant diameter. Aberrant divisions into the lumen of 
the developing tubule will restrict the passageway and lead to pinching / fluid 
retention. Aberrant divisions into the surrounding tissue will lead to tubule 
enlargement and dilation. Both eventualities are clear steps towards an abnormally 
dilated tubule / duct and are likely to create highly cystogenic conditions in our 
haploinsufficient kidneys and livers. However, a striking feature first noted when
I observing the tubules / ducts of 2-3 month old Tsc1+,'} Tsc2+I' or Pkd1+/' mice is the lack of evidence for these misdivisions. No dilated renal tubules are seen, no dilated , bile ducts are seen and no cells growing into or out of tubule / duct lumen are 
I observed. Indeed, mutant animals ultimately form tubules / ducts that are structurally 
indistinguishable from wild-type mice, and do not develop cysts for several months.
* Clearly, secondary factors are influencing the expression of a cystic phenotype. 
' These may be numerous, but are likely to include enhanced cell proliferation,
induction of the mTOR pathway, cessation of fluid flow, aberrant GF and Ca2+ 
signalling, renal injury and defective apoptosis. We hypothesise that apoptosis may 
‘rescue’ renal tubules and hepatic bile ducts from aberrant divisions by selectively 
killing off cells that have misdivided. This level of selection is suggested to occur 
through lack of cell-cell contact, removal of ECM survival signals and the triggering 
of anoikis. Defects in this process, through gain-of-function somatic mutations in pro­
survival signalling, could therefore lead to the persistence of an aberrantly divided 
cell and the subsequent clonal expansion of a new cyst. These cysts may have 
sufficient heterozygous levels of tuberin / hamartin to retain mTOR control, but 
secondary mutations in pro-survival pathways. We have now identified Bcl2 as the 
mediator of this survival, and put forward Stat3 and Jak2 as likely inducers of this
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protein. Furthermore, gain-of-function mutations have been observed in the 
regulatory region of Jak2 in DNA taken from simple cysts in our Tsc1+I' and Tsc2+t' 
mice. The delay period in Tsc / Pkd-associated cystogenesis may therefore 
represent the time needed for activating secondary mutations, which do not 
necessarily have to be in the remaining wild-type Tsc1 or Tsc2 locus. We propose a 
model where cystogenesis can occur by two distinct routes (termed mTOR-mediated 
and mTOR-independent) (Figure 7.2).
7.2.1 mTOR-mediated cyst formation
Our laboratory has previously shown somatic mutations in Tsc1 are infrequent in 
cysts but common in advanced lesions from Tsc1+,~ mice (Wilson et al. 2006). When 
assessed for mTOR activation, a similar pattern is seen, with ~60% of simple cysts 
showing mTOR activity and advanced lesions staining positive for mTOR activation 
all of the time. We therefore suggest, but have not yet proven, that mTOR activation 
occurs after somatic inactivation of the corresponding wild-type Tsc1 or Tsc2 allele in 
our Tsc1+I~ and Tsc2+I~ mice. Renal tubule cells in Tsc1+t' and Tsc2+h mice with 
somatic inactivation of the corresponding wild-type Tsc1 or Tsc2 allele will have a 
strong drive towards cystogenesis due to mTOR-dependent proliferation and growth. 
Under these conditions, the walls of a tubule will expand with hyperplastic Tsc1 or 
Tsc2 null cells, develop into mTOR-active simple cysts, and then advance through to 
cystadenomas and RCCs.
7.2.2 mTOR-independent cyst formation
We propose that TSC-associated cystogenesis is a multifaceted process. The end 
result of a cyst in our Tsc1+/' and Tsc2+'~ mice is likely to be the culmination of 
dysregulation in several pathways and processes. The crucial contribution of this 
thesis to the field of TSC research will be the evidence collected for an mTOR- 
independent route of TSC-associated cystogenesis. The heart of this alternative 
theory of cyst formation is that haploinsufficiency for Tsc1 or Tsc2 will lead to 
widespread polarity defects across the kidney and liver. This provides the context for 
all other cystic changes to take place in. How this defective polarity is brought about
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is a perhaps less clear (Figure 7.3), with evidence for both abnormal primary cilia- 
mediated polarity defects and a reduction in hamartin-tuberin leading to direct 
disruption of polarity signalling through PatJ. We suggest that abnormal primary cilia 
are a symptom of these polarity defects, due to their highly polar nature. The role 
hamartin, tuberin and polycystin-1 play in ciliogenesis cannot be ignored either 
(Chapter 1, Sections 1.1.10 and 1.3.2). Against the background of defective polarity, 
additional factors, such as renal injury or defective apoptosis can then drive 
cystogenesis in the absence of mTOR dysregulation. Ischemic renal injury (IRI) has 
been shown to promote cell proliferation in surviving tubular epithelial cells. Patel et 
al. (2008) and Takakura et al. (2009) found that following unilateral IRI, Kif3a mutant 
mice and Pkd1 mutant mice developed renal cysts, whilst no cyst formation was 
observed in the uninjured corresponding kidney. In this case, it appears the sudden 
stimulation of cell proliferation was enough to tip the balance towards cystogenesis, 
in much the same way as induction of the mTOR pathway. Alternatively, or perhaps 
concurrently, defects in apoptosis are likely to promote polarity-driven cystogenesis 
through unopposed misorientated divisions. The somatic mutations we have found 
(Figure 7.4) in the regulatory region of Jak2 in DNA from cysts in Tsc1+I' and Tsc2+I’ 
animals suggest this is a valid and physiologically relevant mechanism of cyst 
formation. The random occurrence of these second hits may explain both the focal 
nature, and delayed appearance of TSC-associated cystogenesis. The model of 
apoptosis as a rescue mechanism for defective polarity in renal tubules is supported 
by our findings of elevated cell death in the developing tubules of Tsc1+I', Tsc2+I~ and 
Pkd1H' mice, compared to wild-type littermates. This elevation is the third pre-cystic 
haploinsufficient change we detected in our mutant mice (Figure 7.1), and is likely to 
not represent a disease-causing process, but rather the attempt by the kidney to 
resist pathogenesis.
7.2.3 mTOR-dependent cyst progression
We occasionally found cysts that were clearly negative for mTOR activation but 
displayed a positive pS6 papillae projection (Figure 7.2). We suggest that these 
cysts may have arisen through defective polarity but eventually acquired a second 
hit in Tsc1 or Tsc2 in a single cell of the cyst epithelium. The subsequent mTOR
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activation and clonal expansion could then promote formation of a papillae 
projection, which given enough time, would progress through to a cystadenoma and 
eventually, a R C C . Th ese  cysts are rare events to capture under the microscope, as 
not only would the cyst need to be negative for m TO R activation, but must also be in 
the early stages of acquiring localised m TO R  activation. The massive growth and 
proliferation advantages offered by dysregulation of the m TO R  pathway will probably 
mean these early hits are quickly hidden by rapid clonal expansion of the activated 
cell. However, exam ples of such a cyst go some w ay to explain why m TOR  
activation appears so strongly correlated with lesion progression. It also 
demonstrates that multiple routes of cystogenesis are viable in TSC.
7.3 Implications for clinical trials
Due to the role hamartin and tuberin play in the regulation of m T O R C I signalling, a 
large portion of T S C  treatm ent has focussed on restoring repression to the TS C 1/2 - 
m TOR axis, primarily through specific inhibitors such as Rapamycin. Similarly, 
m TOR has been shown to be aberrantly activated in A D P K D  (Shillingford et al. 
2010), leading to trials of Rapam ycin to treat the renal and hepatic phenotype 
associated with this disease. W e  have used animal models to recapitulate these 
diseases and w e now discuss the clinical implications of our findings.
7.3.1 Inhibition of the mTOR pathway in TSC
As reviewed in C hapter 1 (Section 1 .1 .10 .5 ), Rapam ycin is a naturally occurring 
inhibitor of the m T O R C I complex. Through repression of this signalling axis, control 
can theoretically be restored to T S C 1 /2  mutant cells with dysregulated m TOR  
activation. Hum an trials have returned mixed results, with reports of lesion 
regression following cessation of treatm ent and poor effects on lesion initiation. The  
data collected in this thesis m ay go som e w ay to explain the unfortunate inefficacy of 
this drug. A key problem with targeting the m T O R  pathway in the treatm ent of a TSC  
kidney phenotype is that while the majority of later lesions in our Tsc mice have 
mTOR activation, m any of the earliest cysts do not. By exclusively targeting mTOR, 
many lesions m ay still develop through pathways outside the m TO R axis. Indeed,
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Kenerson et al. (2005) treated Eker rats with Rapamycin and found no effect on the 
numbers of microscopic precursor lesions. Interestingly, inhibition of this pathway 
may be beneficial in the advanced stages of a TSC-associated renal phenotype 
because volume reductions in later kidney lesions have been reported by two 
separate studies (Bissler et al. 2008, Davies et al. 2008). While Rapamycin can help 
control tumour progression, it cannot completely prevent lesion initiation because our 
work shows these early cysts may have arisen through an mTOR-independent 
mechanism. We suggest that mTOR inhibition should remain in treating the renal 
phenotype associated with TSC, but by targeting this one axis alone, opportunities 
are missed to effectively block renal cyst initiation. The ultimate answer may 
therefore lie in combination therapy to target multiple routes of cyst formation 
(discussed in Section 7.3.2). Additionally, the TSC patient’s stage of renal disease 
could be taken into account, with early preventative therapy targeting multiple routes 
of cyst initiation, and later stage Rapamycin-heavy treatment to induce regression of 
strongly mTOR-active lesions.
7.3.2 JAK2 or STAT3 inhibitors in TSC?
We have shown a route of cyst initiation that is mTOR-independent and instead 
relies on defective polarity (through haploinsufficiency of tuberin / hamartin) and 
inappropriate cell survival. Jak2-Stat3-Bcl2 signalling pathway appears to be 
mediating this survival in our mTOR inactive cysts, and so novel therapeutic options 
may now be available in treating the renal cystic manifestations of TSC. JAK2 has a 
role in signalling through cytokine receptors, such as those that bind erythropoietin 
and thrombopoietin, and activation of this molecule is linked to haematologic 
malignancies (Yu et al. 2004), and much work has already been done on developing 
inhibitors to suppress aberrant JAK2 signalling. Currently no JAK2 inhibitors are 
approved for human use, although clinical trials are underway (Sayyah et al. 2009).
The first JAK2 inhibitor indentified was AG490 (Meydan et al. 1996), which is able to 
block constitutive Jak2 signalling and trigger caspase-dependent apoptosis in 
leukemic cells derived from human patients. Although potent, this inhibitor lacks 
specificity for Jak2 (Gu et al. 2001), which is actually a widespread problem across
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this class of drugs. For example, Atiptimod has been shown to reduce levels of 
phosphorylated STAT3, STAT5 and Akt, coupled with an induction of apoptosis and 
capsase-3 activity (Faderl et al. 2007) in constitutively active JAK2 cells, but targets 
both JAK2 and JAK3 molecules (Quintas-Cardama et al. 2010). Non-specific 
pathway disruption may have unforeseen consequences in the human body and 
possible deleterious effects. Chemicals that target STATs directly appear to have 
higher specificity (Yu et al. 2004).
Numerous groups have reported on the induction of apoptosis that follows blocking 
constitutively activated STAT3 in tumour cells (Bowman et al. 2000, Buettner et al. 
2002, Battle et al. 2002). Promisingly, blocking STAT3 in normal cells does not 
generally lead to apoptosis (Bowman etal. 2001, Turkson etal. 2001), suggesting an 
exploitable difference between STAT3 activated and normal cells. This selective 
inhibition of growth may reflect an irreversible dependence of STAT3-activated cells 
on the stimulatory outcomes of STAT3 signalling, with normal cells being able to 
withstand lower levels of STAT3 activity or use alternative pathways (Yu et al. 2004).
Small molecule inhibitors of STAT3 would have increased specificity, although direct 
inhibition of specific transcription factors is notoriously challenging. However, 
progress has been made towards this goal, with STAT3 peptide inhibitors (based on 
rational design) showing specific blocking of STAT3 dimerisation / activity and 
induction of tumour cell death, with little effect on normal cells (Turkson etal. 2001).
During development, STAT3 is activated by HGF and mediates epithelial 
tubulogenesis (regulating genes responsible for forming branched tubule structures) 
(Boccaccio et al. 1998), along with roles in cell differentiation (Bonni et al. 1998) and 
suppression of apoptosis (Akira 1999). The need for this protein is highlighted by 
Stat3 null mice that die early embryogenesis, prior to gastrulation (Takeda et al. 
1997).
Several groups have investigated using IFNy as a treatment for TSC, as it has been 
previously shown that elevated IFNy expression is associated with decreased 
severity of kidney tumours in TSC patients and mouse models (Dabora et al. 2002, 
Hino et al. 2002b). IFNy is an activator of the JAK/STAT signalling pathway, 
specifically inducing STAT1 phosphorylation at Tyr701 through JAK1 and JAK2
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(Ramana et al. 2002). Treatment of Tsc1 or Tsc2 null cell lines with IFNy caused 
elevation of phospho-Statl (Y701), a reduction in both phospho-Stat3 (Y705) and 
bcl2, with a subsequent induction of apoptosis (El-Hashemite et al. 2004). Clearly 
IFNy is an exciting prospect in TSC treatment and appears to be able to abolish 
aberrant Stat3 and Bcl2-mediated cell survival in cell lines and mouse models. While 
IFNy could block aberrant pro-survival signalling in cysts that develop outside the 
mTOR pathway, it may be wise to treat the renal phenotype of TSC with a 
combination of IFNy and Rapamycin to block multiple cyst initiation routes. Reports 
of synergism between the action of these drugs in Tsc1 / Tsc2 null cell lines in 
raising phospho-Statl (Y701) levels and reducing the bcl2 expression provides early 
support for this line of treatment (El-Hashemite etal. 2004). Furthermore, Rapamycin 
has been shown to stimulate IFNy secretion in vitro in a dose dependent manner, in 
a signalling pathway likely to involve repression of mTOR (El-Hashemite et al. 2004).
In conclusion, our results highlight a role for hamartin, tuberin and polycystin-1 in the 
polarity of renal tubule epithelial cells and hepatic bile duct cholangiocytes. The 
precise mechanism of this role remains undefined, but multiple links have emerged 
between these proteins and polarity signalling. The interaction between A/B, PCP 
and the primary cilium also remains unclear, but our data suggest defects in these 
processes are the earliest pathogenic mechanisms in disease progression. We have 
suggested a rescue mechanism may prevent early cystogenesis, and have 
subsequently found evidence for its dysregulation in a proportion of our simple cysts. 
The identification of the Bcl2-Stat3-Jak2 axis as a route to cystogenesis outside the 
mTOR pathway is an important finding and one which may lead to new and exciting 
therapeutic options for TSC patients.
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